GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: October 22, 2003, 15:46:12 ; Search time 34.0587 Seconds
(without alignments)
1067.227 Million cell updates/sec

Title: US-09-856-320A-2_COPY_54_282
Perfect score: 1258
Sequence: 1 IIKGFECKPHSQPWQAALFE.....GVYTKVCKYVDWIQETMKNN 229

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1107863 seqs, 158726573 residues

Total number of hits satisfying chosen parameters: 1107863

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_19Jun03:*
1: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*
24: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2003.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	1258	100.0	250	21	AAB21325	Human TLSP. Homo
2	1258	100.0	250	21	AAY99390	Human PRO1279 (UNQ
3	1258	100.0	250	22	ABB50479	Human secreted pro
4	1258	100.0	250	22	AAU12424	Human PRO1279 poly
5	1258	100.0	250	22	AAB66139	Protein of the inv
6	1258	100.0	250	23	ABG61816	Prostate cancer-as
7	1258	100.0	250	23	ABB95526	Human angiogenesis
8	1258	100.0	250	23	ABB84920	Human PRO1279 prot
9	1258	100.0	250	23	AAU83684	Human PRO protein,
10	1258	100.0	250	24	ABU66822	Human PRO polypept
11	1258	100.0	250	24	ABU67098	Human secreted/tra
12	1258	100.0	250	24	ABU59903	Novel secreted and
13	1258	100.0	250	24	ABU56739	Lung cancer-associ
14	1258	100.0	282	20	AAY42439	CASB12 amino acid
15	1258	100.0	282	21	AAB11712	Human serine prote
16	1258	100.0	282	21	AAY43636	A human prostate-a
17	1252	99.5	281	20	AAY42440	CASB12 polypeptide
18	1235.5	98.2	275	21	AAB11714	Human serine prote
19	1231	97.9	228	21	AAB21312	Human TLSP. Homo
20	1228	97.6	250	20	AAY36093	Extended human sec
21	1227	97.5	248	22	AAE08017	Human PS133 consen
22	1219.5	96.9	289	21	AAB36483	Fusion gene with h
23	1219.5	96.9	289	22	AAB67543	Amino acid sequenc
24	1062	84.4	276	21	AAB11713	Mouse serine prote
25	1014.5	80.6	247	23	ABG70276	Human Serine Prote
26	736	58.5	250	21	AAB21298	Human KLK-L3 prote
27	736	58.5	250	23	ABP64969	Human protein SEQ
28	736	58.5	251	22	AAU16971	Human novel secret
29	734	58.3	247	22	AAU23217	Novel human enzyme
30	731.5	58.1	296	21	AAB21297	Human KLK-L3 prote
31	716	56.9	247	22	AAU86677	Novel human connec
32	716	56.9	247	22	AAU23752	Novel human enzyme
33	716	56.9	247	22	AAU17043	Human novel secret
34	688	54.7	275	21	AAB21311	Human neuropsin.
35	684	54.4	260	17	AAW10694	Human recombinant
36	684	54.4	260	18	AAW12393	Mouse neuropsin pr
37	684	54.4	260	23	ABB57219	Mouse ischaemic co
38	682	54.2	256	23	AAU79390	Novel human kallik
39	682	54.2	320	23	AAE19166	Human protease, PR
40	682	54.2	320	23	AAU82732	Amino acid sequenc
41	681	54.1	260	20	AAY41744	Human PRO322 prote
42	681	54.1	260	20	AAY32852	Human serine prote
43	681	54.1	260	20	AAY03220	Amino acid sequenc
44	681	54.1	260	20	AAW87703	A human serine pro
45	681	54.1	260	21	AAB21322	Human neuropsin.

ALIGNMENTS

RESULT 1
AAB21325
ID AAB21325 standard; Protein; 250 AA.
XX
AC AAB21325;
XX
DT 02-FEB-2001 (first entry)
XX
DE Human TLSP.
XX
KW Human; KLK-L1; KLK-L2; KLK-L3; KLK-L4; KLK-L5; KLK-L6; TLSP;
KW trypsin-like serine protease; kallikrein-like protein; serine protease;
KW cytostatic; cancer; prostrate cancer.
XX
OS Homo sapiens.
XX
PN WO200053776-A2.
XX
PD 14-SEP-2000.
XX
PF 09-MAR-2000; 2000WO-CA00258.
XX
PR 11-MAR-1999; 99US-0124260.
PR 01-APR-1999; 99US-0127386.
PR 21-JUL-1999; 99US-0144919.
XX
PA (MOUN) MOUNT SINAI HOSPITAL.
XX
PI Yousef GM, Diamandis EP;
XX
DR WPI; 2000-587440/55.
XX

PT New kallikrein-like (KLK-L) proteins for diagnosing and treating KLK-L
PT protein mediated disorders, especially cancer. -
XX
PS Example 5; Fig 27; 184pp; English.
XX
CC The present sequence is human trypsin-like serine protease (TLSP), a
CC member of the serine protease family. Kallikreins and
CC kallikrein-like proteins are a subgroup of the serine protease enzyme
CC family. They catalyse the selective cleavage of specific polypeptide
CC precursors to release peptides with potent biological activity. Nucleic
CC acids encoding kallikrein-like proteins KLK-L1, KLK-L2, KLK-L3, KLK-L4,
CC KLK-L5 and KLK-L6 have been isolated. The proteins are useful in the
CC treatment, monitoring and diagnosis of cancers, especially prostrate
CC cancer. They can also be used to identify a substance that can associate
CC with or mediate the biological activity of the proteins. Antibodies can
CC be used to treat conditions mediated by the kallikrein-like proteins.
XX
SQ Sequence 250 AA;

Query Match 100.0%; Score 1258; DB 21; Length 250;
Best Local Similarity 100.0%; Pred. No. 6.3e-113;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         22 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 81

Qy         61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 141

Qy        121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        142 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 201

Qy        181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
              |||||||||||||||||||||||||||||||||||||||||||||||||
Db        202 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 250
```

RESULT 2
AAY99390
ID AAY99390 standard; Protein; 250 AA.
XX
AC AAY99390;
XX
DT 08-AUG-2000 (first entry)
XX
DE Human PRO1279 (UNQ649) amino acid sequence SEQ ID NO:170.
XX
KW Human; PRO polypeptide; membrane bound protein; receptor; diagnosis;
KW transmembrane; secretion; immunoadhesion; pharmaceutical; screening.
XX
OS Homo sapiens.
XX
PN WO200012708-A2.
XX
PD 09-MAR-2000.
XX
PF 01-SEP-1999; 99WO-US20111.
XX
PR 01-SEP-1998; 98US-0098716.
PR 01-SEP-1998; 98US-0098749.
PR 01-SEP-1998; 98US-0098750.
PR 02-SEP-1998; 98US-0098803.
PR 02-SEP-1998; 98US-0098821.
PR 02-SEP-1998; 98US-0098843.
PR 09-SEP-1998; 98US-0099536.
PR 09-SEP-1998; 98US-0099596.
PR 09-SEP-1998; 98US-0099598.
PR 09-SEP-1998; 98US-0099602.
PR 09-SEP-1998; 98US-0099642.
PR 10-SEP-1998; 98US-0099741.
PR 10-SEP-1998; 98US-0099754.
PR 10-SEP-1998; 98US-0099763.
PR 10-SEP-1998; 98US-0099792.
PR 10-SEP-1998; 98US-0099808.
PR 10-SEP-1998; 98US-0099812.
PR 10-SEP-1998; 98US-0099815.
PR 10-SEP-1998; 98US-0099816.
PR 15-SEP-1998; 98US-0100385.
PR 15-SEP-1998; 98US-0100388.
PR 15-SEP-1998; 98US-0100390.
PR 16-SEP-1998; 98US-0100584.
PR 16-SEP-1998; 98US-0100627.
PR 16-SEP-1998; 98US-0100661.
PR 16-SEP-1998; 98US-0100662.
PR 16-SEP-1998; 98US-0100664.
PR 17-SEP-1998; 98US-0100683.
PR 17-SEP-1998; 98US-0100684.
PR 17-SEP-1998; 98US-0100710.
PR 17-SEP-1998; 98US-0100711.
PR 17-SEP-1998; 98US-0100919.
PR 17-SEP-1998; 98US-0100930.
PR 18-SEP-1998; 98US-0100848.
PR 18-SEP-1998; 98US-0100849.
PR 18-SEP-1998; 98US-0101014.
PR 18-SEP-1998; 98US-0101068.
PR 18-SEP-1998; 98US-0101071.
PR 22-SEP-1998; 98US-0101279.
PR 23-SEP-1998; 98US-0101471.
PR 23-SEP-1998; 98US-0101472.
PR 23-SEP-1998; 98US-0101474.
PR 23-SEP-1998; 98US-0101475.
PR 23-SEP-1998; 98US-0101476.
PR 23-SEP-1998; 98US-0101477.
PR 23-SEP-1998; 98US-0101479.
PR 24-SEP-1998; 98US-0101738.
PR 24-SEP-1998; 98US-0101741.
PR 24-SEP-1998; 98US-0101743.
PR 24-SEP-1998; 98US-0101915.
PR 24-SEP-1998; 98US-0101916.
PR 29-SEP-1998; 98US-0102207.
PR 29-SEP-1998; 98US-0102240.
PR 29-SEP-1998; 98US-0102307.
PR 29-SEP-1998; 98US-0102330.
PR 29-SEP-1998; 98US-0102331.
PR 30-SEP-1998; 98US-0102484.
PR 30-SEP-1998; 98US-0102487.
PR 30-SEP-1998; 98US-0102570.
PR 30-SEP-1998; 98US-0102571.
PR 01-OCT-1998; 98US-0102684.
PR 01-OCT-1998; 98US-0102687.
PR 02-OCT-1998; 98US-0102965.
PR 06-OCT-1998; 98US-0103258.
PR 06-OCT-1998; 98US-0103449.
PR 07-OCT-1998; 98US-0103314.
PR 07-OCT-1998; 98US-0103315.
PR 07-OCT-1998; 98US-0103328.
PR 07-OCT-1998; 98US-0103395.
PR 07-OCT-1998; 98US-0103396.
PR 07-OCT-1998; 98US-0103401.
PR 08-OCT-1998; 98US-0103633.
PR 08-OCT-1998; 98US-0103678.
PR 08-OCT-1998; 98US-0103679.
PR 08-OCT-1998; 98US-0103711.
PR 14-OCT-1998; 98US-0104257.
PR 20-OCT-1998; 98US-0104987.
PR 20-OCT-1998; 98US-0105000.
PR 20-OCT-1998; 98US-0105002.
PR 21-OCT-1998; 98US-0105104.
PR 22-OCT-1998; 98US-0105169.
PR 22-OCT-1998; 98US-0105266.
PR 26-OCT-1998; 98US-0105693.
PR 26-OCT-1998; 98US-0105694.
PR 27-OCT-1998; 98US-0105807.

PR 27-OCT-1998; 98US-0105881.
PR 27-OCT-1998; 98US-0105882.
PR 27-OCT-1998; 98US-0106062.
PR 28-OCT-1998; 98US-0106023.
PR 28-OCT-1998; 98US-0106029.
PR 28-OCT-1998; 98US-0106030.
PR 28-OCT-1998; 98US-0106032.
PR 28-OCT-1998; 98US-0106033.
PR 28-OCT-1998; 98US-0106178.
PR 29-OCT-1998; 98US-0106248.
PR 29-OCT-1998; 98US-0106384.
PR 29-OCT-1998; 98US-0108500.
PR 30-OCT-1998; 98US-0106464.
PR 03-NOV-1998; 98US-0106856.
PR 03-NOV-1998; 98US-0106902.
PR 03-NOV-1998; 98US-0106905.
PR 03-NOV-1998; 98US-0106919.
PR 03-NOV-1998; 98US-0106932.
PR 03-NOV-1998; 98US-0106934.
PR 10-NOV-1998; 98US-0107783.
PR 17-NOV-1998; 98US-0108775.
PR 17-NOV-1998; 98US-0108779.
PR 17-NOV-1998; 98US-0108787.
PR 17-NOV-1998; 98US-0108788.
PR 17-NOV-1998; 98US-0108801.
PR 17-NOV-1998; 98US-0108802.
PR 17-NOV-1998; 98US-0108806.
PR 17-NOV-1998; 98US-0108807.
PR 17-NOV-1998; 98US-0108867.
PR 17-NOV-1998; 98US-0108925.
PR 18-NOV-1998; 98US-0108848.
PR 18-NOV-1998; 98US-0108849.
PR 18-NOV-1998; 98US-0108850.
PR 18-NOV-1998; 98US-0108851.
PR 18-NOV-1998; 98US-0108852.
PR 18-NOV-1998; 98US-0108858.
PR 18-NOV-1998; 98US-0108904.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker K, Goddard A, Gurney AL, Smith V, Watanabe CK, Wood WI;
XX
DR WPI; 2000-237871/20.
DR N-PSDB; AAA37072.
XX
PT New mammalian DNA sequences encoding transmembrane, receptor or
PT secreted PRO polypeptides, useful for screening of potential peptide or
PT small molecule inhibitors of the relevant receptor/ligand interactions
XX
PS Claim 12; Fig 102; 773pp; English.
XX
CC AAA37022 to AAA37144 encode the new isolated human transmembrane,
CC receptor or secreted PRO polypeptides given in AAY99340 to AAY99462. The
CC transmembrane and receptor PRO proteins can be used for screening of
CC potential peptide or small molecule inhibitors of the relevant
CC receptor/ligand interactions. The polypeptides and nucleotide sequences
CC encoding then have various industrial applications, including uses as
CC pharmaceutical and diagnostic agents. AAA37145 to AAA37330 represent
CC PCR primers and hybridisation probes used in the isolation of the PRO
CC polypeptides from the present invention.
XX
SQ Sequence 250 AA;

Query Match 100.0%; Score 1258; DB 21; Length 250;
Best Local Similarity 100.0%; Pred. No. 6.3e-113;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         22 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 81

Qy         61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 141

Qy        121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        142 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 201

Qy        181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
              |||||||||||||||||||||||||||||||||||||||||||||||||
Db        202 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 250
```

RESULT 3
ABB50479
ID ABB50479 standard; Protein; 250 AA.
XX
AC ABB50479;
XX
DT 07-FEB-2002 (first entry)
XX
DE Human secreted protein encoded by gene 179 SEQ ID NO:427.
XX
KW Human; secreted protein; immunomodulatory; antisclerotic; anti-HIV;
KW dermatological; immunosuppressive; antiinflammatory; immunostimulant;
KW cytostatic; cardiant; vascular; anti-angiogenic; ophthalmological;
KW neuroprotective; nootropic; anticonvulsant; antialzheimers; vulnerary;
KW antiparkinsonian; antimicrobial; gene therapy; vaccine; immune disorder;
KW multiple sclerosis; systemic lupus erythematosus; HIV infection; cancer;
KW human immunodeficiency virus; hyperproliferative disorder; wound healing;
KW Gaucher's disease; cardiovascular disease; Scimitar syndrome; chemotaxis;
KW Chaga's cardiomyopathy; coronary arteriosclerosis; angiogenic disorder;
KW corneal graft neovascularisation; diabetic retinopathy; regeneration;
KW neurological disorder; Huntington's chorea; Alzheimer's disease;
KW Parkinson's disease; infectious disease.
XX
OS Homo sapiens.
XX
PN WO200162891-A2.
XX
PD 30-AUG-2001.
XX
PF 21-FEB-2001; 2001WO-US05614.
XX
PR 24-FEB-2000; 2000US-184836P.
PR 29-MAR-2000; 2000US-193170P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ni J, Ebner R, Lafleur DW, Moore PA, Olsen HS, Rosen CA;
PI Ruben SM, Soppet DR, Young PE, Shi Y, Florence KA, Wei Y;
PI Florence C, Hu J, Li Y, Kyaw H, Fischer CL, Ferrie AM, Fan P;
PI Feng P, Endress GA, Dillon PJ, Carter KC, Brewer LA, Yu G;
PI Zeng Z, Greene JM;
XX
DR WPI; 2001-625724/72.
DR N-PSDB; ABA83372.
XX
PT Nucleic acids encoding 207 human secreted polypeptides, useful for
PT preventing, diagnosing and/or treating, e.g. cancers, Parkinson's
PT disease and diabetic retinopathy -
XX
PS Claim 11; Page 1181-1182; 1533pp; English.
XX
CC ABB50301 to ABB51287 and ABA83194 to ABA83441 represent human secreted
CC proteins (I) and polynucleotide (II) sequences. (I) and (II) have various
CC activities based on the tissues and cells the genes are expressed in.
CC Example of these activities include: immunomodulatory; antisclerotic;
CC dermatological; immunosuppressive; antiinflammatory; immunostimulant;
CC anti-HIV; cytostatic; cardiant; anti-angiogenic; ophthalmological;
CC neuroprotective; nootropic; anticonvulsant; antialzheimers; vascular;
CC antiparkinsonian; antimicrobial; and vulnerary. (I) and (II) can be used
CC in gene therapy and vaccine production. (I) and (II) can be used in the
CC prevention, diagnosis and treatment of immune disorders (e.g. multiple
CC sclerosis, systemic lupus erythematosus and human immunodeficiency virus

CC (HIV) infections), hyperproliferative disorders (e.g. cancers and
CC Gaucher's disease), cardiovascular diseases (e.g. Scimitar syndrome,
CC Chaga's cardiomyopathy and coronary arteriosclerosis), angiogenic
CC disorders (e.g. corneal graft neovascularisation and diabetic
CC retinopathy), neurological disorders (e.g. Huntington's chorea,
CC Alzheimer's disease and Parkinson's disease), infectious diseases and/or
CC for promoting wound healing, regeneration and/or chemotaxis. ABA83185 to
CC ABA83193 and ABB50300 represent sequences used in the exemplification of
CC the present invention.
XX
SQ Sequence 250 AA;

Query Match 100.0%; Score 1258; DB 22; Length 250;
Best Local Similarity 100.0%; Pred. No. 6.3e-113;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         22 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 81

Qy         61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 141

Qy        121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        142 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 201

Qy        181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
              |||||||||||||||||||||||||||||||||||||||||||||||||
Db        202 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 250
```

RESULT 4
AAU12424
ID AAU12424 standard; Protein; 250 AA.
XX
AC AAU12424;
XX
DT 24-OCT-2001 (first entry)
XX
DE Human PRO1279 polypeptide sequence.
XX
KW Human secretory and transmembrane; PRO; mammalian; cancer; lung;
KW breast; prostate; cervical; tumour necrosis factor-alpha; TNF-alpha;
KW cartilage; ear; proliferation; glucose; free fatty acid; skeletal muscle;
KW adipocyte; A-peptide; factor VIIA; gene therapy.
XX
OS Homo sapiens.
XX
PN WO200140466-A2.
XX
PD 07-JUN-2001.
XX
PF 01-DEC-2000; 2000WO-US32678.
XX
PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 02-DEC-1999; 99WO-US28551.
PR 02-DEC-1999; 99WO-US28564.
PR 02-DEC-1999; 99WO-US28565.
PR 09-DEC-1999; 99US-0170262.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 20-DEC-1999; 99WO-US30999.
PR 30-DEC-1999; 99WO-US31243.
PR 06-JAN-2000; 2000WO-US00277.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 18-FEB-2000; 2000WO-US04342.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 01-MAR-2000; 2000WO-US05601.
PR 20-MAR-2000; 2000WO-US07377.
PR 21-MAR-2000; 2000WO-US07532.
PR 30-MAR-2000; 2000WO-US08439.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 10-NOV-2000; 2000WO-US30873.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2001-408281/43.
DR N-PSDB; AAS21496.
XX
PT Isolated, secretory and transmembrane PRO polypeptide used to detect
PT other PRO polypeptides, link bioactive molecules to cells expressing
PT PRO polypeptides, and detect the presence of mammalian tumours e.g.
PT lung, breast, prostate, cervical -
XX
PS Claim 12; Fig 506; 813pp; English.
XX
CC AAU12172-AAU12446 represent novel human secretory and transmembrane
CC PRO polypeptides. The PRO polypeptides are useful to detect other
CC PRO polypeptides, to link bioactive molecules to cells expressing
CC PRO polypeptides, to modulate biological activities of cells expressing
CC PRO polypeptides, and to detect the presence of mammalian lung, colon,
CC breast, prostate, rectal, cervical or liver tumours by comparing PRO
CC polypeptide expression in a cell sample to that in a control sample.
CC Some of the 275 sequences are also useful to stimulate the release of
CC tumour necrosis factor-alpha (TNF-alpha) from human blood, the
CC proliferation or differentiation of chondrocytes, the proliferation or
CC gene expression in pericyte cells, the release of proteoglycans from
CC cartilage, the proliferation of inner ear utricular supporting cells or
CC of T-lymphocytes, the release of a cytokine from peripheral blood
CC monocytes (PBMCs), or the proliferation of endothelial cells. Some of
CC the PRO polypeptides may modulate glucose or free fatty acid uptake by
CC skeletal muscle cells or by adipocytes; or inhibit binding of A-peptide
CC to factor VIIA. The PRO polypeptides can be used in assays to identify
CC molecules involved in binding interactions. The polynucleotides encoding
CC PRO polypeptides can be used to generate probes, antisense RNA/DNA,
CC transgenic or knock out animals and can be used in gene therapy.
XX
SQ Sequence 250 AA;

Query Match 100.0%; Score 1258; DB 22; Length 250;
Best Local Similarity 100.0%; Pred. No. 6.3e-113;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         22 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 81

Qy         61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 141

Qy        121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        142 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 201

Qy        181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
              |||||||||||||||||||||||||||||||||||||||||||||||||
Db        202 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 250
```

RESULT 5
AAB66139

```
ID   AAB66139 standard; protein; 250 AA.
XX
AC   AAB66139;
XX
DT   02-APR-2001  (first entry)
XX
DE   Protein of the invention #51.
XX
KW   Secreted; transmembrane; gene therapy.
XX
OS   Unidentified.
XX
PN   WO200078961-A1.
XX
PD   28-DEC-2000.
XX
PF   18-FEB-2000; 2000WO-US04342.
XX
PR   23-JUN-1999;   99US-0141037.
PR   20-JUL-1999;   99US-0144758.
PR   26-JUL-1999;   99US-0145698.
PR   01-SEP-1999;   99WO-US20111.
PR   29-OCT-1999;   99US-0162506.
PR   30-NOV-1999;   99WO-US28313.
PR   02-DEC-1999;   99WO-US28551.
PR   16-DEC-1999;   99WO-US30095.
PR   05-JAN-2000; 2000WO-US00219.
PR   06-JAN-2000; 2000WO-US00376.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Botstein D,  Desnoyers L,  Eaton DL,  Ferrara N,  Fong S;
PI   Gao W,  Goddard A,  Godowski PJ,  Grimaldi CJ,  Gurney AL,  Hillan KJ;
PI   Pan J,  Paoni NF,  Roy MA,  Smith V,  Stewart TA,  Tumas D;
PI   Watanabe CK,  Williams PM,  Wood WI;
XX
DR   WPI; 2001-071395/08.
XX
PT   Secreted and transmembrane proteins and nucleic acids designated PRO,
PT   useful as hybridization probes, in chromosome and gene mapping and gene
PT   therapy -
XX
PS   Claim 1; Fig 102; 787pp; English.
XX
CC   The present invention relates to secreted and transmembrane proteins.
CC   These proteins and the DNA encoding them may be used as hybridization
CC   probes, in chromosome and gene mapping and in the generation of
CC   anti-sense RNA and DNA. They may also be used used to generate either
CC   transgenic animals or knockout animals which are in turn useful for
CC   development and screening of therapeutically useful reagents.
CC   The nucleic acids may also be used in gene therapy.
XX
SQ   Sequence   250 AA;

  Query Match           100.0%;  Score 1258;  DB 22;  Length 250;
  Best Local Similarity  100.0%;  Pred. No. 6.3e-113;
  Matches  229;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         22 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 81

Qy         61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 141

Qy        121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        142 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 201

Qy        181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
              |||||||||||||||||||||||||||||||||||||||||||||||||
Db        202 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 250
```

```
RESULT 6
ABG61816
ID   ABG61816 standard; Protein; 250 AA.
XX
AC   ABG61816;
XX
DT   15-AUG-2002  (first entry)
XX
DE   Prostate cancer-associated protein #17.
XX
KW   Prostate cancer; prostate tumour tissue; human; mammal; cytostatic.
XX
OS   Mammalia.
XX
PN   WO200230268-A2.
XX
PD   18-APR-2002.
XX
PF   12-OCT-2001; 2001WO-US32045.
XX
PR   13-OCT-2000; 2000US-0687576.
PR   08-DEC-2000; 2000US-0733288.
PR   08-DEC-2000; 2000US-0733742.
PR   24-JAN-2001; 2001US-263957P.
PR   16-MAR-2001; 2001US-276791P.
PR   16-MAR-2001; 2001US-276888P.
PR   06-APR-2001; 2001US-281922P.
PR   24-APR-2001; 2001US-286214P.
PR   30-APR-2001; 2001US-0847046.
PR   04-MAY-2001; 2001US-288569P.
XX
PA   (EOSB-) EOS BIOTECHNOLOGY INC.
XX
PI   Gish KC,  Mack DH,  Wilson KE,  Afar D,  Hevezi P;
XX
DR   WPI; 2002-471335/50.
DR   N-PSDB; ABK92131.
XX
PT   Detecting a prostate cancer-associated transcript in a cell in a
PT   patient, useful for diagnosing prostate cancer (PC) or screening
PT   modulators of PC, by determining if prostate cancer-associated genes
PT   are expressed in a prostate tissue  -
XX
PS   Claim 27; Page 314; 436pp; English.
XX
CC   The present invention relates to methods of detecting a prostate
CC   cancer-associated transcript in a cell from a patient. The method
CC   comprises contacting a biological sample from the patient with
CC   prostate cancer-associated polynucleotides (designated PC genes) that
CC   selectively hybridise to a sequence that is at least 80% identical
CC   to them. The prostate cancer-associated polynucleotide sequences
CC   are differentially expressed in prostate tumour tissue or in
CC   prostate cancer and are derived from the tissues of various
CC   organisms such as humans or other mammals (e.g. mice, sheep and dogs).
CC   The methods of the invention are useful for diagnosing and treating
CC   prostate cancer in mammals. The prostate cancer-associated genes are
CC   useful for diagnosing or treating prostate cancer, as well as for
CC   identifying modulators of prostate cancer or agents that inhibit
CC   prostate cancer. The nucleic acid sequences are particularly useful
CC   in gene therapy, as a vaccine or in antisense applications.
CC   ABG61800-ABG61944 represent prostate cancer-associated proteins.
XX
SQ   Sequence   250 AA;

  Query Match           100.0%;  Score 1258;  DB 23;  Length 250;
  Best Local Similarity  100.0%;  Pred. No. 6.3e-113;
  Matches  229;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         22 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 81
```

```
Qy          61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 141

Qy         121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         142 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 201

Qy         181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
               |||||||||||||||||||||||||||||||||||||||||||||||||
Db         202 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 250
```

RESULT 7
ABB95526
ID ABB95526 standard; Protein; 250 AA.
XX
AC ABB95526;
XX
DT 19-JUL-2002 (first entry)
XX
DE Human angiogenesis related protein PRO1279 SEQ ID NO: 208.
XX
KW Human; angiogenesis; PRO protein; cardiovascularisation; wound; cancer;
KW atherosclerosis; cardiac hypertrophy; gene therapy; endothelial disorder;
KW cardiant; cytostatic; antiangiogenic; hypotensive; vulnerary;
KW antiarteriosclerotic.
XX
OS Homo sapiens.
XX
PN WO200208284-A2.
XX
PD 31-JAN-2002.
XX
PF 09-JUL-2001; 2001WO-US21735.
XX
PR 20-JUL-2000; 2000US-219556P.
PR 25-JUL-2000; 2000US-220624P.
PR 25-JUL-2000; 2000US-220664P.
PR 28-JUL-2000; 2000WO-US20710.
PR 02-AUG-2000; 2000US-222695P.
PR 17-AUG-2000; 2000US-0643657.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 07-SEP-2000; 2000US-230978P.
PR 15-SEP-2000; 2000US-000000P.
PR 18-SEP-2000; 2000US-0664610.
PR 18-SEP-2000; 2000US-0665350.
PR 24-OCT-2000; 2000US-242922P.
PR 08-NOV-2000; 2000US-0709238.
PR 08-NOV-2000; 2000WO-US30952.
PR 10-NOV-2000; 2000WO-US30873.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000US-0747259.
PR 20-DEC-2000; 2000WO-US34956.
PR 22-JAN-2001; 2001US-0767609.
PR 28-FEB-2001; 2001US-0796498.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-MAR-2001; 2001WO-US06666.
PR 09-MAR-2001; 2001US-0802706.
PR 14-MAR-2001; 2001US-0808689.
PR 22-MAR-2001; 2001US-0816744.
PR 05-APR-2001; 2001US-0828366.
PR 10-MAY-2001; 2001US-0854208.
PR 10-MAY-2001; 2001US-0854280.
PR 25-MAY-2001; 2001US-0866028.
PR 25-MAY-2001; 2001US-0866034.
PR 25-MAY-2001; 2001WO-US17092.
PR 30-MAY-2001; 2001US-0870574.
PR 30-MAY-2001; 2001WO-US17443.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 28-JUN-2001; 2001WO-US00000.
XX
PA (GETH) GENENTECH INC.
PA (BAKE/) BAKER K P.
PA (FERR/) FERRARA N.
PA (GERB/) GERBER H.
PA (GERR/) GERRITSEN M E.
PA (GODD/) GODDARD A.
PA (GODO/) GODOWSKI P J.
PA (GURN/) GURNEY A L.
PA (HILL/) HILLAN K J.
PA (MARS/) MARSTERS S A.
PA (PANJ/) PAN J.
PA (PAON/) PAONI N F.
PA (STEP/) STEPHAN J F.
PA (WATA/) WATANABE C K.
PA (WILL/) WILLIAMS P M.
PA (WOOD/) WOOD W I.
XX
PI Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Paoni NF;
PI Stephan JF, Watanabe CK, Williams PM, Wood WI, Ye W;
XX
DR WPI; 2002-171999/22.
DR N-PSDB; ABL95664.
XX
PT One hundred and eighty seven nucleic acids encoding PRO polypeptides,
PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial
PT infarction), endothelial or angiogenic disorders in a mammal -
XX
PS Claim 11; Fig 208; 567pp; English.
XX
CC The present invention provides the protein and coding sequences of human
CC PRO proteins. These are useful for treating or diagnosing a
CC cardiovascular, endothelial or angiogenic disorder, including cardiac
CC hypertrophy, trauma, cancer, age-related macular degeneration,
CC atherosclerosis, hypertension, arterial restenosis, rheumatoid arthritis,
CC angina, myocardial infarctions, thrombophlebitis, lymphangitis, tumour
CC angiogenesis (such as breast carcinoma and liver carcinoma) and wound
CC healing. The present sequence is a PRO protein of the invention.
XX
SQ Sequence 250 AA;

Query Match 100.0%; Score 1258; DB 23; Length 250;
Best Local Similarity 100.0%; Pred. No. 6.3e-113;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy           1 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          22 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 81

Qy          61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 141

Qy         121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         142 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 201

Qy         181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
               |||||||||||||||||||||||||||||||||||||||||||||||||
Db         202 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 250
```

RESULT 8
ABB84920
ID ABB84920 standard; Protein; 250 AA.
XX
AC ABB84920;
XX
DT 16-MAY-2002 (first entry)
XX
DE Human PRO1279 protein sequence SEQ ID NO:208.

```
XX
KW   Human; angiogenesis; cardiant; cytostatic; antiangiogenic; hypotensive;
KW   vulnerary; antiarteriosclerotic; PRO agonist; PRO antagonist; trauma;
KW   gene therapy; cardiovascular disorder; endothelial disorder; cancer;
KW   angiogenic disorder; cardiac hypertrophy; atherosclerosis; hypertension;
KW   age-related macular degeneration; arterial restenosis; angina;
KW   rheumatoid arthritis; myocardial infarction; thrombophlebitis;
KW   lymphangitis; tumour angiogenesis; breast carcinoma; liver carcinoma;
KW   wound healing; chromosome mapping; gene mapping.
XX
OS   Homo sapiens.
XX
PN   WO200200690-A2.
XX
PD   03-JAN-2002.
XX
PF   20-JUN-2001; 2001WO-US19692.
XX
PR   23-JUN-2000; 2000US-213637P.
PR   20-JUL-2000; 2000US-219556P.
PR   25-JUL-2000; 2000US-220624P.
PR   25-JUL-2000; 2000US-220664P.
PR   28-JUL-2000; 2000WO-US20710.
PR   02-AUG-2000; 2000US-222695P.
PR   17-AUG-2000; 2000US-0643657.
PR   23-AUG-2000; 2000WO-US23522.
PR   24-AUG-2000; 2000WO-US23328.
PR   07-SEP-2000; 2000US-230978P.
PR   18-SEP-2000; 2000US-0664610.
PR   18-SEP-2000; 2000US-0665350.
PR   24-OCT-2000; 2000US-242922P.
PR   08-NOV-2000; 2000US-0709238.
PR   08-NOV-2000; 2000WO-US30952.
PR   10-NOV-2000; 2000WO-US30873.
PR   01-DEC-2000; 2000WO-US32678.
PR   20-DEC-2000; 2000US-0747259.
PR   20-DEC-2000; 2000WO-US34956.
PR   22-JAN-2001; 2001US-0767609.
PR   28-FEB-2001; 2001US-0796498.
PR   28-FEB-2001; 2001WO-US06520.
PR   01-MAR-2001; 2001WO-US06666.
PR   09-MAR-2001; 2001US-0802706.
PR   14-MAR-2001; 2001US-0808689.
PR   22-MAR-2001; 2001US-0816744.
PR   05-APR-2001; 2001US-0828366.
PR   10-MAY-2001; 2001US-0854208.
PR   10-MAY-2001; 2001US-0854280.
PR   25-MAY-2001; 2001US-0866028.
PR   25-MAY-2001; 2001US-0866034.
PR   25-MAY-2001; 2001WO-US17092.
PR   30-MAY-2001; 2001US-0870574.
PR   30-MAY-2001; 2001WO-US17443.
PR   01-JUN-2001; 2001WO-US17800.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;
PI   Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Paoni NF;
PI   Stephan JF, Watanabe CK, Williams PM, Wood WI, Ye W;
XX
DR   WPI; 2002-090516/12.
DR   N-PSDB; ABL88175.
XX
PT   One hundred and eighty seven nucleic acids encoding PRO polypeptides,
PT   useful in diagnosis and treatment of cardiovascular (e.g. myocardial
PT   infarction), endothelial or angiogenic disorders in a mammal -
XX
PS   Claim 11; Fig 208; 565pp; English.
XX
CC   ABL88072 to ABL88258 encode the PRO proteins given in ABB84817 to
CC   ABB85003. The PRO proteins and polynucleotides have cardiant, cytostatic,
CC   antiangiogenic, hypotensive, vulnerary and antiarteriosclerotic
CC   activities, and can be used in gene therapy. The PRO polynucleotides,
CC   proteins, agonists and antagonists are useful for treating or diagnosing
CC   a cardiovascular, endothelial or angiogenic disorder in a mammal,
CC   e.g. cardiac hypertrophy, trauma, cancer, age-related macular
CC   degeneration, atherosclerosis, hypertension, arterial restenosis,
CC   rheumatoid arthritis, angina, myocardial infarctions, thrombophlebitis,
CC   lymphangitis, tumour angiogenesis (such as breast carcinoma and liver
CC   carcinoma) and wound healing. The PRO polynucleotides have applications
CC   in molecular biology, including use as hybridisation probes, and in
CC   chromosome and gene mapping. ABL88259 to ABL88267 represent primers and
CC   probes used in the exemplification of the present invention.
XX
SQ   Sequence   250 AA;

  Query Match           100.0%;  Score 1258;  DB 23;  Length 250;
  Best Local Similarity  100.0%;  Pred. No. 6.3e-113;
  Matches  229;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         22 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 81

Qy         61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 141

Qy        121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        142 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 201

Qy        181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
              |||||||||||||||||||||||||||||||||||||||||||||||||
Db        202 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 250


RESULT 9
AAU83684
ID   AAU83684 standard; Protein; 250 AA.
XX
AC   AAU83684;
XX
DT   08-MAY-2002  (first entry)
XX
DE   Human PRO protein, Seq ID No 186.
XX
KW   Human; secreted protein; PRO; tumour; lung cancer; colon cancer;
KW   breast cancer; prostate tumour; rectal tumour; liver tumour;
KW   pericyte cell proliferation; chondrocyte cell proliferation;
KW   tumour necrosis factor-alpha.
XX
OS   Homo sapiens.
XX
PN   WO200208288-A2.
XX
PD   31-JAN-2002.
XX
PF   29-JUN-2001; 2001WO-US21066.
XX
PR   20-JUL-2000; 2000US-219556P.
PR   25-JUL-2000; 2000US-220585P.
PR   25-JUL-2000; 2000US-220605P.
PR   25-JUL-2000; 2000US-220607P.
PR   25-JUL-2000; 2000US-220624P.
PR   25-JUL-2000; 2000US-220638P.
PR   25-JUL-2000; 2000US-220664P.
PR   25-JUL-2000; 2000US-220666P.
PR   26-JUL-2000; 2000US-220893P.
PR   28-JUL-2000; 2000WO-US20710.
PR   23-AUG-2000; 2000WO-US23522.
PR   24-AUG-2000; 2000WO-US23328.
PR   15-SEP-2000; 2000US-000000P.
PR   10-NOV-2000; 2000WO-US30873.
PR   28-NOV-2000; 2000US-253646P.
PR   01-DEC-2000; 2000WO-US32678.
```

```
PR   20-DEC-2000; 2000US-0747259.
PR   20-DEC-2000; 2000WO-US34956.
PR   28-FEB-2001; 2001WO-US06520.
PR   10-MAY-2001; 2001US-0854280.
PR   25-MAY-2001; 2001WO-US17092.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI   Grimaldi JC, Gurney AL, Smith V, Stephan JP, Watanabe CK, Wood WI;
XX
DR   WPI; 2002-172001/22.
DR   N-PSDB; ABK33628.
XX
PT   One hundred and twenty two nucleic acids encoding PRO polypeptides,
PT   useful for treating a PRO related disorder and for diagnosing tumours
PT   such as lung cancer, colon cancer, breast tumour, prostate tumour, rectal
PT   tumour or liver tumour -
XX
PS   Claim 11; Figure 186; 359pp; English.
XX
CC   The invention relates to one hundred and twenty two nucleic acids
CC   encoding PRO polypeptides. The sequences of the 122 PRO polynucleotides
CC   encode human secreted proteins. The PRO nucleic acids, polypeptides,
CC   agonists and antagonists are useful for treating a PRO related disorder.
CC   The PRO polypeptides are useful for diagnosing tumours, especially lung
CC   cancer, colon cancer, breast tumour, prostate tumour, rectal tumour or
CC   liver tumour. The PRO polypeptides are useful for stimulating the
CC   proliferation of, or gene expression, in pericyte cells, for stimulating
CC   the proliferation or differentiation of chondrocyte cells, for
CC   stimulating the release of tumour necrosis factor-alpha from human blood,
CC   for stimulating or inhibiting the proliferation of normal human dermal
CC   fibroblast cells. The PRO polypeptide may also be used as molecular
CC   weight markers and for tissue typing. The PRO nucleic acids have
CC   applications in molecular biology, including use as hybridisation probes,
CC   and in chromosome and gene mapping. AAU83592-AAU83713 represent human PRO
CC   protein sequences of the invention.
XX
SQ   Sequence   250 AA;

  Query Match             100.0%;  Score 1258;  DB 23;  Length 250;
  Best Local Similarity   100.0%;  Pred. No. 6.3e-113;
  Matches  229;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         22 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 81

Qy         61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 141

Qy        121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        142 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 201

Qy        181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
              |||||||||||||||||||||||||||||||||||||||||||||||||
Db        202 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 250


RESULT 10
ABU66822
ID   ABU66822 standard; Protein; 250 AA.
XX
AC   ABU66822;
XX
DT   23-MAY-2003  (first entry)
XX
DE   Human PRO polypeptide #253.
XX
KW   Human; PRO polypeptide; secreted and transmembrane protein;
KW   tumour necrosis factor-alpha; TNF-alpha; blood; proliferation;
KW   differentiation; chondrocyte; tumour; genetic disorder;
KW   cytostatic.
XX
OS   Homo sapiens.
XX
PN   US2003036180-A1.
XX
PD   20-FEB-2003.
XX
PF   09-MAY-2002; 2002US-0143114.
XX
PR   31-MAR-1997;   97WO-US05230.
PR   12-JUN-1998;   98WO-US12456.
PR   14-JUL-1998;   98WO-US14552.
PR   28-AUG-1998;   98WO-US17888.
PR   10-SEP-1998;   98WO-US18824.
PR   14-SEP-1998;   98WO-US19093.
PR   14-SEP-1998;   98WO-US19094.
PR   14-SEP-1998;   98WO-US19177.
PR   16-SEP-1998;   98WO-US19330.
PR   17-SEP-1998;   98WO-US19437.
PR   07-OCT-1998;   98WO-US21141.
PR   29-OCT-1998;   98WO-US22991.
PR   29-OCT-1998;   98WO-US22992.
PR   20-NOV-1998;   98WO-US24855.
PR   01-DEC-1998;   98WO-US25108.
PR   05-JAN-1999;   99WO-US00106.
PR   08-MAR-1999;   99WO-US05028.
PR   10-MAR-1999;   99WO-US05190.
PR   20-APR-1999;   99WO-US08615.
PR   14-MAY-1999;   99WO-US10733.
PR   02-JUN-1999;   99WO-US12252.
PR   01-SEP-1999;   99WO-US20111.
PR   08-SEP-1999;   99WO-US20594.
PR   13-SEP-1999;   99WO-US20944.
PR   15-SEP-1999;   99WO-US21090.
PR   15-SEP-1999;   99WO-US21547.
PR   05-OCT-1999;   99WO-US23089.
PR   29-NOV-1999;   99WO-US28214.
PR   30-NOV-1999;   99WO-US28313.
PR   30-NOV-1999;   99WO-US28409.
PR   01-DEC-1999;   99WO-US28301.
PR   01-DEC-1999;   99WO-US28634.
PR   02-DEC-1999;   99WO-US28551.
PR   02-DEC-1999;   99WO-US28564.
PR   02-DEC-1999;   99WO-US28565.
PR   16-DEC-1999;   99WO-US30095.
PR   20-DEC-1999;   99WO-US30911.
PR   20-DEC-1999;   99WO-US30999.
PR   22-DEC-1999;   99WO-US30720.
PR   30-DEC-1999;   99WO-US31243.
PR   30-DEC-1999;   99WO-US31274.
PR   05-JAN-2000; 2000WO-US00219.
PR   06-JAN-2000; 2000WO-US00277.
PR   06-JAN-2000; 2000WO-US00376.
PR   11-FEB-2000; 2000WO-US03565.
PR   18-FEB-2000; 2000WO-US04341.
PR   18-FEB-2000; 2000WO-US04342.
PR   22-FEB-2000; 2000WO-US04414.
PR   24-FEB-2000; 2000WO-US04914.
PR   24-FEB-2000; 2000WO-US05004.
PR   01-MAR-2000; 2000WO-US05601.
PR   02-MAR-2000; 2000WO-US05746.
PR   02-MAR-2000; 2000WO-US05841.
PR   10-MAR-2000; 2000WO-US06319.
PR   15-MAR-2000; 2000WO-US06884.
PR   20-MAR-2000; 2000WO-US07377.
PR   21-MAR-2000; 2000WO-US07532.
PR   30-MAR-2000; 2000WO-US08439.
PR   17-MAY-2000; 2000WO-US13705.
PR   22-MAY-2000; 2000WO-US14042.
PR   30-MAY-2000; 2000WO-US14941.
PR   02-JUN-2000; 2000WO-US15264.
```

PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 10-NOV-2000; 2000WO-US30873.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-MAR-2001; 2001WO-US06666.
PR 25-MAY-2001; 2001WO-US17092.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 22-JUN-2001; 2001WO-US20116.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 20-DEC-2000; 2000US-0747259.
PR 28-FEB-2001; 2001US-0796498.
PR 09-MAR-2001; 2001US-0802706.
PR 14-MAR-2001; 2001US-0808689.
PR 22-MAR-2001; 2001US-0816744.
PR 05-APR-2001; 2001US-0828366.
PR 10-MAY-2001; 2001US-0854208.
PR 10-MAY-2001; 2001US-0854280.
PR 18-MAY-2001; 2001US-0860216.
PR 25-MAY-2001; 2001US-0866028.
PR 25-MAY-2001; 2001US-0866034.
PR 01-JUN-2001; 2001US-0872035.
PR 05-JUN-2001; 2001US-0874503.
PR 14-JUN-2001; 2001US-0882636.
PR 19-JUN-2001; 2001US-0886342.
PR 21-JUN-2001; 2001US-0887879.
PR 18-JUL-2001; 2001US-0908827.
PR 06-AUG-2001; 2001US-0924419.
PR 09-AUG-2001; 2001US-0927796.
PR 16-AUG-2001; 2001US-0931836.
PR 19-DEC-2001; 2001US-0028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-332040/31.
DR N-PSDB; ACA03855.
XX
PT New secreted and transmembrane PRO nucleic acids, useful for gene
PT therapy, in chromosome and gene mapping, as chromosome markers, in
PT tissue typing, and in chromosome identification -
XX
PS Claim 12; Fig 506; 660pp; English.
XX
CC The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The
CC PRO polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides are useful for detecting other PRO polypeptides, for
CC linking bioactive molecules to cells expressing PRO polypeptides,
CC for modulating biological activities of cells expressing PRO
CC polypeptides, and for for identifying agonists or antagonists.
CC The PRO polypeptides are useful for for stimulating the release of
CC tumour necrosis factor (TNF)-alpha from human blood, for stimulating
CC the proliferation or differentiation of chondrocytes, and detecting the
CC presence of tumours. The polynucleotide sequences encoding PRO
CC polypeptides are useful as hybridisation probes, in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptides, for generating transgenic animals or
CC knockout animals, for the genetic analysis of individuals with genetic
CC disorders, and in gene therapy. ABU66570-ABU66844 represent the human
CC PRO polypeptides of the invention.
CC Note: The sequence data for this patent was obtained in electronic
CC format directly from the USPTO web site at
CC seqdata.uspto.gov/psipsDIDEntry.html.

XX
SQ Sequence 250 AA;

Query Match 100.0%; Score 1258; DB 24; Length 250;
Best Local Similarity 100.0%; Pred. No. 6.3e-113;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         22 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 81

Qy         61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 141

Qy        121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        142 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 201

Qy        181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
              |||||||||||||||||||||||||||||||||||||||||||||||||
Db        202 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 250
```

RESULT 11
ABU67098
ID ABU67098 standard; Protein; 250 AA.
XX
AC ABU67098;
XX
DT 27-MAY-2003 (first entry)
XX
DE Human secreted/transmembrane, PRO, protein SEQ ID 506.
XX
KW Human; secreted protein; transmembrane protein; PRO;
KW inflammatory disease; organ failure; atherosclerosis; cardiac injury;
KW infertility; birth defects; premature aging; AIDS; biosensor;
KW acquired immunodeficiency syndrome; cancer; diabetic complication;
KW bioreactor; tumour.
XX
OS Homo sapiens.
XX
PN US2003032155-A1.
XX
PD 13-FEB-2003.
XX
PF 03-MAY-2002; 2002US-0137865.
XX
PR 31-MAR-1997; 97WO-US05230.
PR 12-JUN-1998; 98WO-US12456.
PR 14-JUL-1998; 98WO-US14552.
PR 28-AUG-1998; 98WO-US17888.
PR 10-SEP-1998; 98WO-US18824.
PR 14-SEP-1998; 98WO-US19093.
PR 14-SEP-1998; 98WO-US19094.
PR 14-SEP-1998; 98WO-US19177.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 29-OCT-1998; 98WO-US22991.
PR 29-OCT-1998; 98WO-US22992.
PR 20-NOV-1998; 98WO-US24855.
PR 01-DEC-1998; 98WO-US25108.
PR 05-JAN-1999; 99WO-US00106.
PR 08-MAR-1999; 99WO-US05028.
PR 10-MAR-1999; 99WO-US05190.
PR 20-APR-1999; 99WO-US08615.
PR 14-MAY-1999; 99WO-US10733.
PR 02-JUN-1999; 99WO-US12252.
PR 01-SEP-1999; 99WO-US20111.
PR 08-SEP-1999; 99WO-US20594.
PR 13-SEP-1999; 99WO-US20944.
PR 15-SEP-1999; 99WO-US21090.

PR 15-SEP-1999; 99WO-US21547.
PR 05-OCT-1999; 99WO-US23089.
PR 29-NOV-1999; 99WO-US28214.
PR 30-NOV-1999; 99WO-US28313.
PR 30-NOV-1999; 99WO-US28409.
PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 02-DEC-1999; 99WO-US28551.
PR 02-DEC-1999; 99WO-US28564.
PR 02-DEC-1999; 99WO-US28565.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 20-DEC-1999; 99WO-US30999.
PR 22-DEC-1999; 99WO-US30720.
PR 30-DEC-1999; 99WO-US31243.
PR 30-DEC-1999; 99WO-US31274.
PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00277.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 18-FEB-2000; 2000WO-US04342.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 01-MAR-2000; 2000WO-US05601.
PR 02-MAR-2000; 2000WO-US05746.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 21-MAR-2000; 2000WO-US07532.
PR 30-MAR-2000; 2000WO-US08439.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 10-NOV-2000; 2000WO-US30873.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-MAR-2001; 2001WO-US06666.
PR 25-MAY-2001; 2001WO-US17092.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 22-JUN-2001; 2001WO-US20116.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 20-DEC-2000; 2000US-0747259.
PR 28-FEB-2001; 2001US-0796498.
PR 09-MAR-2001; 2001US-0802706.
PR 14-MAR-2001; 2001US-0808689.
PR 22-MAR-2001; 2001US-0816744.
PR 05-APR-2001; 2001US-0828366.
PR 10-MAY-2001; 2001US-0854208.
PR 10-MAY-2001; 2001US-0854280.
PR 18-MAY-2001; 2001US-0860216.
PR 25-MAY-2001; 2001US-0866028.
PR 25-MAY-2001; 2001US-0866034.
PR 01-JUN-2001; 2001US-0872035.
PR 05-JUN-2001; 2001US-0874503.
PR 14-JUN-2001; 2001US-0882636.
PR 19-JUN-2001; 2001US-0886342.
PR 21-JUN-2001; 2001US-0887879.
PR 18-JUL-2001; 2001US-0908827.
PR 06-AUG-2001; 2001US-0924419.
PR 09-AUG-2001; 2001US-0927796.
PR 16-AUG-2001; 2001US-0931836.
PR 19-DEC-2001; 2001US-0028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-331925/31.
DR N-PSDB; ACA04276.
XX
PT New secreted and transmembrane nucleic acids and polypeptides,
PT designated as PRO, useful for treating inflammation, organ failure,
PT atherosclerosis, cardiac injury, infertility, birth defects, premature
PT aging, AIDS, or cancer -
XX
PS Claim 12; Fig 506; 659pp; English.
XX
CC The invention relates to an isolated nucleic acid comprising, or which is
CC at least 80% identical to, or the full-length coding sequence of, any of
CC the 275 nucleotide sequences, encoding the corresponding PRO polypeptide
CC (one of 275 secreted or transmembrane proteins). The nucleic acid
CC further comprises the full-length coding sequence of the DNA deposited
CC under American Type Culture Collection (ATCC) accession number in a list
CC given in the specification. Also included are vectors and host
CC cells for producing PRO proteins, PRO fusion proteins, anti-PRO
CC antibodies, PRO extracellular domains and mature sequences, methods
CC of detecting PRO proteins, methods for stimulating the release of
CC TNF-alpha (tumour necrosis factor alpha) from human blood,
CC (and the proliferation of differentiation of chondrocyte cells, the
CC proliferation of, or gene expression in pericyte cells, the release or
CC proteoglycans from cartilage, proliferation of inner ear urticular
CC supporting cells, the proliferation of T-lymphocyte cells, the release
CC of a cytokine from peripheral blood mononuclear cells (PBMC), or the
CC proliferation of endothelial cells), a method for modulating the uptake
CC of glucose or free fatty acid (FFA) by skeletal muscle cells,
CC a method for inhibiting the binding of A-peptide to factor VIIA,
CC or the differentiation of adipocyte cells, a method for detecting the
CC presence of a tumour in a mammal and an oligonucleotide probe derived
CC from any of the nucleotide sequences cited above. The nucleic acids and
CC polypeptides are useful for treating inflammatory diseases, organ
CC failure, atherosclerosis, cardiac injury, infertility, birth defects,
CC premature aging, AIDS (acquired immunodeficiency syndrome), cancer, or
CC diabetic complications. The nucleic acids are useful as hybridisation
CC probes, in chromosome and gene mapping, and in generating antisense RNA
CC or DNA. The polypeptides are useful as pharmaceuticals, diagnostics,
CC biosensors or bioreactors. Both are useful in tissue typing.
CC The present sequence represents a PRO protein of the invention.
XX
SQ Sequence 250 AA;

Query Match 100.0%; Score 1258; DB 24; Length 250;
Best Local Similarity 100.0%; Pred. No. 6.3e-113;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 IIKGPECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         22 IIKGPECKPHSQPWQAALFEKTRLLCGATLIAPRNLLTAAHCLKPRYIVHLGQHNLQKEE 81

Qy         61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 141

Qy        121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        142 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 201

Qy        181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
              |||||||||||||||||||||||||||||||||||||||||||||||||
Db        202 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 250
```

RESULT 12

ABU59903
ID ABU59903 standard; Protein; 250 AA.
XX
AC ABU59903;
XX
DT 13-MAY-2003 (first entry)
XX
DE Novel secreted and transmembrane protein PRO1279.
XX
KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW cardiac insufficiency disorder; cancer; tumour; immune response;
KW adrenal cortical capillary endothelial growth; c-fos induction;
KW vascular endothelial growth factor inhibition; VEGF inhibition;
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW retinal neurons cell survival; rod photoreceptor cell survival;
KW retinal disorder; retinitis pigmentosum; kidney disorder;
KW mammalian kidney mesangial cell proliferation; Berger disease;
KW dermatitis; herpetiformis; Crohn's disease; chondrocyte proliferation;
KW chondrocyte redifferentiation; sports injury; arthritis.
XX
OS Homo sapiens.
XX
PN US2003017563-A1.
XX
PD 23-JAN-2003.
XX
PF 07-MAY-2002; 2002US-0140808.
XX
PR 31-MAR-1997; 97WO-US05230.
PR 12-JUN-1998; 98WO-US12456.
PR 14-JUL-1998; 98WO-US14552.
PR 28-AUG-1998; 98WO-US17888.
PR 10-SEP-1998; 98WO-US18824.
PR 14-SEP-1998; 98WO-US19093.
PR 14-SEP-1998; 98WO-US19094.
PR 14-SEP-1998; 98WO-US19177.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 29-OCT-1998; 98WO-US22991.
PR 29-OCT-1998; 98WO-US22992.
PR 20-NOV-1998; 98WO-US24855.
PR 01-DEC-1998; 98WO-US25108.
PR 05-JAN-1999; 99WO-US00106.
PR 08-MAR-1999; 99WO-US05028.
PR 10-MAR-1999; 99WO-US05190.
PR 20-APR-1999; 99WO-US08615.
PR 14-MAY-1999; 99WO-US10733.
PR 02-JUN-1999; 99WO-US12252.
PR 01-SEP-1999; 99WO-US20111.
PR 08-SEP-1999; 99WO-US20594.
PR 13-SEP-1999; 99WO-US20944.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 05-OCT-1999; 99WO-US23089.
PR 29-NOV-1999; 99WO-US28214.
PR 30-NOV-1999; 99WO-US28313.
PR 30-NOV-1999; 99WO-US28409.
PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 02-DEC-1999; 99WO-US28551.
PR 02-DEC-1999; 99WO-US28564.
PR 02-DEC-1999; 99WO-US28565.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 20-DEC-1999; 99WO-US30999.
PR 22-DEC-1999; 99WO-US30720.
PR 30-DEC-1999; 99WO-US31243.
PR 30-DEC-1999; 99WO-US31274.
PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00277.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 18-FEB-2000; 2000WO-US04342.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 01-MAR-2000; 2000WO-US05601.
PR 02-MAR-2000; 2000WO-US05746.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 21-MAR-2000; 2000WO-US07532.
PR 30-MAR-2000; 2000WO-US08439.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 10-NOV-2000; 2000WO-US30873.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-MAR-2001; 2001WO-US06666.
PR 25-MAY-2001; 2001WO-US17092.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 22-JUN-2001; 2001WO-US20116.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 20-DEC-2000; 2000US-0747259.
PR 28-FEB-2001; 2001US-0796498.
PR 09-MAR-2001; 2001US-0802706.
PR 14-MAR-2001; 2001US-0808689.
PR 22-MAR-2001; 2001US-0816744.
PR 05-APR-2001; 2001US-0828366.
PR 10-MAY-2001; 2001US-0854208.
PR 10-MAY-2001; 2001US-0854280.
PR 18-MAY-2001; 2001US-0860216.
PR 25-MAY-2001; 2001US-0866028.
PR 25-MAY-2001; 2001US-0866034.
PR 01-JUN-2001; 2001US-0872035.
PR 05-JUN-2001; 2001US-0874503.
PR 14-JUN-2001; 2001US-0882636.
PR 19-JUN-2001; 2001US-0886342.
PR 21-JUN-2001; 2001US-0887879.
PR 18-JUL-2001; 2001US-0908827.
PR 06-AUG-2001; 2001US-0924419.
PR 09-AUG-2001; 2001US-0927796.
PR 16-AUG-2001; 2001US-0931836.
PR 19-DEC-2001; 2001US-0028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-148238/14.
DR N-PSDB; ABX89393.
XX
PT Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346
PT and PRO1375, which stimulate proliferation of stimulated T-lymphocytes
PT are therapeutically useful for enhancing immune response and in cancer
PT treatments -
XX
PS Claim 12; Fig 506; 659pp; English.
XX
CC The invention describes an isolated human PRO polypeptide. The PRO
CC polypeptides are useful in detecting PRO polypeptides in a sample, in

CC linking a bioactive molecule to a cell expressing a PRO polypeptide, and
CC in modulating at least one biological activity of a cell expressing a PRO
CC polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus
CC useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186
CC stimulate adrenal cortical capillary endothelial growth, and PRO536,
CC PRO943, PRO828, PRO826, PRO1068 or PRO535, PRO826, PRO819, PRO1126,
CC PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus
CC useful for treating conditions or disorders where angiogenesis would be
CC beneficial, e.g. wound healing and antagonist of this polypeptide are
CC useful for treating cancerous tumours. PRO812 inhibits vascular
CC endothelial growth factor (VEGF) stimulated proliferation of endothelial
CC cells and is thus useful for inhibiting endothelial cell growth in
CC mammals which would be beneficial in inhibiting tumour growth. PRO826,
CC PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of
CC stimulated T-lymphocytes and are therapeutically useful for enhancing
CC immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of
CC retinal neurons cells (PRO1132 is also enhances survival/proliferation of
CC rod photoreceptor cells) and therefore are useful for treating retinal
CC disorders of injuries, e.g. retinitis pigmentosum, AMD. PRO819, PRO813
CC and PRO11066 induce proliferation of mammalian kidney mesangial cells,
CC and therefore are useful for treating kidney disorders associated with
CC decreased mesangial cell function such as Berger disease or other
CC nephropathies associated with dermatitis, herpetiformis or Crohn's
CC disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the
CC proliferation and/or redifferentiation of chondrocytes in culture and
CC are thus useful for treating sports injuries, and arthritis. This
CC is the amino acid sequence of a novel human PRO protein.
XX
SQ Sequence 250 AA;

Query Match 100.0%; Score 1258; DB 24; Length 250;
Best Local Similarity 100.0%; Pred. No. 6.3e-113;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         22 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 81

Qy         61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 141

Qy        121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        142 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 201

Qy        181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
              |||||||||||||||||||||||||||||||||||||||||||||||||
Db        202 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 250
```

RESULT 13
ABU56739
ID ABU56739 standard; Protein; 250 AA.
XX
AC ABU56739;
XX
DT 02-APR-2003 (first entry)
XX
DE Lung cancer-associated polypeptide #332.
XX
KW Lung cancer-associated polypeptide; cytostatic; emphysema;
KW antiinflammatory; antiasthmatic; non-small cell lung cancer; atelectasis;
KW small cell lung cancer; benign lesion; precancerous lesion; bronchitis;
KW chronic obstructive pulmonary disease; hypersensitivity pneumonitis;
KW interstitial pulmonary fibrosis; fibrosis; asthma; bronchiectasis.
XX
OS Unidentified.
XX
PN WO200286443-A2.
XX
PD 31-OCT-2002.
XX
PF 18-APR-2002; 2002WO-US12476.
XX
PR 18-APR-2001; 2001US-284770P.
PR 10-MAY-2001; 2001US-290492P.
PR 09-NOV-2001; 2001US-339245P.
PR 13-NOV-2001; 2001US-350656P.
PR 29-NOV-2001; 2001US-334370P.
PR 12-APR-2002; 2002US-372246P.
XX
PA (EOSB-) EOS BIOTECHNOLOGY INC.
XX
PI Aziz N, Murray R;
XX
DR WPI; 2003-093161/08.
DR N-PSDB; ABX76468.
XX
PT Detecting a lung cancer-associated transcript in a cell from a patient
PT for treating lung cancer, by contacting a biological sample from the
PT patient with a polynucleotide that exhibits increased or decreased
PT expression in lung cancer -
XX
PS Claim 27; Page 443-444; 453pp; English.
XX
CC The invention relates to a method for detecting a lung cancer-associated
CC transcript in a cell from a patient, comprising contacting a biological
CC sample from the patient with a polynucleotide that selectively hybridises
CC to a sequence that is at least 80 % identical to a gene that exhibits
CC increased or decreased expression in lung cancer samples. Lung
CC cancer-associated polynucleotides and polypeptides are used for
CC identifying a compound that modulates a lung cancer-associated
CC polypeptide, for inhibiting proliferation of a lung cancer-associated
CC cell to treat lung cancer in a patient and for treating a mammal having
CC lung cancer by administering a modulatory compound identified. The
CC methods are useful for treating lung cancer, such as small cell lung
CC cancer, non-small cell lung cancer or other benign or precancerous
CC lesions, e.g. atelectasis, emphysema, bronchitis, chronic obstructive
CC pulmonary disease, fibrosis, hypersensitivity pneumonitis, interstitial
CC pulmonary fibrosis, asthma and bronchiectasis. The genes, polynucleotides
CC and polypeptides are useful for diagnostic purposes and as targets for
CC screening for therapeutic compounds that modulate lung cancer, such as
CC antibodies. Sequences ABU56408-ABU56745 represent lung cancer-associated
CC polypeptides of the invention.
XX
SQ Sequence 250 AA;

Query Match 100.0%; Score 1258; DB 24; Length 250;
Best Local Similarity 100.0%; Pred. No. 6.3e-113;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         22 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 81

Qy         61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 141

Qy        121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        142 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 201

Qy        181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
              |||||||||||||||||||||||||||||||||||||||||||||||||
Db        202 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 250
```

RESULT 14
AAY42439
ID AAY42439 standard; Protein; 282 AA.
XX
AC AAY42439;
XX
DT 08-DEC-1999 (first entry)

XX
DE CASB12 amino acid sequence.
XX
KW neuropsin; cancer; assay; inhibitor; serine protease; immunogenic;
KW autoimmune disease.
XX
OS Homo sapiens.
XX
PN WO9949055-A1.
XX
PD 30-SEP-1999.
XX
PF 17-MAR-1999; 99WO-EP01894.
XX
PR 20-MAR-1998; 98GB-0006095.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals-bassols C;
XX
DR WPI; 1999-580450/49.
DR N-PSDB; AAZ22638.
XX
PT New human serine protease CASB12, for treatment, prevention and
PT diagnosis of cancer and autoimmune diseases -
XX
PS Claim 3; Page 48; 58pp; English.
XX
CC This is the amino acid sequence of the CASB12 protein. The nucleotide
CC sequence of AAZ22638 shows homology with neuropsin and the encoded
CC protein AAY42439 is structurally related to other proteins of the
CC serine protease family, having homology and/or structural similarity
CC with neuropsin. It is expected that as well as similar structure, these
CC proteins will also share similar biological functions and properties.
CC The CASB12 polypeptides and polynucleotides can be used to develop
CC methods for identifying agonists and antagonists/inhibitors of these
CC molecules, and thereby treating conditions associated with CASB12
CC polypeptide imbalance. The invention also provides for diagnostic assays
CC for detecting diseases associated with inappropriate CASB12 polypeptide
CC activity or levels.
CC Since CASB12 is either specifically expressed or highly over-expressed
CC in tumors compared to normal cells, the polypeptides and polynucleotides
CC of the invention are believed to be important immunogens for specific
CC prophylactic or therapeutic immunization against tumors. The
CC polypeptides and polynucleotides can therefore be targeted by antigen
CC specific immune reactions (which result in the destruction of the tumor
CC cell) or they can be used to diagnose the occurrence of tumor cells
XX
SQ Sequence 282 AA;

Query Match 100.0%; Score 1258; DB 20; Length 282;
Best Local Similarity 100.0%; Pred. No. 7.4e-113;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         54 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 113

Qy         61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        114 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 173

Qy        121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        174 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 233

Qy        181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
              |||||||||||||||||||||||||||||||||||||||||||||||||
Db        234 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 282
```

RESULT 15
AAB11712

ID AAB11712 standard; Protein; 282 AA.
XX
AC AAB11712;
XX
DT 23-OCT-2000 (first entry)
XX
DE Human serine protease BSSP6 (hBSSP6) SEQ ID NO:2.
XX
KW BSSP6; serine protease; human; hBSSP6; mouse; mBSSP6; brain;
KW diagnostic marker; antibody; transgenic animal; Alzheimer's disease;
KW epilepsy; cancer; inflammation; infertility; pancreatitis;
KW prostatic hypertrophy.
XX
OS Homo sapiens.
XX
PN WO200031257-A1.
XX
PD 02-JUN-2000.
XX
PF 19-NOV-1999; 99WO-JP06476.
XX
PR 20-NOV-1998; 98JP-0347802.
XX
PA (FUSO) FUSO PHARM IND LTD.
XX
PI Uemura H, Okui A, Kominami K, Yamaguchi N, Mitsui S;
XX
DR WPI; 2000-400067/34.
DR N-PSDB; AAA61763.
XX
PT Serine protease BSSP6, useful in detecting homologs, mutants and
PT polymorphic variants as markers for diagnosis of Alzheimer's disease,
PT epilepsy, cancer, inflammation, infertility and prostate hypertrophy,
PT using blood or other tissues -
XX
PS Claim 1; Page 69-70; 94pp; Japanese.
XX
CC The invention relates to novel serine proteases designated BSSP6
CC (AAB11712-B11714), and to nucleic acids encoding them (AAA61763-A61765).
CC The invention also relates to vectors and transformants comprising BSSP6
CC nucleic acids; transgenic animals in which the expression level of BSSP6
CC can be varied; and an mBSSP6 knockout mouse. The invention additionally
CC encompasses anti-BSSP6 antibodies and methods of production of such
CC antibodies, methods of BSSP6 detection using the antibodies, and the
CC use of BSSP6 proteins or fragments as diagnostic markers for certain
CC medical conditions. Nucleotides encoding BSSP6 were initially
CC isolated in a human brain cDNA library using degenerate PCR primers
CC (AAA61795-A61796) based on conserved regions of serine proteases. The
CC BSSP6 serine proteases and nucleotides encoding them are useful in
CC detecting homologues, mutants and polymorphic variants in biological
CC samples (e.g., blood, urine, brain, prostate gland, placenta, testis
CC and spleen) as diagnostic markers for conditions such as Alzheimer's
CC disease, epilepsy, cancer, inflammation, infertility and prostatic
CC hypertrophy. Sequences AAB11712 and AAB11714 represent human BSSP6
CC variants (hBSSP6), and sequence AAB11713 represents murine BSSP6
CC (mBSSP6).
XX
SQ Sequence 282 AA;

Query Match 100.0%; Score 1258; DB 21; Length 282;
Best Local Similarity 100.0%; Pred. No. 7.4e-113;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 IIKGFECKPHSQPWQAALPEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         54 IIKGFECKPHSQPWQAALPEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 113

Qy         61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        114 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 173

Qy        121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db        174 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 233

Qy        181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
              ||||||||||||||||||||||||||||||||||||||||||||||||||
Db        234 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 282
```

Search completed: October 22, 2003, 15:51:34
Job time : 35.0587 secs

GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: October 22, 2003, 15:50:17 ; Search time 21.9589 Seconds
(without alignments)
1746.375 Million cell updates/sec

Title: US-09-856-320A-2_COPY_54_282
Perfect score: 1258
Sequence: 1 IIKGPECKPHSQPWQAALFE.....GVYTKVCKYVDWIQETMKNN 229

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 629382 seqs, 167460630 residues

Total number of hits satisfying chosen parameters: 629382

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published_Applications_AA:*
1: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pep:*
2: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pep:*
3: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep:*
4: /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pep:*
5: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep:*
6: /cgn2_6/ptodata/2/pubpaa/PCTUS_PUBCOMB.pep:*
7: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep:*
8: /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pep:*
9: /cgn2_6/ptodata/2/pubpaa/US09A_PUBCOMB.pep:*
10: /cgn2_6/ptodata/2/pubpaa/US09B_PUBCOMB.pep:*
11: /cgn2_6/ptodata/2/pubpaa/US09C_PUBCOMB.pep:*
12: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pep:*
13: /cgn2_6/ptodata/2/pubpaa/US10A_PUBCOMB.pep:*
14: /cgn2_6/ptodata/2/pubpaa/US10B_PUBCOMB.pep:*
15: /cgn2_6/ptodata/2/pubpaa/US10C_PUBCOMB.pep:*
16: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep:*
17: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep:*
18: /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	1258	100.0	250	11	US-09-946-374-170	Sequence 170, App
2	1258	100.0	250	12	US-10-015-387A-170	Sequence 170, App
3	1258	100.0	250	12	US-10-137-870-506	Sequence 506, App
4	1258	100.0	250	12	US-10-140-018-506	Sequence 506, App
5	1258	100.0	250	12	US-10-140-021-506	Sequence 506, App
6	1258	100.0	250	12	US-10-140-274-506	Sequence 506, App
7	1258	100.0	250	12	US-10-140-471-506	Sequence 506, App
8	1258	100.0	250	12	US-10-140-807-506	Sequence 506, App
9	1258	100.0	250	12	US-10-140-922-506	Sequence 506, App
10	1258	100.0	250	12	US-10-140-924-506	Sequence 506, App
11	1258	100.0	250	12	US-10-140-926-506	Sequence 506, App
12	1258	100.0	250	12	US-10-141-698-506	Sequence 506, App
13	1258	100.0	250	12	US-10-141-702-506	Sequence 506, App
14	1258	100.0	250	12	US-10-141-704-506	Sequence 506, App
15	1258	100.0	250	12	US-10-142-421-506	Sequence 506, App
16	1258	100.0	250	12	US-10-142-432-506	Sequence 506, App
17	1258	100.0	250	12	US-10-142-767-506	Sequence 506, App
18	1258	100.0	250	12	US-10-143-033-506	Sequence 506, App
19	1258	100.0	250	12	US-10-144-994-506	Sequence 506, App
20	1258	100.0	250	12	US-10-145-628-506	Sequence 506, App
21	1258	100.0	250	12	US-10-145-631-506	Sequence 506, App
22	1258	100.0	250	12	US-10-145-633-506	Sequence 506, App
23	1258	100.0	250	12	US-10-145-746-506	Sequence 506, App
24	1258	100.0	250	12	US-10-145-748-506	Sequence 506, App
25	1258	100.0	250	12	US-10-145-823-506	Sequence 506, App
26	1258	100.0	250	12	US-10-145-826-506	Sequence 506, App
27	1258	100.0	250	12	US-10-145-870-506	Sequence 506, App
28	1258	100.0	250	12	US-10-145-876-506	Sequence 506, App
29	1258	100.0	250	12	US-10-145-959-506	Sequence 506, App
30	1258	100.0	250	12	US-10-146-724-506	Sequence 506, App
31	1258	100.0	250	12	US-10-146-725-506	Sequence 506, App
32	1258	100.0	250	12	US-10-146-795-506	Sequence 506, App
33	1258	100.0	250	12	US-10-147-495-506	Sequence 506, App
34	1258	100.0	250	12	US-10-147-501-506	Sequence 506, App
35	1258	100.0	250	12	US-10-147-504-506	Sequence 506, App
36	1258	100.0	250	12	US-10-147-506-506	Sequence 506, App
37	1258	100.0	250	12	US-10-147-509-506	Sequence 506, App
38	1258	100.0	250	12	US-10-147-510-506	Sequence 506, App
39	1258	100.0	250	12	US-10-147-511-506	Sequence 506, App
40	1258	100.0	250	12	US-10-147-529-506	Sequence 506, App
41	1258	100.0	250	12	US-10-152-397-506	Sequence 506, App
42	1258	100.0	250	12	US-10-153-586-506	Sequence 506, App
43	1258	100.0	250	12	US-10-158-783-506	Sequence 506, App
44	1258	100.0	250	12	US-10-158-786-506	Sequence 506, App
45	1258	100.0	250	12	US-10-006-130A-170	Sequence 170, App

ALIGNMENTS

RESULT 1
US-09-946-374-170
; Sequence 170, Application US/09946374
; Publication No. US20030073129A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C1
; CURRENT APPLICATION NUMBER: US/09/946,374
; CURRENT FILING DATE: 2001-09-04
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750

; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099602
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099642
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099741
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099754
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099763
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099792
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099808
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099815
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099815
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100388
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100584
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100661
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100662
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100664
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100683
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100684
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100710
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100711
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100849
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100930
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101014
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101068
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101071
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101279
; PRIOR FILING DATE: 1998-09-22
; PRIOR APPLICATION NUMBER: 60/101471
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101472
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101474
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101475
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101476
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101479
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101743
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101915
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/102207
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102240
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102307
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102330
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102331
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102484
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102487
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102570
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102571
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102684
; PRIOR FILING DATE: 1998-10-01
; PRIOR APPLICATION NUMBER: 60/102687
; PRIOR FILING DATE: 1998-10-01
; PRIOR APPLICATION NUMBER: 60/102965
; PRIOR FILING DATE: 1998-10-02
; PRIOR APPLICATION NUMBER: 60/103258
; PRIOR FILING DATE: 1998-10-06
; PRIOR APPLICATION NUMBER: 60/103314
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103315
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103328
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103395
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103396
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103401
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103449
; PRIOR FILING DATE: 1998-10-06
; PRIOR APPLICATION NUMBER: 60/103633
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103678
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103679
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103711
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/104257

; PRIOR FILING DATE: 1998-10-14
; PRIOR APPLICATION NUMBER: 60/104987
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105000
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105002
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105104
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/105169
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105266
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105693
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105694
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105807

Query Match 100.0%; Score 1258; DB 11; Length 250;
Best Local Similarity 100.0%; Pred. No. 1.4e-118;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         22 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 81

Qy         61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 141

Qy        121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        142 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 201

Qy        181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
              |||||||||||||||||||||||||||||||||||||||||||||||||
Db        202 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 250
```

RESULT 2
US-10-015-387A-170
; Sequence 170, Application US/10015387A
; Publication No. US20030135034A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan 1.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C54
; CURRENT APPLICATION NUMBER: US/10/015,387A
; CURRENT FILING DATE: 2001-12-12
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 170
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-015-387A-170

Query Match 100.0%; Score 1258; DB 12; Length 250;
Best Local Similarity 100.0%; Pred. No. 1.4e-118;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         22 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 81

Qy         61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 141

Qy        121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        142 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 201

Qy        181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
              |||||||||||||||||||||||||||||||||||||||||||||||||
Db        202 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 250
```

RESULT 3
US-10-137-870-506
; Sequence 506, Application US/10137870
; Publication No. US20030138883A1
; GENERAL INFORMATION:
; APPLICANT: Baker,Kevin P.
; APPLICANT: Beresini,Maureen
; APPLICANT: DeForge,Laura
; APPLICANT: Desnoyers,Luc
; APPLICANT: Filvaroff,Ellen
; APPLICANT: Gao,Wei-Qiang
; APPLICANT: Gerritsen,Mary E.
; APPLICANT: Goddard,Audrey
; APPLICANT: Godowski,Paul J.
; APPLICANT: Gurney,Austin L.
; APPLICANT: Sherwood,Steven
; APPLICANT: Smith,Victoria
; APPLICANT: Stewart,Timothy A.
; APPLICANT: Tumas,Daniel
; APPLICANT: Watanabe,Colin K
; APPLICANT: Wood,William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C155
; CURRENT APPLICATION NUMBER: US/10/137,870
; CURRENT FILING DATE: 2002-05-03
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 506
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-137-870-506

Query Match 100.0%; Score 1258; DB 12; Length 250;
Best Local Similarity 100.0%; Pred. No. 1.4e-118;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         22 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 81

Qy         61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 141

Qy        121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        142 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 201

Qy        181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
              |||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db        202 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 250

RESULT 4
US-10-140-018-506
; Sequence 506, Application US/10140018
; Publication No. US20030138885A1
; GENERAL INFORMATION:
;  APPLICANT: Baker,Kevin P.
;  APPLICANT:  Beresini,Maureen
;  APPLICANT:  DeForge,Laura
;  APPLICANT:  Desnoyers,Luc
;  APPLICANT:  Filvaroff,Ellen
;  APPLICANT:  Gao,Wei-Qiang
;  APPLICANT:  Gerritsen,Mary E.
;  APPLICANT:  Goddard,Audrey
;  APPLICANT:  Godowski,Paul J.
;  APPLICANT:  Gurney,Austin L.
;  APPLICANT:  Sherwood,Steven
;  APPLICANT:  Smith,Victoria
;  APPLICANT:  Stewart,Timothy A.
;  APPLICANT:  Tumas,Daniel
;  APPLICANT:  Watanabe,Colin K
;  APPLICANT:  Wood,William
;  APPLICANT:  Zhang, Zemin
;  TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
;  TITLE OF INVENTION:  ACIDS ENCODING THE SAME
;  FILE REFERENCE: P3330R1C158
;  CURRENT APPLICATION NUMBER: US/10/140,018
;  CURRENT FILING DATE:  2002-05-06
;  Prior Application removed - See Palm or File Wrapper
;  NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 506
;   LENGTH: 250
;   TYPE: PRT
;   ORGANISM: Homo Sapien
US-10-140-018-506

  Query Match             100.0%;  Score 1258;  DB 12;  Length 250;
  Best Local Similarity   100.0%;  Pred. No. 1.4e-118;
  Matches  229;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 IIKGPECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         22 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 81

Qy         61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 141

Qy        121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        142 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 201

Qy        181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
              |||||||||||||||||||||||||||||||||||||||||||||||||
Db        202 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 250


RESULT 5
US-10-140-021-506
; Sequence 506, Application US/10140021
; Publication No. US20030138886A1
; GENERAL INFORMATION:
;  APPLICANT: Baker,Kevin P.
;  APPLICANT:  Beresini,Maureen
;  APPLICANT:  DeForge,Laura
;  APPLICANT:  Desnoyers,Luc
;  APPLICANT:  Filvaroff,Ellen
;  APPLICANT:  Gao,Wei-Qiang
;  APPLICANT:  Gerritsen,Mary E.
;  APPLICANT:  Goddard,Audrey
;  APPLICANT:  Godowski,Paul J.
;  APPLICANT:  Gurney,Austin L.
;  APPLICANT:  Sherwood,Steven
;  APPLICANT:  Smith,Victoria
;  APPLICANT:  Stewart,Timothy A.
;  APPLICANT:  Tumas,Daniel
;  APPLICANT:  Watanabe,Colin K
;  APPLICANT:  Wood,William
;  APPLICANT:  Zhang, Zemin
;  TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
;  TITLE OF INVENTION:  ACIDS ENCODING THE SAME
;  FILE REFERENCE: P3330R1C167
;  CURRENT APPLICATION NUMBER: US/10/140,021
;  CURRENT FILING DATE:  2002-05-06
;  Prior Application removed - See Palm or File Wrapper
;  NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 506
;   LENGTH: 250
;   TYPE: PRT
;   ORGANISM: Homo Sapien
US-10-140-021-506

  Query Match             100.0%;  Score 1258;  DB 12;  Length 250;
  Best Local Similarity   100.0%;  Pred. No. 1.4e-118;
  Matches  229;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         22 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 81

Qy         61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 141

Qy        121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        142 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 201

Qy        181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
              |||||||||||||||||||||||||||||||||||||||||||||||||
Db        202 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 250


RESULT 6
US-10-140-274-506
; Sequence 506, Application US/10140274
; Publication No. US20030143674A1
; GENERAL INFORMATION:
;  APPLICANT: Baker,Kevin P.
;  APPLICANT:  Beresini,Maureen
;  APPLICANT:  DeForge,Laura
;  APPLICANT:  Desnoyers,Luc
;  APPLICANT:  Filvaroff,Ellen
;  APPLICANT:  Gao,Wei-Qiang
;  APPLICANT:  Gerritsen,Mary E.
;  APPLICANT:  Goddard,Audrey
;  APPLICANT:  Godowski,Paul J.
;  APPLICANT:  Gurney,Austin L.
;  APPLICANT:  Sherwood,Steven
;  APPLICANT:  Smith,Victoria
;  APPLICANT:  Stewart,Timothy A.
;  APPLICANT:  Tumas,Daniel
;  APPLICANT:  Watanabe,Colin K
;  APPLICANT:  Wood,William
;  APPLICANT:  Zhang, Zemin
;  TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
;  TITLE OF INVENTION:  ACIDS ENCODING THE SAME
;  FILE REFERENCE: P3330R1C161
;  CURRENT APPLICATION NUMBER: US/10/140,274
;  CURRENT FILING DATE:  2002-05-06
;  Prior Apploication removed - See File Wrapper or Palm
;  NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 506
;   LENGTH: 250
```

```
;   TYPE: PRT
;   ORGANISM: Homo Sapien
US-10-140-274-506

  Query Match           100.0%;  Score 1258;  DB 12;  Length 250;
  Best Local Similarity  100.0%;  Pred. No. 1.4e-118;
  Matches  229;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         22 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 81

Qy         61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 141

Qy        121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        142 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 201

Qy        181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
              |||||||||||||||||||||||||||||||||||||||||||||||||
Db        202 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 250


RESULT 7
US-10-140-471-506
; Sequence 506, Application US/10140471
; Publication No. US20030138887A1
; GENERAL INFORMATION:
;  APPLICANT: Baker,Kevin P.
;  APPLICANT:  Beresini,Maureen
;  APPLICANT:  DeForge,Laura
;  APPLICANT:  Desnoyers,Luc
;  APPLICANT:  Filvaroff,Ellen
;  APPLICANT:  Gao,Wei-Qiang
;  APPLICANT:  Gerritsen,Mary E.
;  APPLICANT:  Goddard,Audrey
;  APPLICANT:  Godowski,Paul J.
;  APPLICANT:  Gurney,Austin L.
;  APPLICANT:  Sherwood,Steven
;  APPLICANT:  Smith,Victoria
;  APPLICANT:  Stewart,Timothy A.
;  APPLICANT:  Tumas,Daniel
;  APPLICANT:  Watanabe,Colin K
;  APPLICANT:  Wood,William
;  APPLICANT:  Zhang, Zemin
;  TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
;  TITLE OF INVENTION:  ACIDS ENCODING THE SAME
;  FILE REFERENCE: P3330R1C163
;  CURRENT APPLICATION NUMBER: US/10/140,471
;  CURRENT FILING DATE:  2002-05-06
;  Prior Apploication removed - See File Wrapper or Palm
;  NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 506
;   LENGTH: 250
;   TYPE: PRT
;   ORGANISM: Homo Sapien
US-10-140-471-506

  Query Match           100.0%;  Score 1258;  DB 12;  Length 250;
  Best Local Similarity  100.0%;  Pred. No. 1.4e-118;
  Matches  229;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         22 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 81

Qy         61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 141

Qy        121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        142 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 201

Qy        181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
              |||||||||||||||||||||||||||||||||||||||||||||||||
Db        202 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 250


RESULT 8
US-10-140-807-506
; Sequence 506, Application US/10140807
; Publication No. US20030134354A1
; GENERAL INFORMATION:
;  APPLICANT: Baker,Kevin P.
;  APPLICANT:  Beresini,Maureen
;  APPLICANT:  DeForge,Laura
;  APPLICANT:  Desnoyers,Luc
;  APPLICANT:  Filvaroff,Ellen
;  APPLICANT:  Gao,Wei-Qiang
;  APPLICANT:  Gerritsen,Mary E.
;  APPLICANT:  Goddard,Audrey
;  APPLICANT:  Godowski,Paul J.
;  APPLICANT:  Gurney,Austin L.
;  APPLICANT:  Sherwood,Steven
;  APPLICANT:  Smith,Victoria
;  APPLICANT:  Stewart,Timothy A.
;  APPLICANT:  Tumas,Daniel
;  APPLICANT:  Watanabe,Colin K
;  APPLICANT:  Wood,William
;  APPLICANT:  Zhang, Zemin
;  TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
;  TITLE OF INVENTION:  ACIDS ENCODING THE SAME
;  FILE REFERENCE: P3330R1C174
;  CURRENT APPLICATION NUMBER: US/10/140,807
;  CURRENT FILING DATE:  2002-05-07
;  Prior Apploication removed - See File Wrapper or Palm
;  NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 506
;   LENGTH: 250
;   TYPE: PRT
;   ORGANISM: Homo Sapien
US-10-140-807-506

  Query Match           100.0%;  Score 1258;  DB 12;  Length 250;
  Best Local Similarity  100.0%;  Pred. No. 1.4e-118;
  Matches  229;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 IIKGFECKPHSQPWQAALFEXTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         22 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 81

Qy         61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 141

Qy        121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        142 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 201

Qy        181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
              |||||||||||||||||||||||||||||||||||||||||||||||||
Db        202 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 250


RESULT 9
US-10-140-922-506
; Sequence 506, Application US/10140922
; Publication No. US20030138889A1
; GENERAL INFORMATION:
;  APPLICANT: Baker,Kevin P.
;  APPLICANT:  Beresini,Maureen
;  APPLICANT:  DeForge,Laura
;  APPLICANT:  Desnoyers,Luc
```

```
;  APPLICANT:  Filvaroff,Ellen
;  APPLICANT:  Gao,Wei-Qiang
;  APPLICANT:  Gerritsen,Mary E.
;  APPLICANT:  Goddard,Audrey
;  APPLICANT:  Godowski,Paul J.
;  APPLICANT:  Gurney,Austin L.
;  APPLICANT:  Sherwood,Steven
;  APPLICANT:  Smith,Victoria
;  APPLICANT:  Stewart,Timothy A.
;  APPLICANT:  Tumas,Daniel
;  APPLICANT:  Watanabe,Colin K
;  APPLICANT:  Wood,William
;  APPLICANT:  Zhang, Zemin
;  TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
;  TITLE OF INVENTION:  ACIDS ENCODING THE SAME
;  FILE REFERENCE: P3330R1C179
;  CURRENT APPLICATION NUMBER: US/10/140,922
;  CURRENT FILING DATE:  2002-05-07
;  Prior Application removed - See Palm or File Wrapper
;  NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 506
;   LENGTH: 250
;   TYPE: PRT
;   ORGANISM: Homo Sapien
US-10-140-922-506

  Query Match             100.0%;  Score 1258;  DB 12;  Length 250;
  Best Local Similarity   100.0%;  Pred. No. 1.4e-118;
  Matches  229;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         22 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 81

Qy         61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 141

Qy        121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        142 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 201

Qy        181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
              |||||||||||||||||||||||||||||||||||||||||||||||||
Db        202 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 250


RESULT 10
US-10-140-924-506
; Sequence 506, Application US/10140924
; Publication No. US20030134355A1
; GENERAL INFORMATION:
;  APPLICANT: Baker,Kevin P.
;  APPLICANT:  Beresini,Maureen
;  APPLICANT:  DeForge,Laura
;  APPLICANT:  Desnoyers,Luc
;  APPLICANT:  Filvaroff,Ellen
;  APPLICANT:  Gao,Wei-Qiang
;  APPLICANT:  Gerritsen,Mary E.
;  APPLICANT:  Goddard,Audrey
;  APPLICANT:  Godowski,Paul J.
;  APPLICANT:  Gurney,Austin L.
;  APPLICANT:  Sherwood,Steven
;  APPLICANT:  Smith,Victoria
;  APPLICANT:  Stewart,Timothy A.
;  APPLICANT:  Tumas,Daniel
;  APPLICANT:  Watanabe,Colin K
;  APPLICANT:  Wood,William
;  APPLICANT:  Zhang, Zemin
;  TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
;  TITLE OF INVENTION:  ACIDS ENCODING THE SAME
;  FILE REFERENCE: P3330R1C177
;  CURRENT APPLICATION NUMBER: US/10/140,924
;  CURRENT FILING DATE:  2002-05-07
;  Prior Apploication removed - See File Wrapper or Palm
;  NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 506
;   LENGTH: 250
;   TYPE: PRT
;   ORGANISM: Homo Sapien
US-10-140-924-506

  Query Match             100.0%;  Score 1258;  DB 12;  Length 250;
  Best Local Similarity   100.0%;  Pred. No. 1.4e-118;
  Matches  229;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         22 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 81

Qy         61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 141

Qy        121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        142 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 201

Qy        181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
              |||||||||||||||||||||||||||||||||||||||||||||||||
Db        202 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 250


RESULT 11
US-10-140-926-506
; Sequence 506, Application US/10140926
; Publication No. US20030134356A1
; GENERAL INFORMATION:
;  APPLICANT: Baker,Kevin P.
;  APPLICANT:  Beresini,Maureen
;  APPLICANT:  DeForge,Laura
;  APPLICANT:  Desnoyers,Luc
;  APPLICANT:  Filvaroff,Ellen
;  APPLICANT:  Gao,Wei-Qiang
;  APPLICANT:  Gerritsen,Mary E.
;  APPLICANT:  Goddard,Audrey
;  APPLICANT:  Godowski,Paul J.
;  APPLICANT:  Gurney,Austin L.
;  APPLICANT:  Sherwood,Steven
;  APPLICANT:  Smith,Victoria
;  APPLICANT:  Stewart,Timothy A.
;  APPLICANT:  Tumas,Daniel
;  APPLICANT:  Watanabe,Colin K
;  APPLICANT:  Wood,William
;  APPLICANT:  Zhang, Zemin
;  TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
;  TITLE OF INVENTION:  ACIDS ENCODING THE SAME
;  FILE REFERENCE: P3330R1C187
;  CURRENT APPLICATION NUMBER: US/10/140,926
;  CURRENT FILING DATE:  2002-05-07
;  Prior Apploication removed - See File Wrapper or Palm
;  NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 506
;   LENGTH: 250
;   TYPE: PRT
;   ORGANISM: Homo Sapien
US-10-140-926-506

  Query Match             100.0%;  Score 1258;  DB 12;  Length 250;
  Best Local Similarity   100.0%;  Pred. No. 1.4e-118;
  Matches  229;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         22 IIKGFECKPHSQPWQAALPEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 81
```

```
Qy          61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 141

Qy         121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         142 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 201

Qy         181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
               |||||||||||||||||||||||||||||||||||||||||||||||||
Db         202 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 250


RESULT 12
US-10-141-698-506
; Sequence 506, Application US/10141698
; Publication No. US20030134357A1
; GENERAL INFORMATION:
;  APPLICANT: Baker,Kevin P.
;  APPLICANT:  Beresini,Maureen
;  APPLICANT:  DeForge,Laura
;  APPLICANT:  Desnoyers,Luc
;  APPLICANT:  Filvaroff,Ellen
;  APPLICANT:  Gao,Wei-Qiang
;  APPLICANT:  Gerritsen,Mary E.
;  APPLICANT:  Goddard,Audrey
;  APPLICANT:  Godowski,Paul J.
;  APPLICANT:  Gurney,Austin L.
;  APPLICANT:  Sherwood,Steven
;  APPLICANT:  Smith,Victoria
;  APPLICANT:  Stewart,Timothy A.
;  APPLICANT:  Tumas,Daniel
;  APPLICANT:  Watanabe,Colin K
;  APPLICANT:  Wood,William
;  APPLICANT:  Zhang, Zemin
;  TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
;  TITLE OF INVENTION:  ACIDS ENCODING THE SAME
;  FILE REFERENCE: P3330R1C206
;  CURRENT APPLICATION NUMBER: US/10/141,698
;  CURRENT FILING DATE:  2002-05-08
;  Prior Application removed - See Palm or File Wrapper
;  NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 506
;   LENGTH: 250
;   TYPE: PRT
;   ORGANISM: Homo Sapien
US-10-141-698-506

  Query Match             100.0%;  Score 1258;  DB 12;  Length 250;
  Best Local Similarity   100.0%;  Pred. No. 1.4e-118;
  Matches  229;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy           1 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          22 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 81

Qy          61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 141

Qy         121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         142 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 201

Qy         181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
               |||||||||||||||||||||||||||||||||||||||||||||||||
Db         202 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 250


RESULT 13
US-10-141-702-506
; Sequence 506, Application US/10141702
; Publication No. US20030134358A1
; GENERAL INFORMATION:
;  APPLICANT: Baker,Kevin P.
;  APPLICANT:  Beresini,Maureen
;  APPLICANT:  DeForge,Laura
;  APPLICANT:  Desnoyers,Luc
;  APPLICANT:  Filvaroff,Ellen
;  APPLICANT:  Gao,Wei-Qiang
;  APPLICANT:  Gerritsen,Mary E.
;  APPLICANT:  Goddard,Audrey
;  APPLICANT:  Godowski,Paul J.
;  APPLICANT:  Gurney,Austin L.
;  APPLICANT:  Sherwood,Steven
;  APPLICANT:  Smith,Victoria
;  APPLICANT:  Stewart,Timothy A.
;  APPLICANT:  Tumas,Daniel
;  APPLICANT:  Watanabe,Colin K
;  APPLICANT:  Wood,William
;  APPLICANT:  Zhang, Zemin
;  TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
;  TITLE OF INVENTION:  ACIDS ENCODING THE SAME
;  FILE REFERENCE: P3330R1C208
;  CURRENT APPLICATION NUMBER: US/10/141,702
;  CURRENT FILING DATE:  2002-05-08
;  Prior Application removed - See Palm or File Wrapper
;  NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 506
;   LENGTH: 250
;   TYPE: PRT
;   ORGANISM: Homo Sapien
US-10-141-702-506

  Query Match             100.0%;  Score 1258;  DB 12;  Length 250;
  Best Local Similarity   100.0%;  Pred. No. 1.4e-118;
  Matches  229;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy           1 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          22 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 81

Qy          61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 141

Qy         121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         142 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 201

Qy         181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
               |||||||||||||||||||||||||||||||||||||||||||||||||
Db         202 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 250


RESULT 14
US-10-141-704-506
; Sequence 506, Application US/10141704
; Publication No. US20030134359A1
; GENERAL INFORMATION:
;  APPLICANT: Baker,Kevin P.
;  APPLICANT:  Beresini,Maureen
;  APPLICANT:  DeForge,Laura
;  APPLICANT:  Desnoyers,Luc
;  APPLICANT:  Filvaroff,Ellen
;  APPLICANT:  Gao,Wei-Qiang
;  APPLICANT:  Gerritsen,Mary E.
;  APPLICANT:  Goddard,Audrey
;  APPLICANT:  Godowski,Paul J.
;  APPLICANT:  Gurney,Austin L.
;  APPLICANT:  Sherwood,Steven
;  APPLICANT:  Smith,Victoria
;  APPLICANT:  Stewart,Timothy A.
;  APPLICANT:  Tumas,Daniel
;  APPLICANT:  Watanabe,Colin K
;  APPLICANT:  Wood,William
```

```
;  APPLICANT:  Zhang, Zemin
;  TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
;  TITLE OF INVENTION:  ACIDS ENCODING THE SAME
;  FILE REFERENCE: P3330R1C209
;  CURRENT APPLICATION NUMBER: US/10/141,704
;  CURRENT FILING DATE:  2002-05-08
;  Prior Application removed - See Palm or File Wrapper
;  NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 506
;   LENGTH: 250
;   TYPE: PRT
;   ORGANISM: Homo Sapien
US-10-141-704-506

  Query Match           100.0%;  Score 1258;  DB 12;  Length 250;
  Best Local Similarity  100.0%;  Pred. No. 1.4e-118;
  Matches  229;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         22 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 81

Qy         61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 141

Qy        121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        142 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 201

Qy        181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
              |||||||||||||||||||||||||||||||||||||||||||||||||
Db        202 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 250


RESULT 15
US-10-142-421-506
; Sequence 506, Application US/10142421
; Publication No. US20030134360A1
; GENERAL INFORMATION:
;  APPLICANT: Baker,Kevin P.
;  APPLICANT:  Beresini,Maureen
;  APPLICANT:  DeForge,Laura
;  APPLICANT:  Desnoyers,Luc
;  APPLICANT:  Filvaroff,Ellen
;  APPLICANT:  Gao,Wei-Qiang
;  APPLICANT:  Gerritsen,Mary E.
;  APPLICANT:  Goddard,Audrey
;  APPLICANT:  Godowski,Paul J.
;  APPLICANT:  Gurney,Austin L.
;  APPLICANT:  Sherwood,Steven
;  APPLICANT:  Smith,Victoria
;  APPLICANT:  Stewart,Timothy A.
;  APPLICANT:  Tumas,Daniel
;  APPLICANT:  Watanabe,Colin K
;  APPLICANT:  Wood,William
;  APPLICANT:  Zhang, Zemin
;  TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
;  TITLE OF INVENTION:  ACIDS ENCODING THE SAME
;  FILE REFERENCE: P3330R1C218
;  CURRENT APPLICATION NUMBER: US/10/142,421
;  CURRENT FILING DATE:  2002-05-09
;  Prior Apploication removed - See File Wrapper or Palm
;  NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 506
;   LENGTH: 250
;   TYPE: PRT
;   ORGANISM: Homo Sapien
US-10-142-421-506

  Query Match           100.0%;  Score 1258;  DB 12;  Length 250;
  Best Local Similarity  100.0%;  Pred. No. 1.4e-118;
  Matches  229;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         22 IIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEE 81

Qy         61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTS 141

Qy        121 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        142 CLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQG 201

Qy        181 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 229
              |||||||||||||||||||||||||||||||||||||||||||||||||
Db        202 DSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN 250

Search completed: October 22, 2003, 15:54:44
Job time : 22.9589 secs
```

GenCore version 5.1.6

OM protein - nucleic search, using frame_plus_p2n model

Run on: October 23, 2003, 14:08:00 ; Search time 3410.8 Seconds
(without alignments)
2746.659 Million cell updates/sec

Title: US-09-856-320A-2_COPY_54_282
Perfect score: 1258
Sequence: 1 IIKGFECKPHSQPWQAALFE.....GVYTKVCKYVDWIQETMKNN 229

Scoring table: BLOSUM62
Xgapop 10.0 , Xgapext 0.5
Ygapop 10.0 , Ygapext 0.5
Fgapop 6.0 , Fgapext 7.0
Delop 6.0 , Delext 7.0

Searched: 2888711 seqs, 20454813386 residues

Total number of hits satisfying chosen parameters: 5777422

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Command line parameters:
-MODEL=frame+_p2n.model -DEV=xlh
-Q=/cgn2_1/USPTO_spool/US09856320/runat_22102003_121414_25661/app_query.fasta_1.846
-DB=GenEmbl -QFMT=fastap -SUFFIX=rge -MINMATCH=0.1 -LOOPCL=0 -LOOPEXT=0
-UNITS=bits -START=1 -END=-1 -MATRIX=blosum62 -TRANS=human40.cdi -LIST=45
-DOCALIGN=200 -THR_SCORE=pct -THR_MAX=100 -THR_MIN=0 -ALIGN=15 -MODE=LOCAL
-OUTFMT=pto -NORM=ext -HEAPSIZE=500 -MINLEN=0 -MAXLEN=2000000000
-USER=US09856320_@CGN_1_1_4326_@runat_22102003_121414_25661 -NCPU=6 -ICPU=3
-NO_MMAP -LARGEQUERY -NEG_SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG
-DEV_TIMEOUT=120 -WARN_TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5 -FGAPOP=6
-FGAPEXT=7 -YGAPOP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Database : GenEmbl:*
1: gb_ba:*
2: gb_htg:*
3: gb_in:*
4: gb_om:*
5: gb_ov:*
6: gb_pat:*
7: gb_ph:*
8: gb_pl:*
9: gb_pr:*
10: gb_ro:*
11: gb_sts:*
12: gb_sy:*
13: gb_un:*
14: gb_vi:*
15: em_ba:*
16: em_fun:*
17: em_hum:*
18: em_in:*
19: em_mu:*
20: em_om:*
21: em_or:*
22: em_ov:*
23: em_pat:*
24: em_ph:*
25: em_pl:*
26: em_ro:*
27: em_sts:*
28: em_un:*
29: em_vi:*
30: em_htg_hum:*
31: em_htg_inv:*
32: em_htg_other:*
33: em_htg_mus:*
34: em_htg_pln:*
35: em_htg_rod:*
36: em_htg_mam:*
37: em_htg_vrt:*
38: em_sy:*
39: em_htgo_hum:*
40: em_htgo_mus:*
41: em_htgo_other:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	1258	100.0	1106	6	AX016287	AX016287 Sequence
	2	1258	100.0	1106	6	BD137019	BD137019 Human CAS
	3	1258	100.0	1158	6	AX016289	AX016289 Sequence
	4	1258	100.0	1158	6	BD137020	BD137020 Human CAS
	5	1258	100.0	1181	9	AB013730	AB013730 Homo sapi
	6	1258	100.0	1186	9	AB012917	AB012917 Homo sapi
	7	1258	100.0	1192	6	AR152174	AR152174 Sequence
	8	1258	100.0	1204	6	AX358932	AX358932 Sequence
	9	1258	100.0	1204	6	AX362425	AX362425 Sequence
	10	1258	100.0	1204	6	AX454622	AX454622 Sequence
	11	1258	100.0	1204	6	AX464372	AX464372 Sequence
	12	1258	100.0	1204	6	AX491100	AX491100 Sequence
	13	1258	100.0	1204	6	AX697101	AX697101 Sequence
	14	1258	100.0	1213	9	BC022068	BC022068 Homo sapi
	15	1258	100.0	1301	6	BD091587	BD091587 Novel ser
	16	1258	100.0	1301	9	AB041036	AB041036 Homo sapi
	17	1258	100.0	1314	6	AR098430	AR098430 Sequence
	18	1258	100.0	1314	6	BD130920	BD130920 Serine pr
	19	1246	99.0	1166	6	AR152173	AR152173 Sequence
	20	1235.5	98.2	930	9	AB078780	AB078780 Homo sapi
	21	1235.5	98.2	934	6	BD091589	BD091589 Novel ser
	22	1228	97.6	1191	6	BD139483	BD139483 Extended
	23	1219.5	96.9	1052	6	AR219287	AR219287 Sequence
	24	1213	96.4	833	6	AR060847	AR060847 Sequence
	25	1213	96.4	833	6	BD082136	BD082136 Novel pro
	26	1062	84.4	1213	10	AB016226	AB016226 Mus muscu
	27	1062	84.4	1256	10	AB016227	AB016227 Mus muscu
	28	1062	84.4	1323	6	BD091588	BD091588 Novel ser
	29	1014.5	80.6	1164	6	AX661915	AX661915 Sequence
	30	956	76.0	9120	9	AF164623	AF164623 Homo sapi
c	31	956	76.0	132323	9	AC011473	AC011473 Homo sapi
c	32	956	76.0	230000	9	AF243527	AF243527 Homo sapi
	33	943	75.0	142334	2	AC073185	AC073185 Homo sapi
	34	916.5	72.9	618	6	AR263825	AR263825 Sequence
c	35	897.5	71.3	178504	2	AC140096	AC140096 Pan trogl
c	36	897.5	71.3	200792	2	AC130782	AC130782 Pan trogl
c	37	885.5	70.4	176647	2	AC130188	AC130188 Papio anu
c	38	782.5	62.2	226890	2	AC135541	AC135541 Rattus no
	39	782.5	62.2	228413	2	AC127853	AC127853 Rattus no
	40	782.5	62.2	243655	2	AC099172	AC099172 Rattus no
	41	687	54.6	974	10	RRA5641	AJ005641 Rattus ra
	42	684	54.4	799	6	BD080531	BD080531 Novel ext
	43	684	54.4	1322	6	AX305781	AX305781 Sequence
	44	684	54.4	1322	10	MUSNEU	D30785 Mouse mRNA
	45	684	54.4	1333	6	E12348	E12348 cDNA encodi

ALIGNMENTS

RESULT 1

```
AX016287
LOCUS       AX016287               1106 bp    DNA     linear   PAT 07-SEP-2000
DEFINITION  Sequence 1 from Patent WO9949055.
ACCESSION   AX016287
VERSION     AX016287.1  GI:10041854
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Bruck,C.E., Coche,T., Cassart,J.P. and Vinals-Bassols,C.
  TITLE     Human casb12 polypeptide, a serine protease
  JOURNAL   Patent: WO 9949055-A 1 30-SEP-1999;
            BRUCK CLAUDINE ELVIRE MARIE (BE); SMITHKLINE BEECHAM BIOLOG (BE);
            COCHE THIERRY (BE); CASSART JEAN POL (BE); VINALS BASSOLS CARLOTA
            (BE)
FEATURES             Location/Qualifiers
     source          1. .1106
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"
BASE COUNT      247 a    348 c    287 g    224 t
ORIGIN

Alignment Scores:
Pred. No.:                4.14e-97        Length:          1106
Score:                    1258.00         Matches:         229
Percent Similarity:       100.00%         Conservative:    0
Best Local Similarity:    100.00%         Mismatches:      0
Query Match:              100.00%         Indels:          0
DB:                       6               Gaps:            0

US-09-856-320A-2_COPY_54_282 (1-229) x AX016287 (1-1106)

Qy          1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        173 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 232

Qy         21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        233 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 292

Qy         41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        293 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 352

Qy         61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAsnSer 80
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        353 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 412

Qy         81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        413 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 472

Qy        101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        473 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 532

Qy        121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        533 TGCCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 592

Qy        141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        593 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 652

Qy        161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        653 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 712

Qy        181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Db        713 GACTCCGGGGGCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 772

Qy        201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        773 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 832

Qy        221 TrpIleGlnGluThrMetLysAsnAsn 229
              |||||||||||||||||||||||||||
Db        833 TGGATCCAGGAGACGATGAAGAACAAT 859

RESULT 2
BD137019
LOCUS       BD137019               1106 bp    DNA     linear   PAT 18-SEP-2002
DEFINITION  Human CASB 12 polypeptide, a serine protease.
ACCESSION   BD137019
VERSION     BD137019.1  GI:23231964
KEYWORDS    JP 2002507425-A/1.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1106)
  AUTHORS   Bruck,C.E.M., Cassart,J.P., Coche,T. and Bassols,C.V.
  TITLE     Human CASB 12 polypeptide, a serine protease
  JOURNAL   Patent: JP 2002507425-A 1 12-MAR-2002;
            SMITHKLINE BEECHAM BIOLOGICALS SA
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002507425-A/1
            PD   12-MAR-2002
            PF   17-MAR-1999 JP 2000538015
            PR   20-MAR-1998 GB    9806095.7
            PI   CLAUDINE ELVIRE MARIE BRUCK,JEAN POL CASSART,THIERRY COCHE, PI
              CARLOTA VINALS BASSOLS
            PC   C12N15/09,A61K31/70,A61K38/00,A61P35/00,A61P37/02,C07K16/40,
            PC   C12N1/15,
            PC   C12N1/19,C12N1/21,C12N5/10,C12N9/64,C12P21/02,C12Q1/02,C12Q1/
            PC   68,G01N33/15,
            PC   G01N33/50,G01N33/50,G01N33/574,G01N33/68,C12N15/00,A61K37/02,
            PC   C12N5/00
            CC   Human CASB 12 polypeptide, a serine protease. FH   Key
              Location/Qualifiers
            FT   source          1. .1106
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .1106
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"
BASE COUNT      247 a    348 c    287 g    224 t
ORIGIN

Alignment Scores:
Pred. No.:                4.14e-97        Length:          1106
Score:                    1258.00         Matches:         229
Percent Similarity:       100.00%         Conservative:    0
Best Local Similarity:    100.00%         Mismatches:      0
Query Match:              100.00%         Indels:          0
DB:                       6               Gaps:            0

US-09-856-320A-2_COPY_54_282 (1-229) x BD137019 (1-1106)

Qy          1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        173 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 232

Qy         21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        233 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 292

Qy         41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        293 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 352
```

```
Qy          61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAsnSer 80
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         353 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 412

Qy          81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         413 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 472

Qy         101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         473 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 532

Qy         121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         533 TGCCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 592

Qy         141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         593 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 652

Qy         161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         653 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 712

Qy         181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         713 GACTCCGGGGGCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 772

Qy         201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         773 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 832

Qy         221 TrpIleGlnGluThrMetLysAsnAsn 229
               ||||||||||||||||||||||||||||
Db         833 TGGATCCAGGAGACGATGAAGAACAAT 859
```

```
RESULT 3
AX016289
LOCUS       AX016289               1158 bp    DNA     linear   PAT 07-SEP-2000
DEFINITION  Sequence 3 from Patent WO9949055.
ACCESSION   AX016289
VERSION     AX016289.1  GI:10041855
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Bruck,C.E., Coche,T., Cassart,J.P. and Vinals-Bassols,C.
  TITLE     Human casb12 polypeptide, a serine protease
  JOURNAL   Patent: WO 9949055-A 3 30-SEP-1999;
            BRUCK CLAUDINE ELVIRE MARIE (BE); SMITHKLINE BEECHAM BIOLOG (BE);
            COCHE THIERRY (BE); CASSART JEAN POL (BE); VINALS BASSOLS CARLOTA
            (BE)
FEATURES             Location/Qualifiers
     source          1. .1158
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"
BASE COUNT      274 a    359 c    306 g    219 t
ORIGIN

Alignment Scores:
Pred. No.:              4.35e-97        Length:         1158
Score:                  1258.00         Matches:        229
Percent Similarity:     100.00%         Conservative:   0
Best Local Similarity:  100.00%         Mismatches:     0
Query Match:            100.00%         Indels:         0
DB:                     6               Gaps:           0

US-09-856-320A-2_COPY_54_282 (1-229) x AX016289 (1-1158)

Qy          1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
```

```
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         243 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 302

Qy          21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         303 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 362

Qy          41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         363 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 422

Qy          61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAsnSer 80
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         423 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 482

Qy          81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         483 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 542

Qy         101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         543 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 602

Qy         121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         603 TGCCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 662

Qy         141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         663 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 722

Qy         161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         723 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 782

Qy         181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         783 GACTCCGGGGGCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 842

Qy         201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         843 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 902

Qy         221 TrpIleGlnGluThrMetLysAsnAsn 229
               ||||||||||||||||||||||||||||
Db         903 TGGATCCAGGAGACGATGAAGAACAAT 929
```

```
RESULT 4
BD137020
LOCUS       BD137020               1158 bp    DNA     linear   PAT 18-SEP-2002
DEFINITION  Human CASB 12 polypeptide, a serine protease.
ACCESSION   BD137020
VERSION     BD137020.1  GI:23231965
KEYWORDS    JP 2002507425-A/2.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1158)
  AUTHORS   Bruck,C.E.M., Cassart,J.P., Coche,T. and Bassols,C.V.
  TITLE     Human CASB 12 polypeptide, a serine protease
  JOURNAL   Patent: JP 2002507425-A 2 12-MAR-2002;
            SMITHKLINE BEECHAM BIOLOGICALS SA
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002507425-A/2
            PD   12-MAR-2002
            PF   17-MAR-1999 JP 2000538015
            PR   20-MAR-1998 GB    9806095.7
            PI   CLAUDINE ELVIRE MARIE BRUCK,JEAN POL CASSART,THIERRY COCHE, PI
              CARLOTA VINALS BASSOLS
            PC   C12N15/09,A61K31/70,A61K38/00,A61P35/00,A61P37/02,C07K16/40,
            PC   C12N1/15,
            PC   C12N1/19,C12N1/21,C12N5/10,C12N9/64,C12P21/02,C12Q1/02,C12Q1/
```

```
           PC   68,G01N33/15,
           PC   G01N33/50,G01N33/50,G01N33/574,G01N33/68,C12N15/00,A61K37/02,
           PC   C12N5/00
           CC   Human CASB 12 polypeptide, a serine protease. FH   Key
                Location/Qualifiers
           FT   source          1. .1158
           FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .1158
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"
BASE COUNT       274 a    359 c    306 g    219 t
ORIGIN

Alignment Scores:
Pred. No.:                4.35e-97      Length:          1158
Score:                    1258.00       Matches:         229
Percent Similarity:       100.00%       Conservative:    0
Best Local Similarity:    100.00%       Mismatches:      0
Query Match:              100.00%       Indels:          0
DB:                       6             Gaps:            0

US-09-856-320A-2_COPY_54_282 (1-229) x BD137020 (1-1158)

Qy          1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        243 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 302

Qy         21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        303 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 362

Qy         41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        363 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 422

Qy         61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAsnSer 80
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        423 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 482

Qy         81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        483 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 542

Qy        101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        543 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 602

Qy        121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        603 TGCCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 662

Qy        141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        663 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 722

Qy        161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        723 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 782

Qy        181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        783 GACTCCGGGGGCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 842

Qy        201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        843 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 902

Qy        221 TrpIleGlnGluThrMetLysAsnAsn 229
              ||||||||||||||||||||||||||
Db        903 TGGATCCAGGAGACGATGAAGAACAAT 929
```

```
RESULT 5
AB013730
LOCUS       AB013730               1181 bp    mRNA    linear   PRI 20-JUN-2000
DEFINITION  Homo sapiens mRNA for Hippostasin, complete cds.
ACCESSION   AB013730
VERSION     AB013730.1  GI:6681453
KEYWORDS    Hippostasin.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (sites)
  AUTHORS   Mitsui,S., Yamada,T., Okui,A., Kominami,K., Uemura,H. and
            Yamaguchi,N.
  TITLE     A novel isoform of a kallikrein-like protease, TLSP/hippostasin,
            (PRSS20), is expressed in the human brain and prostate
  JOURNAL   Biochem. Biophys. Res. Commun. 272 (1), 205-211 (2000)
  MEDLINE   20329229
   PUBMED   10872828
REFERENCE   2  (bases 1 to 1181)
  AUTHORS   Yamaguchi,N. and Mitsui,S.
  TITLE     Direct Submission
  JOURNAL   Submitted (08-MAY-1998) Nozomi Yamaguchi, Kyoto Prefectural
            University of Medicine, Res. Ins. Geriatrics; Kawaramachi Hirokoji,
            Kyoto, Kyoto 602-8566, Japan (E-mail:nozomi@koto.kpu-m.ac.jp,
            Tel:81-75-251-5848, Fax:81-75-251-5848)
FEATURES             Location/Qualifiers
     source          1. .1181
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
                     /tissue_type="Hippocampus and Prostate"
     CDS             121. .873
                     /codon_start=1
                     /product="Hippostasin"
                     /protein_id="BAA88713.1"
                     /db_xref="GI:6681454"
                     /translation="MRILQLILLALATGLVGGETRIIKGFECKPHSQPWQAALFEKTR
                     LLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEEGCEQTRTATESFPHPGFNNSL
                     PNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTSCLISGWGSTSSPQLRLPHT
                     LRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQGDSGGPLVCNQSLQGIIS
                     WGQDPCAITRKPGVYTKVCKYVDWIQETMKNN"
     polyA_site      1181
                     /note="32 a nucleotides"
BASE COUNT       271 a    375 c    287 g    248 t
ORIGIN

Alignment Scores:
Pred. No.:                4.44e-97      Length:          1181
Score:                    1258.00       Matches:         229
Percent Similarity:       100.00%       Conservative:    0
Best Local Similarity:    100.00%       Mismatches:      0
Query Match:              100.00%       Indels:          0
DB:                       9             Gaps:            0

US-09-856-320A-2_COPY_54_282 (1-229) x AB013730 (1-1181)

Qy          1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        184 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 243

Qy         21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        244 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 303

Qy         41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        304 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 363

Qy         61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAsnSer 80
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        364 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 423
```

```
Qy          81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         424 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 483

Qy         101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         484 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 543

Qy         121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         544 TGCCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 603

Qy         141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         604 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 663

Qy         161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         664 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 723

Qy         181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         724 GACTCCGGGGGCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 783

Qy         201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         784 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 843

Qy         221 TrpIleGlnGluThrMetLysAsnAsn 229
               |||||||||||||||||||||||||||
Db         844 TGGATCCAGGAGACGATGAAGAACAAT 870
```

```
RESULT 6
AB012917
LOCUS       AB012917                1186 bp    mRNA    linear   PRI 31-JAN-2003
DEFINITION  Homo sapiens mRNA for serine protease (TLSP), complete cds.
ACCESSION   AB012917
VERSION     AB012917.1  GI:3649790
KEYWORDS    TLSP; serine protease (TLSP).
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Yoshida,S., Taniguchi,M., Suemoto,T., Oka,T., He,X. and Shiosaka,S.
  TITLE     cDNA cloning and expression of a novel serine protease, TLSP
  JOURNAL   Biochim. Biophys. Acta 1399 (2-3), 225-228 (1998)
  MEDLINE   98438738
   PUBMED   9765601
REFERENCE   2  (bases 1 to 1186)
  AUTHORS   Yoshida,S.
  TITLE     Direct Submission
  JOURNAL   Submitted (10-APR-1998) Shigetaka Yoshida, Department of Anatomy 1,
            Asahikawa Medical College; Midorigaoka higashi 2-1-1-1, Asahikawa,
            Hokkaido 078-8510, Japan (E-mail:syoshida@asahikawa-med.ac.jp,
            Tel:81-166-68-2300, Fax:81-166-68-2309)
FEATURES             Location/Qualifiers
     source          1. .1186
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
     CDS             26. .874
                     /codon_start=1
                     /product="serine protease (TLSP)"
                     /protein_id="BAA33404.1"
                     /db_xref="GI:3649791"
                     /translation="MQRLRWLRDWKSSGRGLTAAKEPGARSSPLQAMRILQLILLALA
                     TGLVGGETRIIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIV
                     HLGQHNLQKEEGCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRP
                     LTLSSRCVTAGTSCLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTM
                     VCASVQEGGKDSCQGDSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQ
                     ETMKNN"
     mat_peptide     185. .871
                     /product="TLSP"
     polyA_signal    1164. .1169
     polyA_site      1186
                     /note="12 a nucleotides"
BASE COUNT      271 a    368 c    303 g    244 t
ORIGIN
```

```
Alignment Scores:
Pred. No.:              4.46e-97        Length:         1186
Score:                  1258.00         Matches:        229
Percent Similarity:     100.00%         Conservative:   0
Best Local Similarity:  100.00%         Mismatches:     0
Query Match:            100.00%         Indels:         0
DB:                     9               Gaps:           0

US-09-856-320A-2_COPY_54_282 (1-229) x AB012917 (1-1186)

Qy           1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         185 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 244

Qy          21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         245 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 304

Qy          41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         305 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 364

Qy          61 GlyCysGluGlnThrArgThrAlaThrGluSerProHisProGlyPheAsnAsnSer 80
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         365 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 424

Qy          81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         425 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 484

Qy         101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         485 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 544

Qy         121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         545 TGCCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 604

Qy         141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         605 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 664

Qy         161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         665 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 724

Qy         181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         725 GACTCCGGGGGCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 784

Qy         201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         785 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 844

Qy         221 TrpIleGlnGluThrMetLysAsnAsn 229
               |||||||||||||||||||||||||||
Db         845 TGGATCCAGGAGACGATGAAGAACAAT 871
```

```
RESULT 7
AR152174
LOCUS       AR152174                1192 bp    DNA     linear   PAT 08-AUG-2001
DEFINITION  Sequence 8 from patent US 6232456.
ACCESSION   AR152174
VERSION     AR152174.1  GI:15118224
KEYWORDS    .
SOURCE      Unknown.
```

```
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 1192)
  AUTHORS   Cohen,M., Colpitts,T.L., Priedman,P.N., Granados,E., Klass,M.R.,
            Russell,J.C., Stewart,K.D. and Stroupe,S.D.
  TITLE     Serine protease reagents and methods useful for detecting and
            treating diseases of the prostate
  JOURNAL   Patent: US 6232456-A 8 15-MAY-2001;
FEATURES             Location/Qualifiers
     source          1. .1192
                     /organism="unknown"
BASE COUNT      279 a    385 c    290 g    238 t
ORIGIN

Alignment Scores:
Pred. No.:                4.48e-97      Length:          1192
Score:                    1258.00       Matches:         229
Percent Similarity:       100.00%       Conservative:    0
Best Local Similarity:    100.00%       Mismatches:      0
Query Match:              100.00%       Indels:          0
DB:                       6             Gaps:            0

US-09-856-320A-2_COPY_54_282 (1-229) x AR152174 (1-1192)

Qy          1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        170 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 229

Qy         21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        230 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 289

Qy         41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        290 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 349

Qy         61 GlyCysGluGlnThrArgThrAlaThrGluSerProHisProGlyPheAsnAsnSer 80
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        350 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 409

Qy         81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        410 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 469

Qy        101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        470 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 529

Qy        121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        530 TGCCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 589

Qy        141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        590 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 649

Qy        161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        650 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 709

Qy        181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        710 GACTCCGGGGGCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 769

Qy        201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        770 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 829

Qy        221 TrpIleGlnGluThrMetLysAsnAsn 229
              ||||||||||||||||||||||||||
Db        830 TGGATCCAGGAGACGATGAAGAACAAT 856

RESULT 8
```

```
AX358932
LOCUS       AX358932               1204 bp    DNA     linear   PAT 13-FEB-2002
DEFINITION  Sequence 185 from Patent WO0193983.
ACCESSION   AX358932
VERSION     AX358932.1  GI:18675367
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Baker,K.P., Desnoyers,L., Gerritsen,M.E., Goddard,A.,
            Godowski,P.J., Grimaldi,J.C., Gurney,A.L., Smith,V., Stephan,J.P.,
            Watanabe,C.K. and Wood,W.I.
  TITLE     Secreted and transmembrane polypeptides and nucleic acids encoding
            the same
  JOURNAL   Patent: WO 0193983-A 185 13-DEC-2001;
            Genentech Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .1204
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"
BASE COUNT      306 a    364 c    294 g    240 t
ORIGIN

Alignment Scores:
Pred. No.:                4.53e-97      Length:          1204
Score:                    1258.00       Matches:         229
Percent Similarity:       100.00%       Conservative:    0
Best Local Similarity:    100.00%       Mismatches:      0
Query Match:              100.00%       Indels:          0
DB:                       6             Gaps:            0

US-09-856-320A-2_COPY_54_282 (1-229) x AX358932 (1-1204)

Qy          1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        169 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 228

Qy         21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        229 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 288

Qy         41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        289 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 348

Qy         61 GlyCysGluGlnThrArgThrAlaThrGluSerProHisProGlyPheAsnAsnSer 80
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        349 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 408

Qy         81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        409 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 468

Qy        101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        469 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 528

Qy        121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        529 TGCCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 588

Qy        141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        589 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 648

Qy        161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        649 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 708

Qy        181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
```

```
Db        709 GACTCCGGGGGCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 768

Qy        201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220

Db        769 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 828

Qy        221 TrpIleGlnGluThrMetLysAsnAsn 229

Db        829 TGGATCCAGGAGACGATGAAGAACAAT 855

RESULT 9
AX362425
LOCUS       AX362425                1204 bp    DNA     linear   PAT 15-FEB-2002
DEFINITION  Sequence 185 from Patent WO0208288.
ACCESSION   AX362425
VERSION     AX362425.1  GI:18694670
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Baker,K.P., Desnoyers,L., Gerritsen,M.E., Goddard,A.,
            Godowski,P.J., Grimaldi,J.C., Gurney,A.L., Smith,V., Stephan,J.P.,
            Watanabe,C.K. and Wood,W.I.
  TITLE     Secreted and transmembrane polypeptides and nucleic acids encoding
            the same
  JOURNAL   Patent: WO 0208288-A 185 31-JAN-2002;
            Genentech, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .1204
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"
BASE COUNT      306 a    364 c    294 g    240 t
ORIGIN

Alignment Scores:
Pred. No.:              4.53e-97        Length:         1204
Score:                  1258.00         Matches:        229
Percent Similarity:     100.00%         Conservative:   0
Best Local Similarity:  100.00%         Mismatches:     0
Query Match:            100.00%         Indels:         0
DB:                     6               Gaps:           0

US-09-856-320A-2_COPY_54_282 (1-229) x AX362425 (1-1204)

Qy          1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20

Db        169 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 228

Qy         21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40

Db        229 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 288

Qy         41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60

Db        289 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 348

Qy         61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAsnSer 80

Db        349 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 408

Qy         81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100

Db        409 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 468

Qy        101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120

Db        469 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 528

Qy        121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140

Db        529 TGCCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 588

Qy        141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160

Db        589 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 648

Qy        161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180

Db        649 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 708

Qy        181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200

Db        709 GACTCCGGGGGCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 768

Qy        201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220

Db        769 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 828

Qy        221 TrpIleGlnGluThrMetLysAsnAsn 229

Db        829 TGGATCCAGGAGACGATGAAGAACAAT 855

RESULT 10
AX454622
LOCUS       AX454622                1204 bp    DNA     linear   PAT 06-JUL-2002
DEFINITION  Sequence 207 from Patent WO0208284.
ACCESSION   AX454622
VERSION     AX454622.1  GI:21713935
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Baker,K.P., Ferrara,N., Gerber,H., Gerritsen,M.E., Goddard,A.,
            Godowski,P.J., Gurney,A.L., Hillan,K.J., Marsters,S.A., Pan,J.,
            Paoni,N.F., Stephan,J.P., Watanabe,C.K., Williams,P.M., Wood,W.I.
            and Ye,W.
  TITLE     Compositions and methods for the diagnosis and treatment of
            disorders involving angiogenesis
  JOURNAL   Patent: WO 0208284-A 207 31-JAN-2002;
            Genentech, Inc. (US) ; Baker, Kevin P. (US) ; Ferrara, Napoleone
            (US) ; Gerber, Hanspeter (US) ; Gerritsen, Mary E. (US) ; Goddard,
            Audrey (US) ; Godowski, Paul J. (US) ; Gurney, Austin L. (US) ;
            Hillan, Kenneth J. (US) ; Marsters, Scot A. (US) ; Pan, James (US)
            ; Paoni, Nicholas F. (US) ; Stephan, Jean-Philippe F. (US) ;
            Watanabe, Colin K. (US) ; Williams, P. Mickey (US) ; Wood, William
            I. (US)
FEATURES             Location/Qualifiers
     source          1. .1204
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"
BASE COUNT      306 a    364 c    294 g    240 t
ORIGIN

Alignment Scores:
Pred. No.:              4.53e-97        Length:         1204
Score:                  1258.00         Matches:        229
Percent Similarity:     100.00%         Conservative:   0
Best Local Similarity:  100.00%         Mismatches:     0
Query Match:            100.00%         Indels:         0
DB:                     6               Gaps:           0

US-09-856-320A-2_COPY_54_282 (1-229) x AX454622 (1-1204)

Qy          1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20

Db        169 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 228

Qy         21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
```

```
Db        229 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 288

Qy         41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        289 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 348

Qy         61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAsnSer 80
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        349 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 408

Qy         81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        409 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 468

Qy        101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        469 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 528

Qy        121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        529 TGCCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 588

Qy        141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        589 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 648

Qy        161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        649 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 708

Qy        181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        709 GACTCCGGGGGCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 768

Qy        201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        769 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 828

Qy        221 TrpIleGlnGluThrMetLysAsnAsn 229
              ||||||||||||||||||||||||||
Db        829 TGGATCCAGGAGACGATGAAGAACAAT 855
```

```
RESULT 11
AX464372
LOCUS       AX464372               1204 bp    DNA     linear   PAT 16-JUL-2002
DEFINITION  Sequence 505 from Patent WO0140466.
ACCESSION   AX464372
VERSION     AX464372.1  GI:21899202
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Baker,K.P., Beresini,M., Deforge,L., Desnoyers,L., Filvaroff,E.,
            Gao,W.Q., Gerritsen,M.E., Goddard,A., Godowski,P.J., Gurney,A.L.,
            Sherwood,S., Smith,V., Stewart,T.A., Tumas,D., Watanabe,C.K.,
            Wood,W.L. and Zhang,Z.
  TITLE     Secreted and transmembrane polypeptides and nucleic acids encoding
            same
  JOURNAL   Patent: WO 0140466-A 505 07-JUN-2001;
            Genentech Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .1204
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"
BASE COUNT      306 a    364 c    294 g    240 t
ORIGIN

Alignment Scores:
Pred. No.:              4.53e-97        Length:         1204
Score:                  1258.00         Matches:        229
```

```
Percent Similarity:     100.00%         Conservative:   0
Best Local Similarity:  100.00%         Mismatches:     0
Query Match:            100.00%         Indels:         0
DB:                     6               Gaps:           0

US-09-856-320A-2_COPY_54_282 (1-229) x AX464372 (1-1204)

Qy          1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        169 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 228

Qy         21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        229 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 288

Qy         41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        289 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 348

Qy         61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAsnSer 80
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        349 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 408

Qy         81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        409 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 468

Qy        101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        469 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 528

Qy        121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        529 TGCCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 588

Qy        141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        589 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 648

Qy        161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        649 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 708

Qy        181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        709 GACTCCGGGGGCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 768

Qy        201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        769 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 828

Qy        221 TrpIleGlnGluThrMetLysAsnAsn 229
              ||||||||||||||||||||||||||
Db        829 TGGATCCAGGAGACGATGAAGAACAAT 855
```

```
RESULT 12
AX491100
LOCUS       AX491100               1204 bp    DNA     linear   PAT 16-AUG-2002
DEFINITION  Sequence 207 from Patent WO0200690.
ACCESSION   AX491100
VERSION     AX491100.1  GI:22323887
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Baker,K.P., Ferrara,N., Gerber,H., Gerritsen,M.E., Goddard,A.,
            Godowski,P.J., Gurney,A.L., Hillan,K.J., Marsters,S.A., Pan,J.,
            Paoni,N.F., Stephan,J.P., Watanabe,C.K., Williams,P.M., Wood,W.I.
            and Ye,W.
  TITLE     Compositions and methods for the diagnosis and treatment of
            disorders involving angiogenesis
```

```
  JOURNAL   Patent: WO 0200690-A 207 03-JAN-2002;
            Genentech, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .1204
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"
BASE COUNT      306 a    364 c    294 g    240 t
ORIGIN

Alignment Scores:
Pred. No.:                4.53e-97        Length:          1204
Score:                    1258.00         Matches:         229
Percent Similarity:       100.00%         Conservative:    0
Best Local Similarity:    100.00%         Mismatches:      0
Query Match:              100.00%         Indels:          0
DB:                       6               Gaps:            0

US-09-856-320A-2_COPY_54_282 (1-229) x AX491100 (1-1204)

Qy          1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        169 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 228

Qy         21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        229 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 288

Qy         41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        289 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 348

Qy         61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAsnSer 80
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        349 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 408

Qy         81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        409 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 468

Qy        101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        469 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 528

Qy        121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        529 TGCCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 588

Qy        141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        589 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 648

Qy        161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        649 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 708

Qy        181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        709 GACTCCGGGGGCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 768

Qy        201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        769 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 828

Qy        221 TrpIleGlnGluThrMetLysAsnAsn 229
              |||||||||||||||||||||||||||
Db        829 TGGATCCAGGAGACGATGAAGAACAAT 855

RESULT 13
AX697101
LOCUS       AX697101                1204 bp    DNA     linear   PAT 02-APR-2003
DEFINITION  Sequence 169 from Patent WO0078961.
ACCESSION   AX697101
VERSION     AX697101.1  GI:29498066
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Ferrara,N., Stewart,T.A., Williams,P.M., Baker,K.P., Desnoyers,L.,
            Eaton,D.L., Gao,W.Q., Pan,J., Botstein,D., Fong,S., Goddard,A.,
            Godowski,P.J., Gurney,A.L., Smith,V., Tumas,D., Wood,W.I.,
            Grimaldi,C.J., Hillan,K.J., Paoni,N.F., Roy,M.A. and Watanabe,C.K.
  TITLE     Secreted and transmembrane polypeptides and nucleic acids encoding
            the same
  JOURNAL   Patent: WO 0078961-A 169 28-DEC-2000;
            Genentech Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .1204
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"
BASE COUNT      306 a    364 c    294 g    240 t
ORIGIN

Alignment Scores:
Pred. No.:                4.53e-97        Length:          1204
Score:                    1258.00         Matches:         229
Percent Similarity:       100.00%         Conservative:    0
Best Local Similarity:    100.00%         Mismatches:      0
Query Match:              100.00%         Indels:          0
DB:                       6               Gaps:            0

US-09-856-320A-2_COPY_54_282 (1-229) x AX697101 (1-1204)

Qy          1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        169 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 228

Qy         21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        229 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 288

Qy         41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        289 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 348

Qy         61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAsnSer 80
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        349 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 408

Qy         81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        409 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 468

Qy        101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        469 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 528

Qy        121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        529 TGCCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 588

Qy        141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        589 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 648

Qy        161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        649 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 708

Qy        181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        709 GACTCCGGGGGCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 768
```

```
Qy        201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        769 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 828

Qy        221 TrpIleGlnGluThrMetLysAsnAsn 229
              |||||||||||||||||||||||||||
Db        829 TGGATCCAGGAGACGATGAAGAACAAT 855

RESULT 14
BC022068
LOCUS       BC022068               1213 bp    mRNA    linear   PRI 24-JAN-2002
DEFINITION  Homo sapiens, kallikrein 11, clone MGC:33060 IMAGE:4824387, mRNA,
            complete cds.
ACCESSION   BC022068
VERSION     BC022068.1  GI:18314497
KEYWORDS    MGC.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1213)
  AUTHORS   Strausberg,R.
  TITLE     Direct Submission
  JOURNAL   Submitted (22-JAN-2002) National Institutes of Health, Mammalian
            Gene Collection (MGC), Cancer Genomics Office, National Cancer
            Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
            USA
  REMARK    NIH-MGC Project URL: http://mgc.nci.nih.gov
COMMENT     Contact: MGC help desk
            Email: cgapbs-r@mail.nih.gov
            Tissue Procurement: Miklos Palkovits, M.D., Ph.D.
            cDNA Library Preparation: Michael J. Brownstein (NHGRI) &  Shiraki
            Toshiyuki and Piero Carninci (RIKEN)
            cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
            DNA Sequencing by: Institute for Systems Biology
            http://www.systemsbiology.org
            contact: amadan@systemsbiology.org
            Anup Madan, Jessica Fahey, Erin Helton, Mark Ketteman, Anuradha
            Madan, Stephanie Rodrigues, Amy Sanchez and Michelle Whiting

            Clone distribution: MGC clone distribution information can be found
            through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
            Series: IRAK Plate: 46 Row: m Column: 6
            This clone was selected for full length sequencing because it
            passed the following selection criteria: matched mRNA gi: 5803198.
FEATURES             Location/Qualifiers
     source          1. .1213
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="LocusID:11012"
                     /db_xref="taxon:9606"
                     /clone="MGC:33060 IMAGE:4824387"
                     /tissue_type="Testis"
                     /clone_lib="NIH_MGC_97"
                     /lab_host="DH10B"
                     /note="Vector: pBluescript"
     CDS             133. .885
                     /codon_start=1
                     /product="kallikrein 11"
                     /protein_id="AAH22068.1"
                     /db_xref="GI:18314498"
                     /translation="MRILQLILLALATGLVGGETRIIKGFECKPHSQPWQAALFEKTR
                     LLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEEGCEQTRTATESFPHPGFNNSL
                     PNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTSCLISGWGSTSSPQLRLPHT
                     LRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQGDSGGPLVCNQSLQGIIS
                     WGQDPCAITRKPGVYTKVCKYVDWIQETMKNN"
BASE COUNT      290 a    376 c    296 g    251 t
ORIGIN

Alignment Scores:
Pred. No.:              4.57e-97        Length:         1213
Score:                  1258.00         Matches:        229
Percent Similarity:     100.00%         Conservative:   0
Best Local Similarity:  100.00%         Mismatches:     0
Query Match:            100.00%         Indels:         0
DB:                     9               Gaps:           0

US-09-856-320A-2_COPY_54_282 (1-229) x BC022068 (1-1213)

Qy          1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        196 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 255

Qy         21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        256 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 315

Qy         41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        316 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 375

Qy         61 GlyCysGluGlnThrArgThrAlaThrGluSerProHisProGlyPheAsnAsnSer 80
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        376 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 435

Qy         81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        436 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 495

Qy        101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        496 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 555

Qy        121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        556 TGCCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 615

Qy        141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        616 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 675

Qy        161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        676 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 735

Qy        181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        736 GACTCCGGGGGCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 795

Qy        201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        796 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 855

Qy        221 TrpIleGlnGluThrMetLysAsnAsn 229
              |||||||||||||||||||||||||||
Db        856 TGGATCCAGGAGACGATGAAGAACAAT 882

RESULT 15
BD091587
LOCUS       BD091587               1301 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Novel serine protease BSSP6.
ACCESSION   BD091587
VERSION     BD091587.1  GI:22637198
KEYWORDS    WO 0031257-A/1.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1301)
  AUTHORS   Uemura,H., Okui,A., Kominami,K., Yamaguchi,N. and Mitsui,S.
  TITLE     Novel serine protease BSSP6
  JOURNAL   Patent: WO 0031257-A 1 02-JUN-2000;
            FUSO PHARMACEUTICAL INDUSTRIES LTD,HIDETOSHI UEMURA,AKIRA OKUI,
            KATSUYA KOMINAMI,NOZOMI YAMAGUCHI,SHINICHI MITSUI
COMMENT     OS   Homo sapiens (human)
            PN   WO 0031257-A/1
```

```
            PD   02-JUN-2000
            PF   19-NOV-1999 WO 1999JP006476
            PR   20-NOV-1998 JP 98P   347802
            PI   HIDETOSHI UEMURA,AKIRA OKUI,KATSUYA KOMINAMI,NOZOMI YAMAGUCHI,
            PI   SHINICHI MITSUI
            PC   C12N15/12,C12N9/64,C12N5/06,C12N1/21,C07K16/40,C12P21/08, PC
           A01K67/027,
            PC   G01N33/543
            CC
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .1301
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"
BASE COUNT      332 a    387 c    330 g    252 t
ORIGIN

Alignment Scores:
Pred. No.:              4.92e-97        Length:         1301
Score:                  1258.00         Matches:        229
Percent Similarity:     100.00%         Conservative:   0
Best Local Similarity:  100.00%         Mismatches:     0
Query Match:            100.00%         Indels:         0
DB:                     6               Gaps:           0

US-09-856-320A-2_COPY_54_282 (1-229) x BD091587 (1-1301)

Qy          1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        272 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 331

Qy         21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        332 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 391

Qy         41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        392 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 451

Qy         61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAsnSer 80
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        452 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 511

Qy         81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        512 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 571

Qy        101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        572 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 631

Qy        121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        632 TGCCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 691

Qy        141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        692 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 751

Qy        161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        752 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 811

Qy        181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        812 GACTCCGGGGGCCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 871

Qy        201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        872 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 931

Qy        221 TrpIleGlnGluThrMetLysAsnAsn 229
              ||||||||||||||||||||||||||||
Db        932 TGGATCCAGGAGACGATGAAGAACAAT 958

Search completed: October 23, 2003, 18:05:25
Job time : 3420.8 secs
```

GenCore version 5.1.6

OM protein - nucleic search, using frame_plus_p2n model

Run on: October 23, 2003, 14:05:42 ; Search time 251.855 Seconds
(without alignments)
2454.471 Million cell updates/sec

Title: US-09-856-320A-2_COPY_54_282
Perfect score: 1258
Sequence: 1 IIKGFECKPHSQPWQAALFE.....GVYTKVCKYVDWIQETMKNN 229

Scoring table: BLOSUM62
Xgapop 10.0 , Xgapext 0.5
Ygapop 10.0 , Ygapext 0.5
Fgapop 6.0 , Fgapext 7.0
Delop 6.0 , Delext 7.0

Searched: 2552756 seqs, 1349719017 residues

Total number of hits satisfying chosen parameters: 5105512

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Command line parameters:
-MODEL=frame+_p2n.model -DEV=x1h
-Q=/cgn2_1/USPTO_spool/US09856320/runat_22102003_121413_25652/app_query.fasta_1.846
-DB=N_Geneseq_19Jun03 -QFMT=fastap -SUFFIX=rng -MINMATCH=0.1 -LOOPCL=0
-LOOPEXT=0 -UNITS=bits -START=1 -END=-1 -MATRIX=blosum62 -TRANS=human40.cdi
-LIST=45 -DOCALIGN=200 -THR_SCORE=pct -THR_MAX=100 -THR_MIN=0 -ALIGN=15
-MODE=LOCAL -OUTFMT=pto -NORM=ext -HEAPSIZE=500 -MINLEN=0 -MAXLEN=2000000000
-USER=US09856320_@CGN_1_1_401_@runat_22102003_121413_25652 -NCPU=6 -ICPU=3
-NO_MMAP -LARGEQUERY -NEG_SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG
-DEV_TIMEOUT=120 -WARN_TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5 -FGAPOP=6
-FGAPEXT=7 -YGAPOP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Database : N_Geneseq_19Jun03:*
1: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1980.DAT:*
2: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1981.DAT:*
3: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1982.DAT:*
4: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1983.DAT:*
5: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1984.DAT:*
6: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1985.DAT:*
7: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1986.DAT:*
8: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1987.DAT:*
9: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1988.DAT:*
10: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1989.DAT:*
11: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1990.DAT:*
12: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1991.DAT:*
13: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1992.DAT:*
14: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1993.DAT:*
15: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1994.DAT:*
16: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1995.DAT:*
17: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1996.DAT:*
18: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1997.DAT:*
19: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1998.DAT:*
20: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1999.DAT:*
21: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2000.DAT:*
22: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2001A.DAT:*
23: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2001B.DAT:*
24: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2002.DAT:*
25: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2003.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	1258	100.0	1106	20	AAZ22638	CASB12 nucleotide
2	1258	100.0	1158	20	AAZ22639	CASB12 derived fro
3	1258	100.0	1186	24	ABK92131	Prostate cancer-as
4	1258	100.0	1186	25	ABX76468	Lung cancer-associ
5	1258	100.0	1192	22	AAD14842	Human PS133 gene c
6	1258	100.0	1204	21	AAA37072	Human PRO1279 (UNQ
7	1258	100.0	1204	22	AAS21496	Human cDNA sequenc
8	1258	100.0	1204	22	AAF54320	DNA encoding prote
9	1258	100.0	1204	24	ABL95664	Human angiogenesis
10	1258	100.0	1204	24	ABL88175	Human PRO1279 cDNA
11	1258	100.0	1204	24	ABK33628	cDNA encoding huma
12	1258	100.0	1204	25	ACA03855	cDNA encoding huma
13	1258	100.0	1204	25	ACA04276	Human cDNA encodin
14	1258	100.0	1204	25	ABX89393	DNA encoding novel
15	1258	100.0	1292	22	ABA83372	Human secreted pro
16	1258	100.0	1301	21	AAA61763	cDNA encoding huma
17	1258	100.0	1314	21	AAZ30222	cDNA encoding a hu
18	1248	99.2	1146	20	AAV84589	Human secreted pro
19	1248	99.2	1146	22	ABA83430	Human secreted pro
20	1246	99.0	1166	22	AAD14841	Human PS133 consen
21	1235.5	98.2	934	21	AAA61765	cDNA encoding huma
22	1228	97.6	1191	20	AAX97777	Extended human sec
23	1227.5	97.6	1335	21	AAZ45572	Nucleotide sequenc
24	1219.5	96.9	1052	21	AAC87798	Activation constru
25	1219.5	96.9	1052	22	AAF55270	Nucleotide sequenc
26	1213	96.4	833	19	AAV42925	DNA encoding a hum
27	1062	84.4	1323	21	AAA61764	cDNA encoding mous
28	1014.5	80.6	1164	24	ABS51683	DNA encoding human
29	916.5	72.9	618	24	ABK30233	Human G-protein-co
30	829	65.9	762	21	AAH31050	Human colon cancer
31	829	65.9	762	21	AAH31061	Human colon cancer
32	736	58.5	1375	22	AAS26876	Human cDNA encodin
33	736	58.5	1438	24	ABQ99555	Human coding seque
34	734	58.3	1365	22	AAS41087	cDNA encoding nove
35	716	56.9	924	22	AAS41622	cDNA encoding nove
36	716	56.9	924	22	AAS26948	Human cDNA encodin
37	716	56.9	924	23	ABK41855	cDNA encoding nove
38	684	54.4	1322	24	ABI99534	Mouse ischaemic co
39	684	54.4	1333	17	AAT48519	Human neuropsin-en
40	684	54.4	1333	18	AAT63251	Mouse neuropsin ge
41	683	54.3	942	20	AAZ11030	Human serine prote
42	682	54.2	963	24	AAD30570	Human protease, PR
43	682	54.2	963	24	ABK31774	DNA encoding novel
44	682	54.2	1278	24	ABK48347	cDNA encoding nove
45	681	54.1	809	23	AAS87560	DNA encoding novel

ALIGNMENTS

RESULT 1
AAZ22638
ID AAZ22638 standard; cDNA; 1106 BP.
XX
AC AAZ22638;
XX
DT 08-DEC-1999 (first entry)
XX
DE CASB12 nucleotide sequence.
XX
KW neuropsin; cancer; assay; inhibitor; serine protease; immunogenic;
KW ds.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 14..862

```
FT                   /*tag=  a
FT                   /product= CASB12
XX
PN   WO9949055-A1.
XX
PD   30-SEP-1999.
XX
PF   17-MAR-1999;   99WO-EP01894.
XX
PR   20-MAR-1998;   98GB-0006095.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI   Bruck CEM,  Cassart J,  Coche T,  Vinals-Bassols C;
XX
DR   WPI; 1999-580450/49.
DR   P-PSDB; AAY42439.
XX
PT   New human serine protease CASB12, for treatment, prevention and
PT   diagnosis of cancer and autoimmune diseases  -
XX
PS   Claim 10; Page 47; 58pp; English.
XX
CC   This is the nucleotide sequence of the CASB12 gene. The nucleotide
CC   sequence of AAZ22638 shows homology with neuropsin and the encoded
CC   protein AAY42439 is structurally related to other proteins of the
CC   serine protease family, having homology and/or structural similarity
CC   with neuropsin. It is expected that as well as similar structure, these
CC   proteins will also share similar biological functions and properties.
CC   The CASB12 polypeptides and polynucleotides can be used to develop
CC   methods for identifying agonists and antagonists/inhibitors of these
CC   molecules, and thereby treating conditions associated with CASB12
CC   polypeptide imbalance. The invention also provides for diagnostic assays
CC   for detecting diseases associated with inappropriate CASB12 polypeptide
CC   activity or levels.
CC   Since CASB12 is either specifically expressed or highly over-expressed
CC   in tumors compared to normal cells, the polypeptides and polynucleotides
CC   of the invention are believed to be important immunogens for specific
CC   prophylactic or therapeutic immunization against tumors. The
CC   polypeptides and polynucleotides can therefore be targeted by antigen
CC   specific immune reactions (which result in the destruction of the tumor
CC   cell) or they can be used to diagnose the occurrence of tumor cells.
XX
SQ   Sequence 1106 BP; 247 A; 348 C; 287 G; 224 T; 0 other;

Alignment Scores:
Pred. No.:              4.52e-105      Length:          1106
Score:                  1258.00        Matches:         229
Percent Similarity:     100.00%        Conservative:    0
Best Local Similarity:  100.00%        Mismatches:      0
Query Match:            100.00%        Indels:          0
DB:                     20             Gaps:            0

US-09-856-320A-2_COPY_54_282 (1-229) x AAZ22638 (1-1106)

Qy          1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        173 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 232

Qy         21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        233 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 292

Qy         41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        293 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 352

Qy         61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAsnSer 80
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        353 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 412

Qy         81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Db        413 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 472

Qy        101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        473 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 532

Qy        121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        533 TGCCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 592

Qy        141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        593 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 652

Qy        161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        653 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 712

Qy        181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        713 GACTCCGGGGGCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 772

Qy        201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        773 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 832

Qy        221 TrpIleGlnGluThrMetLysAsnAsn 229
              |||||||||||||||||||||||||||
Db        833 TGGATCCAGGAGACGATGAAGAACAAT 859

RESULT 2
AAZ22639
ID   AAZ22639 standard; cDNA; 1158 BP.
XX
AC   AAZ22639;
XX
DT   08-DEC-1999  (first entry)
XX
DE   CASB12 derived from Expressed Sequence Tag sequences.
XX
KW   neuropsin; cancer; assay; inhibitor; serine protease; immunogenic;
KW   autoimmune disease; ds.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   CDS             84..932
FT                   /*tag=  a
FT                   /product= CASB12
XX
PN   WO9949055-A1.
XX
PD   30-SEP-1999.
XX
PF   17-MAR-1999;   99WO-EP01894.
XX
PR   20-MAR-1998;   98GB-0006095.
XX
PA   (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI   Bruck CEM,  Cassart J,  Coche T,  Vinals-bassols C;
XX
DR   WPI; 1999-580450/49.
DR   P-PSDB; AAY42440.
XX
PT   New human serine protease CASB12, for treatment, prevention and
PT   diagnosis of cancer and autoimmune diseases  -
XX
PS   Claim 26; Page 49; 58pp; English.
XX
CC   This is the nucleotide sequence of the CASB12 gene derived from
CC   Expressed Sequence Tag (EST) search for tumor-specific and
CC   tumor-associated antigens. The nucleotide sequence of AAZ22638 shows
```

```
CC   homology with neuropsin and the encoded protein AAY42439 is structurally
CC   related to other proteins of the serine protease family, having homology
CC   and/or structural similarity with neuropsin. It is expected that as well
CC   as similar structure, these proteins will also share similar biological
CC   functions and properties.
CC   The CASB12 polypeptides and polynucleotides can be used to develop
CC   methods for identifying agonists and antagonists/inhibitors of these
CC   molecules, and thereby treating conditions associated with CASB12
CC   polypeptide imbalance. The invention also provides for diagnostic assays
CC   for detecting diseases associated with inappropriate CASB12 polypeptide
CC   activity or levels.
CC   Since CASB12 is either specifically expressed or highly over-expressed
CC   in tumors compared to normal cells, the polypeptides and polynucleotides
CC   of the invention are believed to be important immunogens for specific
CC   prophylactic or therapeutic immunization against tumors. The
CC   polypeptides and polynucleotides can therefore be targeted by antigen
CC   specific immune reactions (which result in the destruction of the tumor
CC   cell) or they can be used to diagnose the occurrence of tumor cells
XX
SQ   Sequence 1158 BP; 274 A; 359 C; 306 G; 219 T; 0 other;

Alignment Scores:
Pred. No.:                4.8e-105        Length:          1158
Score:                    1258.00         Matches:         229
Percent Similarity:       100.00%         Conservative:    0
Best Local Similarity:    100.00%         Mismatches:      0
Query Match:              100.00%         Indels:          0
DB:                       20              Gaps:            0

US-09-856-320A-2_COPY_54_282 (1-229) x AAZ22639 (1-1158)

Qy          1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        243 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 302

Qy         21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        303 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 362

Qy         41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        363 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 422

Qy         61 GlyCysGluGlnThrArgThrAlaThrGluSerProHisProGlyPheAsnAsnSer 80
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        423 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 482

Qy         81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        483 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 542

Qy        101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        543 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 602

Qy        121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        603 TGCCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 662

Qy        141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        663 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 722

Qy        161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        723 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 782

Qy        181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        783 GACTCCGGGGGCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 842

Qy        201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        843 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 902

Qy        221 TrpIleGlnGluThrMetLysAsnAsn 229
              |||||||||||||||||||||||||||
Db        903 TGGATCCAGGAGACGATGAAGAACAAT 929

RESULT 3
ABK92131
ID   ABK92131 standard; DNA; 1186 BP.
XX
AC   ABK92131;
XX
DT   15-AUG-2002  (first entry)
XX
DE   Prostate cancer-associated DNA sequence #17.
XX
KW   Prostate cancer; prostate tumour tissue; human; mammal; cytostatic;
KW   gene therapy; gene; ds.
XX
OS   Mammalia.
XX
PN   WO200230268-A2.
XX
PD   18-APR-2002.
XX
PF   12-OCT-2001; 2001WO-US32045.
XX
PR   13-OCT-2000; 2000US-0687576.
PR   08-DEC-2000; 2000US-0733288.
PR   08-DEC-2000; 2000US-0733742.
PR   24-JAN-2001; 2001US-263957P.
PR   16-MAR-2001; 2001US-276791P.
PR   16-MAR-2001; 2001US-276888P.
PR   06-APR-2001; 2001US-281922P.
PR   24-APR-2001; 2001US-286214P.
PR   30-APR-2001; 2001US-0847046.
PR   04-MAY-2001; 2001US-288589P.
XX
PA   (EOSB-) EOS BIOTECHNOLOGY INC.
XX
PI   Gish KC,  Mack DH,  Wilson KE,  Afar D,  Hevezi P;
XX
DR   WPI; 2002-471335/50.
DR   P-PSDB; ABG61816.
XX
PT   Detecting a prostate cancer-associated transcript in a cell in a
PT   patient, useful for diagnosing prostate cancer (PC) or screening
PT   modulators of PC, by determining if prostate cancer-associated genes
PT   are expressed in a prostate tissue
XX
PS   Claim 22; Page 313; 436pp; English.
XX
CC   The present invention relates to methods of detecting a prostate
CC   cancer-associated transcript in a cell from a patient. The method
CC   comprises contacting a biological sample from the patient with
CC   prostate cancer-associated polynucleotides (designated PC genes) that
CC   selectively hybridise to a sequence that is at least 80% identical
CC   to them. The prostate cancer-associated polynucleotide sequences
CC   are differentially expressed in prostate tumour tissue or in
CC   prostate cancer and are derived from the tissues of various
CC   organisms such as humans or other mammals (e.g. mice, sheep and dogs).
CC   The methods of the invention are useful for diagnosing and treating
CC   prostate cancer in mammals. The prostate cancer-associated genes are
CC   useful for diagnosing or treating prostate cancer, as well as for
CC   identifying modulators of prostate cancer or agents that inhibit
CC   prostate cancer. The nucleic acid sequences are particularly useful
CC   in gene therapy, as a vaccine or in antisense applications.
CC   ABK92115-ABK92263 represent prostate cancer-associated polynucleotide
CC   sequences.
XX
SQ   Sequence 1186 BP; 272 A; 368 C; 302 G; 244 T; 0 other;

Alignment Scores:
```

Pred. No.:	4.95e-105	Length:	1186
Score:	1258.00	Matches:	229
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	100.00%	Indels:	0
DB:	24	Gaps:	0

US-09-856-320A-2_COPY_54_282 (1-229) x ABK92131 (1-1186)

```
Qy          1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu  20
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        185 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 244

Qy         21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla  40
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        245 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 304

Qy         41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu  60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        305 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 364

Qy         61 GlyCysGluGlnThrArgThrAlaThrGluSerProHisProGlyPheAsnAsnSer  80
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        365 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 424

Qy         81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        425 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 484

Qy        101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        485 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 544

Qy        121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        545 TGCCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 604

Qy        141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        605 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 664

Qy        161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        665 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 724

Qy        181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        725 GACTCCGGGGGCCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 784

Qy        201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        785 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 844

Qy        221 TrpIleGlnGluThrMetLysAsnAsn 229
              ||||||||||||||||||||||||||
Db        845 TGGATCCAGGAGACGATGAAGAACAAT 871
```

RESULT 4
ABX76468
ID ABX76468 standard; DNA; 1186 BP.
XX
AC ABX76468;
XX
DT 02-APR-2003 (first entry)
XX
DE Lung cancer-associated polynucleotide #332.
XX
KW Lung cancer-associated polynucleotide; gene; ds; cytostatic; emphysema;
KW antiinflammatory; antiasthmatic; non-small cell lung cancer; atelectasis;
KW small cell lung cancer; benign lesion; precancerous lesion; bronchitis;
KW chronic obstructive pulmonary disease; hypersensitivity pneumonitis;
KW interstitial pulmonary fibrosis; fibrosis; asthma; bronchiectasis.
XX
OS Unidentified.
XX
PN WO200286443-A2.
XX
PD 31-OCT-2002.
XX
PF 18-APR-2002; 2002WO-US12476.
XX
PR 18-APR-2001; 2001US-284770P.
PR 10-MAY-2001; 2001US-290492P.
PR 09-NOV-2001; 2001US-339245P.
PR 13-NOV-2001; 2001US-350666P.
PR 29-NOV-2001; 2001US-334370P.
PR 12-APR-2002; 2002US-372246P.
XX
PA (EOSB-) EOS BIOTECHNOLOGY INC.
XX
PI Aziz N, Murray R;
XX
DR WPI; 2003-093161/08.
DR P-PSDB; ABU56739.
XX
PT Detecting a lung cancer-associated transcript in a cell from a patient
PT for treating lung cancer, by contacting a biological sample from the
PT patient with a polynucleotide that exhibits increased or decreased
PT expression in lung cancer -
XX
PS Claim 22; Page 443; 453pp; English.
XX
CC The invention relates to a method for detecting a lung cancer-associated
CC transcript in a cell from a patient, comprising contacting a biological
CC sample from the patient with a polynucleotide that selectively hybridises
CC to a sequence that is at least 80 % identical to a gene that exhibits
CC increased or decreased expression in lung cancer samples. Lung
CC cancer-associated polynucleotides and polypeptides are used for
CC identifying a compound that modulates a lung cancer-associated
CC polypeptide, for inhibiting proliferation of a lung cancer-associated
CC cell to treat lung cancer in a patient and for treating a mammal having
CC lung cancer by administering a modulatory compound identified. The
CC methods are useful for treating lung cancer, such as small cell lung
CC cancer, non-small cell lung cancer or other benign or precancerous
CC lesions, e.g. atelectasis, emphysema, bronchitis, chronic obstructive
CC pulmonary disease, fibrosis, hypersensitivity pneumonitis, interstitial
CC pulmonary fibrosis, asthma and bronchiectasis. The genes, polynucleotides
CC and polypeptides are useful for diagnostic purposes and as targets for
CC screening for therapeutic compounds that modulate lung cancer, such as
CC antibodies. Sequences ABX76124-ABX76474 represent lung cancer-associated
CC polynucleotides of the invention.
XX
SQ Sequence 1186 BP; 272 A; 368 C; 302 G; 244 T; 0 other;

Alignment Scores:

Pred. No.:	4.95e-105	Length:	1186
Score:	1258.00	Matches:	229
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	100.00%	Indels:	0
DB:	25	Gaps:	0

US-09-856-320A-2_COPY_54_282 (1-229) x ABX76468 (1-1186)

```
Qy          1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu  20
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        185 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 244

Qy         21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla  40
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        245 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 304

Qy         41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu  60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        305 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 364
```

```
Qy          61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAsnSer 80
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         365 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 424

Qy          81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         425 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 484

Qy         101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         485 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 544

Qy         121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         545 TGCCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 604

Qy         141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         605 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 664

Qy         161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         665 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 724

Qy         181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         725 GACTCCGGGGGCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 784

Qy         201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         785 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 844

Qy         221 TrpIleGlnGluThrMetLysAsnAsn 229
               ||||||||||||||||||||||||||
Db         845 TGGATCCAGGAGACGATGAAGAACAAT 871

RESULT 5
AAD14842
ID   AAD14842 standard; DNA; 1192 BP.
XX
AC   AAD14842;
XX
DT   01-NOV-2001  (first entry)
XX
DE   Human PS133 gene contig.
XX
KW   Human; PS133; prostate disease; cancer; immunogen; gene therapy; EST;
KW   expressed sequence tag; cytostatic; ds.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   CDS             107..859
FT                   /*tag= a
PT                   /product= "Human PS133 protein"
FT                   /transl_except= (pos:188..196, aa:Cys-Pro)
FT                   /transl_except= (pos:224..232, aa:Phe-Lys)
XX
PN   US6232456-B1.
XX
PD   15-MAY-2001.
XX
PF   06-OCT-1997;   97US-0944483.
XX
PR   06-OCT-1997;   97US-0944483.
XX
PA   (ABBO ) ABBOTT LAB.
XX
PI   Cohen M,  Colpitts TL,  Friedman PN,  Granados E,  Klass MR;
PI   Russell JC,  Stewart KD,  Stroupe SD;
XX
DR   WPI; 2001-366357/38.
DR   P-PSDB; AAE08017.
XX
PT   New PS133 polynucleotides, useful for detecting, diagnosing, staging,
PT   monitoring, prognosing, preventing, treating or determining the
PT   predisposition of an individual to a prostate disease, e.g. cancer -
XX
PS   Claim 1; Column 71-74; 93pp; English.
XX
CC   The patent discloses PS133 polynucleotides and polypeptides which
CC   are indicative of prostate disease. The patent also provides a method
CC   for detecting PS133 protein in a test sample. The polynucleotides of
CC   the invention are useful for detecting, diagnosing, staging, monitoring,
CC   prognosing, preventing, treating or determining the predisposition of
CC   an individual to prostate diseases such as cancer. PS133-derived
CC   polynucleotides are used for the detection of normal or altered gene
CC   expression, in assays for detecting, amplifying or quantifying genes
CC   or nucleic acids relating to prostate tissue diseases and conditions,
CC   and to produce probes which can be used in the detection of nucleic
CC   acids in a sample. PS133 proteins are used as immunogens for the
CC   production of antibodies. PS133 sequences are also used in gene
CC   therapy. The present sequence is human PS133 gene contig.
XX
SQ   Sequence 1192 BP; 279 A; 385 C; 290 G; 238 T; 0 other;

Alignment Scores:
Pred. No.:                4.98e-105       Length:          1192
Score:                    1258.00         Matches:         229
Percent Similarity:       100.00%         Conservative:    0
Best Local Similarity:    100.00%         Mismatches:      0
Query Match:              100.00%         Indels:          0
DB:                       22              Gaps:            0

US-09-856-320A-2_COPY_54_282 (1-229) x AAD14842 (1-1192)

Qy           1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         170 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 229

Qy          21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         230 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 289

Qy          41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         290 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 349

Qy          61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAsnSer 80
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         350 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 409

Qy          81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         410 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 469

Qy         101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         470 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 529

Qy         121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         530 TGCCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 589

Qy         141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         590 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 649

Qy         161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         650 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 709

Qy         181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         710 GACTCCGGGGGCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 769
```

```
Qy        201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        770 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 829

Qy        221 TrpIleGlnGluThrMetLysAsnAsn 229
              |||||||||||||||||||||||||||
Db        830 TGGATCCAGGAGACGATGAAGAACAAT 856
```

RESULT 6
AAA37072
ID AAA37072 standard; cDNA; 1204 BP.
XX
AC AAA37072;
XX
DT 08-AUG-2000 (first entry)
XX
DE Human PRO1279 (UNQ649) cDNA sequence SEQ ID NO:169.
XX
KW Human; PRO polypeptide; membrane bound protein; receptor; diagnosis;
KW transmembrane; secretion; immunoadhesion; pharmaceutical; screening;
KW ss.
XX
OS Homo sapiens.
XX
PN WO200012708-A2.
XX
PD 09-MAR-2000.
XX
PF 01-SEP-1999; 99WO-US20111.
XX
PR 01-SEP-1998; 98US-0098716.
PR 01-SEP-1998; 98US-0098749.
PR 01-SEP-1998; 98US-0098750.
PR 02-SEP-1998; 98US-0098803.
PR 02-SEP-1998; 98US-0098821.
PR 02-SEP-1998; 98US-0098843.
PR 09-SEP-1998; 98US-0099536.
PR 09-SEP-1998; 98US-0099596.
PR 09-SEP-1998; 98US-0099598.
PR 09-SEP-1998; 98US-0099602.
PR 09-SEP-1998; 98US-0099642.
PR 10-SEP-1998; 98US-0099741.
PR 10-SEP-1998; 98US-0099754.
PR 10-SEP-1998; 98US-0099763.
PR 10-SEP-1998; 98US-0099792.
PR 10-SEP-1998; 98US-0099808.
PR 10-SEP-1998; 98US-0099812.
PR 10-SEP-1998; 98US-0099815.
PR 10-SEP-1998; 98US-0099816.
PR 15-SEP-1998; 98US-0100385.
PR 15-SEP-1998; 98US-0100388.
PR 15-SEP-1998; 98US-0100390.
PR 16-SEP-1998; 98US-0100584.
PR 16-SEP-1998; 98US-0100627.
PR 16-SEP-1998; 98US-0100661.
PR 16-SEP-1998; 98US-0100662.
PR 16-SEP-1998; 98US-0100664.
PR 17-SEP-1998; 98US-0100683.
PR 17-SEP-1998; 98US-0100684.
PR 17-SEP-1998; 98US-0100710.
PR 17-SEP-1998; 98US-0100711.
PR 17-SEP-1998; 98US-0100919.
PR 17-SEP-1998; 98US-0100930.
PR 18-SEP-1998; 98US-0100848.
PR 18-SEP-1998; 98US-0100849.
PR 18-SEP-1998; 98US-0101014.
PR 18-SEP-1998; 98US-0101068.
PR 18-SEP-1998; 98US-0101071.
PR 22-SEP-1998; 98US-0101279.
PR 23-SEP-1998; 98US-0101471.
PR 23-SEP-1998; 98US-0101472.
PR 23-SEP-1998; 98US-0101474.
PR 23-SEP-1998; 98US-0101475.
PR 23-SEP-1998; 98US-0101476.
PR 23-SEP-1998; 98US-0101477.
PR 23-SEP-1998; 98US-0101479.
PR 24-SEP-1998; 98US-0101738.
PR 24-SEP-1998; 98US-0101741.
PR 24-SEP-1998; 98US-0101743.
PR 24-SEP-1998; 98US-0101915.
PR 24-SEP-1998; 98US-0101916.
PR 29-SEP-1998; 98US-0102207.
PR 29-SEP-1998; 98US-0102240.
PR 29-SEP-1998; 98US-0102307.
PR 29-SEP-1998; 98US-0102330.
PR 29-SEP-1998; 98US-0102331.
PR 30-SEP-1998; 98US-0102484.
PR 30-SEP-1998; 98US-0102487.
PR 30-SEP-1998; 98US-0102570.
PR 30-SEP-1998; 98US-0102571.
PR 01-OCT-1998; 98US-0102684.
PR 01-OCT-1998; 98US-0102687.
PR 02-OCT-1998; 98US-0102965.
PR 06-OCT-1998; 98US-0103258.
PR 06-OCT-1998; 98US-0103449.
PR 07-OCT-1998; 98US-0103314.
PR 07-OCT-1998; 98US-0103315.
PR 07-OCT-1998; 98US-0103328.
PR 07-OCT-1998; 98US-0103395.
PR 07-OCT-1998; 98US-0103396.
PR 07-OCT-1998; 98US-0103401.
PR 08-OCT-1998; 98US-0103633.
PR 08-OCT-1998; 98US-0103678.
PR 08-OCT-1998; 98US-0103679.
PR 08-OCT-1998; 98US-0103711.
PR 14-OCT-1998; 98US-0104257.
PR 20-OCT-1998; 98US-0104987.
PR 20-OCT-1998; 98US-0105000.
PR 20-OCT-1998; 98US-0105002.
PR 21-OCT-1998; 98US-0105104.
PR 22-OCT-1998; 98US-0105159.
PR 22-OCT-1998; 98US-0105256.
PR 26-OCT-1998; 98US-0105693.
PR 26-OCT-1998; 98US-0105694.
PR 27-OCT-1998; 98US-0105807.
PR 27-OCT-1998; 98US-0105881.
PR 27-OCT-1998; 98US-0105882.
PR 27-OCT-1998; 98US-0106062.
PR 28-OCT-1998; 98US-0106023.
PR 28-OCT-1998; 98US-0106029.
PR 28-OCT-1998; 98US-0106030.
PR 28-OCT-1998; 98US-0106032.
PR 28-OCT-1998; 98US-0106033.
PR 28-OCT-1998; 98US-0106178.
PR 29-OCT-1998; 98US-0106248.
PR 29-OCT-1998; 98US-0106384.
PR 29-OCT-1998; 98US-0108500.
PR 30-OCT-1998; 98US-0106464.
PR 03-NOV-1998; 98US-0106856.
PR 03-NOV-1998; 98US-0106902.
PR 03-NOV-1998; 98US-0106905.
PR 03-NOV-1998; 98US-0106919.
PR 03-NOV-1998; 98US-0106932.
PR 03-NOV-1998; 98US-0106934.
PR 10-NOV-1998; 98US-0107783.
PR 17-NOV-1998; 98US-0108775.
PR 17-NOV-1998; 98US-0108779.
PR 17-NOV-1998; 98US-0108787.
PR 17-NOV-1998; 98US-0108788.
PR 17-NOV-1998; 98US-0108801.
PR 17-NOV-1998; 98US-0108802.
PR 17-NOV-1998; 98US-0108806.
PR 17-NOV-1998; 98US-0108807.
PR 17-NOV-1998; 98US-0108867.
PR 17-NOV-1998; 98US-0108925.
PR 18-NOV-1998; 98US-0108848.

```
PR   18-NOV-1998;   98US-0108849.
PR   18-NOV-1998;   98US-0108850.
PR   18-NOV-1998;   98US-0108851.
PR   18-NOV-1998;   98US-0108852.
PR   18-NOV-1998;   98US-0108858.
PR   18-NOV-1998;   98US-0108904.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker K,  Goddard A,  Gurney AL,  Smith V,  Watanabe CK,  Wood WI;
XX
DR   WPI; 2000-237871/20.
DR   P-PSDB; AAY99390.
XX
PT   New mammalian DNA sequences encoding transmembrane, receptor or
PT   secreted PRO polypeptides, useful for screening of potential peptide or
PT   small molecule inhibitors of the relevant receptor/ligand interactions
XX
PS   Claim 2; Fig 101; 773pp; English.
XX
CC - AAA37022 to AAA37144 encode the new isolated human transmembrane,
CC   receptor or secreted PRO polypeptides given in AAY99340 to AAY99462. The
CC   transmembrane and receptor PRO proteins can be used for screening of
CC   potential peptide or small molecule inhibitors of the relevant
CC   receptor/ligand interactions. The polypeptides and nucleotide sequences
CC   encoding then have various industrial applications, including uses as
CC   pharmaceutical and diagnostic agents. AAA37145 to AAA37330 represent
CC   PCR primers and hybridisation probes used in the isolation of the PRO
CC   polypeptides from the present invention.
XX
SQ   Sequence 1204 BP; 306 A; 364 C; 294 G; 240 T; 0 other;

Alignment Scores:
Pred. No.:              5.04e-105      Length:          1204
Score:                  1258.00        Matches:         229
Percent Similarity:     100.00%        Conservative:    0
Best Local Similarity:  100.00%        Mismatches:      0
Query Match:            100.00%        Indels:          0
DB:                     21             Gaps:            0

US-09-856-320A-2_COPY_54_282 (1-229) x AAA37072 (1-1204)

Qy          1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        169 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 228

Qy         21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        229 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 288

Qy         41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        289 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 348

Qy         61 GlyCysGluGlnThrArgThrAlaThrGluSerProHisProGlyPheAsnAsnSer 80
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        349 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 408

Qy         81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        409 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 468

Qy        101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        469 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 528

Qy        121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        529 TGCCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 588

Qy        141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        589 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 648

Qy        161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        649 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 708

Qy        181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        709 GACTCCGGGGGCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 768

Qy        201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        769 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 828

Qy        221 TrpIleGlnGluThrMetLysAsnAsn 229
              |||||||||||||||||||||||||||
Db        829 TGGATCCAGGAGACGATGAAGAACAAT 855

RESULT 7
AAS21496
ID   AAS21496 standard; cDNA; 1204 BP.
XX
AC   AAS21496;
XX
DT   24-OCT-2001  (first entry)
XX
DE   Human cDNA sequence encoding for PRO1279 polypeptide.
XX
KW   Human secretory and transmembrane; PRO; mammalian; cancer; lung;
KW   breast; prostate; cervical; tumour necrosis factor-alpha; TNF-alpha;
KW   cartilage; ear; proliferation; glucose; free fatty acid; skeletal muscle;
KW   adipocyte; A-peptide; factor VIIA; gene therapy; ss.
XX
OS   Homo sapiens.
XX
PN   WO200140466-A2.
XX
PD   07-JUN-2001.
XX
PF   01-DEC-2000; 2000WO-US32678.
XX
PR   01-DEC-1999;   99WO-US28301.
PR   01-DEC-1999;   99WO-US28634.
PR   02-DEC-1999;   99WO-US28551.
PR   02-DEC-1999;   99WO-US28564.
PR   02-DEC-1999;   99WO-US28565.
PR   09-DEC-1999;   99US-0170262.
PR   16-DEC-1999;   99WO-US30095.
PR   20-DEC-1999;   99WO-US30911.
PR   20-DEC-1999;   99WO-US30999.
PR   30-DEC-1999;   99WO-US31243.
PR   06-JAN-2000; 2000WO-US00277.
PR   06-JAN-2000; 2000WO-US00376.
PR   11-FEB-2000; 2000WO-US03565.
PR   18-FEB-2000; 2000WO-US04341.
PR   18-FEB-2000; 2000WO-US04342.
PR   22-FEB-2000; 2000WO-US04414.
PR   24-FEB-2000; 2000WO-US04914.
PR   24-FEB-2000; 2000WO-US05004.
PR   01-MAR-2000; 2000WO-US05601.
PR   20-MAR-2000; 2000WO-US07377.
PR   21-MAR-2000; 2000WO-US07532.
PR   30-MAR-2000; 2000WO-US08439.
PR   17-MAY-2000; 2000WO-US13705.
PR   22-MAY-2000; 2000WO-US14042.
PR   30-MAY-2000; 2000WO-US14941.
PR   02-JUN-2000; 2000WO-US15264.
PR   10-NOV-2000; 2000WO-US30873.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
```

```
XX
DR   WPI; 2001-408281/43.
DR   P-PSDB; AAU12424.
XX
PT   Isolated, secretory and transmembrane PRO polypeptide used to detect
PT   other PRO polypeptides, link bioactive molecules to cells expressing
PT   PRO polypeptides, and detect the presence of mammalian tumours e.g.
PT   lung, breast, prostate, cervical  -
XX
PS   Claim 3; Fig 505; 813pp; English.
XX
CC   AAS21244-AAS21518 encode for novel human secretory and transmembrane
CC   PRO polypeptides. The PRO polypeptides are useful to detect other
CC   PRO polypeptides, to link bioactive molecules to cells expressing
CC   PRO polypeptides, to modulate biological activities of cells expressing
CC   PRO polypeptides, and to detect the presence of mammalian lung, colon,
CC   breast, prostate, rectal, cervical or liver tumours by comparing PRO
CC   polypeptide expression in a cell sample to that in a control sample.
CC   Some of the 275 sequences are also useful to stimulate the release of
CC   tumour necrosis factor-alpha (TNF-alpha) from human blood, the
CC   proliferation or differentiation of chondrocytes, the proliferation or
CC   gene expression in pericyte cells, the release of proteoglycans from
CC   cartilage, the proliferation of inner ear utricular supporting cells or
CC   of T-lymphocytes, the release of a cytokine from peripheral blood
CC   monocytes (PBMCs), or the proliferation of endothelial cells. Some of
CC   the PRO polypeptides may modulate glucose or free fatty acid uptake by
CC   skeletal muscle cells or by adipocytes; or inhibit binding of A-peptide
CC   to factor VIIA. The PRO polypeptides can be used in assays to identify
CC   molecules involved in binding interactions. The polynucleotides encoding
CC   PRO polypeptides can be used to generate probes, antisense RNA/DNA,
CC   transgenic or knock out animals and can be used in gene therapy.
XX
SQ   Sequence 1204 BP; 306 A; 364 C; 294 G; 240 T; 0 other;

Alignment Scores:
Pred. No.:                5.04e-105       Length:          1204
Score:                    1258.00         Matches:         229
Percent Similarity:       100.00%         Conservative:    0
Best Local Similarity:    100.00%         Mismatches:      0
Query Match:              100.00%         Indels:          0
DB:                       22              Gaps:            0

US-09-856-320A-2_COPY_54_282 (1-229) x AAS21496 (1-1204)

Qy          1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        169 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 228

Qy         21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        229 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 288

Qy         41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        289 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 348

Qy         61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAsnSer 80
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        349 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 408

Qy         81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        409 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 468

Qy        101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        469 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 528

Qy        121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        529 TGCCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 588

Qy        141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        589 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 648

Qy        161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        649 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 708

Qy        181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        709 GACTCCGGGGGCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 768

Qy        201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        769 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 828

Qy        221 TrpIleGlnGluThrMetLysAsnAsn 229
              |||||||||||||||||||||||||||
Db        829 TGGATCCAGGAGACGATGAAGAACAAT 855

RESULT 8
AAF54320
ID   AAF54320 standard; DNA; 1204 BP.
XX
AC   AAF54320;
XX
DT   02-APR-2001  (first entry)
XX
DE   DNA encoding protein of the invention #51.
XX
KW   Secreted; transmembrane; gene therapy; ss.
XX
OS   Unidentified.
XX
PN   WO200078961-A1.
XX
PD   28-DEC-2000.
XX
PF   18-FEB-2000; 2000WO-US04342.
XX
PR   23-JUN-1999;   99US-0141037.
PR   20-JUL-1999;   99US-0144758.
PR   26-JUL-1999;   99US-0145698.
PR   01-SEP-1999;   99WO-US20111.
PR   29-OCT-1999;   99US-0162506.
PR   30-NOV-1999;   99WO-US28313.
PR   02-DEC-1999;   99WO-US28551.
PR   16-DEC-1999;   99WO-US30095.
PR   05-JAN-2000; 2000WO-US00219.
PR   06-JAN-2000; 2000WO-US00376.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
PI   Gao W, Goddard A, Godowski PJ, Grimaldi CJ, Gurney AL, Hillan KJ;
PI   Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D;
PI   Watanabe CK, Williams PM, Wood WI;
XX
DR   WPI; 2001-071395/08.
XX
PT   Secreted and transmembrane proteins and nucleic acids designated PRO,
PT   useful as hybridization probes, in chromosome and gene mapping and gene
PT   therapy -
XX
PS   Claim 2; Fig 101; 787pp; English.
XX
CC   The present invention relates to secreted and transmembrane proteins.
CC   These proteins and the DNA encoding them may be used as hybridization
CC   probes, in chromosome and gene mapping and in the generation of
CC   anti-sense RNA and DNA. They may also be used used to generate either
CC   transgenic animals or knockout animals which are in turn useful for
CC   development and screening of therapeutically useful reagents.
CC   The nucleic acids may also be used in gene therapy.
XX
```

```
SQ   Sequence 1204 BP; 306 A; 364 C; 294 G; 240 T; 0 other;

Alignment Scores:
Pred. No.:              5.04e-105       Length:         1204
Score:                  1258.00         Matches:        229
Percent Similarity:     100.00%         Conservative:   0
Best Local Similarity:  100.00%         Mismatches:     0
Query Match:            100.00%         Indels:         0
DB:                     22              Gaps:           0

US-09-856-320A-2_COPY_54_282 (1-229) x AAP54320 (1-1204)

Qy          1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        169 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 228

Qy         21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        229 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 288

Qy         41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        289 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 348

Qy         61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAsnSer 80
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        349 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 408

Qy         81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        409 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 468

Qy        101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        469 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 528

Qy        121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        529 TGCCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 588

Qy        141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        589 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 648

Qy        161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        649 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 708

Qy        181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        709 GACTCCGGGGGCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 768

Qy        201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        769 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 828

Qy        221 TrpIleGlnGluThrMetLysAsnAsn 229
              |||||||||||||||||||||||||||
Db        829 TGGATCCAGGAGACGATGAAGAACAAT 855

RESULT 9
ABL95664
ID   ABL95664 standard; cDNA; 1204 BP.
XX
AC   ABL95664;
XX
DT   19-JUL-2002  (first entry)
XX
DE   Human angiogenesis related cDNA PRO1279 SEQ ID NO: 207.
XX
KW   Human; angiogenesis; PRO protein; cardiovascularisation; wound; cancer;
KW   atherosclerosis; cardiac hypertrophy; gene therapy; endothelial disorder;
KW   cardiant; cytostatic; antiangiogenic; hypotensive; vulnerary;
KW   antiarteriosclerotic; gene; ss.
XX
OS   Homo sapiens.
XX
PN   WO200208284-A2.
XX
PD   31-JAN-2002.
XX
PF   09-JUL-2001; 2001WO-US21735.
XX
PR   20-JUL-2000; 2000US-219556P.
PR   25-JUL-2000; 2000US-220624P.
PR   25-JUL-2000; 2000US-220664P.
PR   28-JUL-2000; 2000WO-US20710.
PR   02-AUG-2000; 2000US-222695P.
PR   17-AUG-2000; 2000US-0643657.
PR   23-AUG-2000; 2000WO-US23522.
PR   24-AUG-2000; 2000WO-US23328.
PR   07-SEP-2000; 2000US-230978P.
PR   15-SEP-2000; 2000US-000000P.
PR   18-SEP-2000; 2000US-0664610.
PR   18-SEP-2000; 2000US-0665350.
PR   24-OCT-2000; 2000US-242922P.
PR   08-NOV-2000; 2000US-0709238.
PR   08-NOV-2000; 2000WO-US30952.
PR   10-NOV-2000; 2000WO-US30873.
PR   01-DEC-2000; 2000WO-US32678.
PR   20-DEC-2000; 2000US-0747259.
PR   20-DEC-2000; 2000WO-US34956.
PR   22-JAN-2001; 2001US-0767609.
PR   28-FEB-2001; 2001US-0796498.
PR   28-FEB-2001; 2001WO-US06520.
PR   01-MAR-2001; 2001WO-US06666.
PR   09-MAR-2001; 2001US-0802706.
PR   14-MAR-2001; 2001US-0808689.
PR   22-MAR-2001; 2001US-0816744.
PR   05-APR-2001; 2001US-0828366.
PR   10-MAY-2001; 2001US-0854208.
PR   10-MAY-2001; 2001US-0854280.
PR   25-MAY-2001; 2001US-0866028.
PR   25-MAY-2001; 2001US-0866034.
PR   25-MAY-2001; 2001WO-US17092.
PR   30-MAY-2001; 2001US-0870574.
PR   30-MAY-2001; 2001WO-US17443.
PR   01-JUN-2001; 2001WO-US17800.
PR   20-JUN-2001; 2001WO-US19692.
PR   28-JUN-2001; 2001WO-US00000.
XX
PA   (GETH ) GENENTECH INC.
PA   (BAKE/) BAKER K P.
PA   (FERR/) FERRARA N.
PA   (GERB/) GERBER H.
PA   (GERR/) GERRITSEN M E.
PA   (GODD/) GODDARD A.
PA   (GODO/) GODOWSKI P J.
PA   (GURN/) GURNEY A L.
PA   (HILL/) HILLAN K J.
PA   (MARS/) MARSTERS S A.
PA   (PANJ/) PAN J.
PA   (PAON/) PAONI N F.
PA   (STEP/) STEPHAN J P.
PA   (WATA/) WATANABE C K.
PA   (WILL/) WILLIAMS P M.
PA   (WOOD/) WOOD W I.
XX
PI   Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;
PI   Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Paoni NF;
PI   Stephan JP, Watanabe CK, Williams PM, Wood WI, Ye W;
XX
DR   WPI; 2002-171999/22.
DR   P-PSDB; ABB95526.
XX
PT   One hundred and eighty seven nucleic acids encoding PRO polypeptides,
```

PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial
PT infarction), endothelial or angiogenic disorders in a mammal -
XX
PS Claim 1; Fig 207; 567pp; English.
XX
CC The present invention provides the protein and coding sequences of human
CC PRO proteins. These are useful for treating or diagnosing a
CC cardiovascular, endothelial or angiogenic disorder, including cardiac
CC hypertrophy, trauma, cancer, age-related macular degeneration,
CC atherosclerosis, hypertension, arterial restenosis, rheumatoid arthritis,
CC angina, myocardial infarctions, thrombophlebitis, lymphangitis, tumour
CC angiogenesis (such as breast carcinoma and liver carcinoma) and wound
CC healing. The present sequence is a coding sequence of the invention.
XX
SQ Sequence 1204 BP; 306 A; 364 C; 294 G; 240 T; 0 other;

Alignment Scores:

Pred. No.:	5.04e-105	Length:	1204
Score:	1258.00	Matches:	229
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	100.00%	Indels:	0
DB:	24	Gaps:	0

US-09-856-320A-2_COPY_54_282 (1-229) x ABL95664 (1-1204)

```
Qy          1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        169 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 228

Qy         21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        229 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 288

Qy         41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        289 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 348

Qy         61 GlyCysGluGlnThrArgThrAlaThrGluSerProHisProGlyPheAsnAsnSer 80
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        349 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 408

Qy         81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        409 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 468

Qy        101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        469 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 528

Qy        121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        529 TGCCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 588

Qy        141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        589 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 648

Qy        161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        649 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 708

Qy        181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        709 GACTCCGGGGGCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 768

Qy        201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        769 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 828

Qy        221 TrpIleGlnGluThrMetLysAsnAsn 229
              |||||||||||||||||||||||||||
Db        829 TGGATCCAGGAGACGATGAAGAACAAT 855
```

RESULT 10
ABL88175
ID ABL88175 standard; cDNA; 1204 BP.
XX
AC ABL88175;
XX
DT 16-MAY-2002 (first entry)
XX
DE Human PRO1279 cDNA sequence SEQ ID NO:207.
XX
KW Human; angiogenesis; cardiant; cytostatic; antiangiogenic; hypotensive;
KW vulnerary; antiarteriosclerotic; PRO agonist; PRO antagonist; trauma;
KW gene therapy; cardiovascular disorder; endothelial disorder; cancer;
KW angiogenic disorder; cardiac hypertrophy; atherosclerosis; hypertension;
KW age-related macular degeneration; arterial restenosis; angina;
KW rheumatoid arthritis; myocardial infarction; thrombophlebitis;
KW lymphangitis; tumour angiogenesis; breast carcinoma; liver carcinoma;
KW wound healing; chromosome mapping; gene mapping; gene; ss.
XX
OS Homo sapiens.
XX
PN WO200200690-A2.
XX
PD 03-JAN-2002.
XX
PF 20-JUN-2001; 2001WO-US19692.
XX
PR 23-JUN-2000; 2000US-213637P.
PR 20-JUL-2000; 2000US-219556P.
PR 25-JUL-2000; 2000US-220624P.
PR 25-JUL-2000; 2000US-220664P.
PR 28-JUL-2000; 2000WO-US20710.
PR 02-AUG-2000; 2000US-222695P.
PR 17-AUG-2000; 2000US-0643657.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 07-SEP-2000; 2000US-230978P.
PR 18-SEP-2000; 2000US-0664610.
PR 18-SEP-2000; 2000US-0665350.
PR 24-OCT-2000; 2000US-242922P.
PR 08-NOV-2000; 2000US-0709238.
PR 08-NOV-2000; 2000WO-US30952.
PR 10-NOV-2000; 2000WO-US30873.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000US-0747259.
PR 20-DEC-2000; 2000WO-US34956.
PR 22-JAN-2001; 2001US-0767609.
PR 28-FEB-2001; 2001US-0796498.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-MAR-2001; 2001WO-US06666.
PR 09-MAR-2001; 2001US-0802706.
PR 14-MAR-2001; 2001US-0808689.
PR 22-MAR-2001; 2001US-0816744.
PR 05-APR-2001; 2001US-0828366.
PR 10-MAY-2001; 2001US-0854208.
PR 10-MAY-2001; 2001US-0854280.
PR 25-MAY-2001; 2001US-0866028.
PR 25-MAY-2001; 2001US-0866034.
PR 25-MAY-2001; 2001WO-US17092.
PR 30-MAY-2001; 2001US-0870574.
PR 30-MAY-2001; 2001WO-US17443.
PR 01-JUN-2001; 2001WO-US17800.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Paoni NF;
PI Stephan JF, Watanabe CK, Williams PM, Wood WI, Ye W;
XX
DR WPI; 2002-090516/12.
DR P-PSDB; ABB84920.
XX

```
PT   One hundred and eighty seven nucleic acids encoding PRO polypeptides,
PT   useful in diagnosis and treatment of cardiovascular (e.g. myocardial
PT   infarction), endothelial or angiogenic disorders in a mammal -
XX
PS   Claim 2; Fig 207; 565pp; English.
XX
CC   ABL88072 to ABL88258 encode the PRO proteins given in ABB84817 to
CC   ABB85003. The PRO proteins and polynucleotides have cardiant, cytostatic,
CC   antiangiogenic, hypotensive, vulnerary and antiarteriosclerotic
CC   activities, and can be used in gene therapy. The PRO polynucleotides,
CC   proteins, agonists and antagonists are useful for treating or diagnosing
CC   a cardiovascular, endothelial or angiogenic disorder in a mammal,
CC   e.g. cardiac hypertrophy, trauma, cancer, age-related macular
CC   degeneration, atherosclerosis, hypertension, arterial restenosis,
CC   rheumatoid arthritis, angina, myocardial infarctions, thrombophlebitis,
CC   lymphangitis, tumour angiogenesis (such as breast carcinoma and liver
CC   carcinoma) and wound healing. The PRO polynucleotides have applications
CC   in molecular biology, including use as hybridisation probes, and in
CC   chromosome and gene mapping. ABL88259 to ABL88267 represent primers and
CC   probes used in the exemplification of the present invention.
XX
SQ   Sequence 1204 BP; 306 A; 364 C; 294 G; 240 T; 0 other;

Alignment Scores:
Pred. No.:                5.04e-105       Length:          1204
Score:                    1258.00         Matches:         229
Percent Similarity:       100.00%         Conservative:    0
Best Local Similarity:    100.00%         Mismatches:      0
Query Match:              100.00%         Indels:          0
DB:                       24              Gaps:            0

US-09-856-320A-2_COPY_54_282 (1-229) x ABL88175 (1-1204)

Qy          1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        169 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 228

Qy         21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        229 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 288

Qy         41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        289 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 348

Qy         61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAsnSer 80
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        349 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 408

Qy         81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        409 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 468

Qy        101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        469 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 528

Qy        121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        529 TGCCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 588

Qy        141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        589 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 648

Qy        161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        649 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 708

Qy        181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        709 GACTCCGGGGGCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 768

Qy        201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        769 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 828

Qy        221 TrpIleGlnGluThrMetLysAsnAsn 229
              |||||||||||||||||||||||||||
Db        829 TGGATCCAGGAGACGATGAAGAACAAT 855

RESULT 11
ABK33628
ID   ABK33628 standard; cDNA; 1204 BP.
XX
AC   ABK33628;
XX
DT   08-MAY-2002  (first entry)
XX
DE   cDNA encoding human PRO protein, Seq ID No 185.
XX
KW   Human; secreted protein; PRO; tumour; lung cancer; colon cancer;
KW   breast cancer; prostate tumour; rectal tumour; liver tumour;
KW   pericyte cell proliferation; chondrocyte cell proliferation;
KW   tumour necrosis factor-alpha; gene; ss.
XX
OS   Homo sapiens.
XX
PN   WO200208288-A2.
XX
PD   31-JAN-2002.
XX
PF   29-JUN-2001; 2001WO-US21066.
XX
PR   20-JUL-2000; 2000US-219556P.
PR   25-JUL-2000; 2000US-220585P.
PR   25-JUL-2000; 2000US-220605P.
PR   25-JUL-2000; 2000US-220607P.
PR   25-JUL-2000; 2000US-220624P.
PR   25-JUL-2000; 2000US-220638P.
PR   25-JUL-2000; 2000US-220664P.
PR   25-JUL-2000; 2000US-220666P.
PR   26-JUL-2000; 2000US-220893P.
PR   28-JUL-2000; 2000WO-US20710.
PR   23-AUG-2000; 2000WO-US23522.
PR   24-AUG-2000; 2000WO-US23328.
PR   15-SEP-2000; 2000US-000000P.
PR   10-NOV-2000; 2000WO-US30873.
PR   28-NOV-2000; 2000US-253646P.
PR   01-DEC-2000; 2000WO-US32678.
PR   20-DEC-2000; 2000US-0747259.
PR   20-DEC-2000; 2000WO-US34956.
PR   28-FEB-2001; 2001WO-US06520.
PR   10-MAY-2001; 2001US-0854280.
PR   25-MAY-2001; 2001WO-US17092.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI   Grimaldi JC, Gurney AL, Smith V, Stephan JP, Watanabe CK, Wood WI;
XX
DR   WPI; 2002-172001/22.
DR   P-PSDB; AAU83684.
XX
PT   One hundred and twenty two nucleic acids encoding PRO polypeptides,
PT   useful for treating a PRO related disorder and for diagnosing tumours
PT   such as lung cancer, colon cancer, breast tumour, prostate tumour, rectal
PT   tumour or liver tumour -
XX
PS   Claim 2; Figure 185; 359pp; English.
XX
CC   The invention relates to one hundred and twenty two nucleic acids
CC   encoding PRO polypeptides. The sequences of the 122 PRO polynucleotides
CC   encode human secreted proteins. The PRO nucleic acids, polypeptides,
CC   agonists and antagonists are useful for treating a PRO related disorder.
CC   The PRO polypeptides are useful for diagnosing tumours, especially lung
```

```
CC   cancer, colon cancer, breast tumour, prostate tumour, rectal tumour or
CC   liver tumour. The PRO polypeptides are useful for stimulating the
CC   proliferation of, or gene expression, in pericyte cells, for stimulating
CC   the proliferation or differentiation of chondrocyte cells, for
CC   stimulating the release of tumour necrosis factor-alpha from human blood,
CC   for stimulating or inhibiting the proliferation of normal human dermal
CC   fibroblast cells. The PRO polypeptide may also be used as molecular
CC   weight markers and for tissue typing. The PRO nucleic acids have
CC   applications in molecular biology, including use as hybridisation probes,
CC   and in chromosome and gene mapping. ABK33536-ABK33657 represent human
CC   PRO protein coding sequences of the invention.
XX
SQ   Sequence 1204 BP; 306 A; 364 C; 294 G; 240 T; 0 other;

Alignment Scores:
Pred. No.:              5.04e-105       Length:         1204
Score:                  1258.00         Matches:        229
Percent Similarity:     100.00%         Conservative:   0
Best Local Similarity:  100.00%         Mismatches:     0
Query Match:            100.00%         Indels:         0
DB:                     24              Gaps:           0

US-09-856-320A-2_COPY_54_282 (1-229) x ABK33628 (1-1204)

Qy          1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        169 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 228

Qy         21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        229 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 288

Qy         41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        289 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 348

Qy         61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAsnSer 80
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        349 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 408

Qy         81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        409 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 468

Qy        101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        469 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 528

Qy        121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        529 TGCCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 588

Qy        141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        589 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 648

Qy        161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        649 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 708

Qy        181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        709 GACTCCGGGGGCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 768

Qy        201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        769 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 828

Qy        221 TrpIleGlnGluThrMetLysAsnAsn 229
              ||||||||||||||||||||||||||
Db        829 TGGATCCAGGAGACGATGAAGAACAAT 855

RESULT 12
ACA03855
ID   ACA03855 standard; cDNA; 1204 BP.
XX
AC   ACA03855;
XX
DT   23-MAY-2003  (first entry)
XX
DE   cDNA encoding human PRO polypeptide #253.
XX
KW   Human; PRO polypeptide; secreted and transmembrane protein;
KW   tumour necrosis factor-alpha; TNF-alpha; blood; proliferation;
KW   differentiation; chondrocyte; tumour; genetic disorder;
KW   cytostatic; gene; ss.
XX
OS   Homo sapiens.
XX
PN   US2003036180-A1.
XX
PD   20-FEB-2003.
XX
PF   09-MAY-2002; 2002US-0143114.
XX
PR   31-MAR-1997;    97WO-US05230.
PR   12-JUN-1998;    98WO-US12456.
PR   14-JUL-1998;    98WO-US14552.
PR   28-AUG-1998;    98WO-US17888.
PR   10-SEP-1998;    98WO-US18824.
PR   14-SEP-1998;    98WO-US19093.
PR   14-SEP-1998;    98WO-US19094.
PR   14-SEP-1998;    98WO-US19177.
PR   16-SEP-1998;    98WO-US19330.
PR   17-SEP-1998;    98WO-US19437.
PR   07-OCT-1998;    98WO-US21141.
PR   29-OCT-1998;    98WO-US22991.
PR   29-OCT-1998;    98WO-US22992.
PR   20-NOV-1998;    98WO-US24855.
PR   01-DEC-1998;    98WO-US25108.
PR   05-JAN-1999;    99WO-US00106.
PR   08-MAR-1999;    99WO-US05028.
PR   10-MAR-1999;    99WO-US05190.
PR   20-APR-1999;    99WO-US08615.
PR   14-MAY-1999;    99WO-US10733.
PR   02-JUN-1999;    99WO-US12252.
PR   01-SEP-1999;    99WO-US20111.
PR   08-SEP-1999;    99WO-US20594.
PR   13-SEP-1999;    99WO-US20944.
PR   15-SEP-1999;    99WO-US21090.
PR   15-SEP-1999;    99WO-US21547.
PR   05-OCT-1999;    99WO-US23089.
PR   29-NOV-1999;    99WO-US28214.
PR   30-NOV-1999;    99WO-US28313.
PR   30-NOV-1999;    99WO-US28409.
PR   01-DEC-1999;    99WO-US28301.
PR   01-DEC-1999;    99WO-US28634.
PR   02-DEC-1999;    99WO-US28551.
PR   02-DEC-1999;    99WO-US28564.
PR   02-DEC-1999;    99WO-US28565.
PR   16-DEC-1999;    99WO-US30095.
PR   20-DEC-1999;    99WO-US30911.
PR   20-DEC-1999;    99WO-US30999.
PR   22-DEC-1999;    99WO-US30720.
PR   30-DEC-1999;    99WO-US31243.
PR   30-DEC-1999;    99WO-US31274.
PR   05-JAN-2000; 2000WO-US00219.
PR   06-JAN-2000; 2000WO-US00277.
PR   06-JAN-2000; 2000WO-US00376.
PR   11-FEB-2000; 2000WO-US03565.
PR   18-FEB-2000; 2000WO-US04341.
PR   18-FEB-2000; 2000WO-US04342.
PR   22-FEB-2000; 2000WO-US04414.
PR   24-FEB-2000; 2000WO-US04914.
PR   24-FEB-2000; 2000WO-US05004.
PR   01-MAR-2000; 2000WO-US05601.
```

PR 02-MAR-2000; 2000WO-US05746.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 21-MAR-2000; 2000WO-US07532.
PR 30-MAR-2000; 2000WO-US08439.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 10-NOV-2000; 2000WO-US30873.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-MAR-2001; 2001WO-US06666.
PR 25-MAY-2001; 2001WO-US17092.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 22-JUN-2001; 2001WO-US20116.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 20-DEC-2000; 2000US-0747259.
PR 28-FEB-2001; 2001US-0796498.
PR 09-MAR-2001; 2001US-0802706.
PR 14-MAR-2001; 2001US-0808689.
PR 22-MAR-2001; 2001US-0816744.
PR 05-APR-2001; 2001US-0828366.
PR 10-MAY-2001; 2001US-0854208.
PR 10-MAY-2001; 2001US-0854280.
PR 18-MAY-2001; 2001US-0860216.
PR 25-MAY-2001; 2001US-0866028.
PR 25-MAY-2001; 2001US-0866034.
PR 01-JUN-2001; 2001US-0872035.
PR 05-JUN-2001; 2001US-0874503.
PR 14-JUN-2001; 2001US-0882636.
PR 19-JUN-2001; 2001US-0886342.
PR 21-JUN-2001; 2001US-0887879.
PR 18-JUL-2001; 2001US-0908827.
PR 06-AUG-2001; 2001US-0924419.
PR 09-AUG-2001; 2001US-0927796.
PR 16-AUG-2001; 2001US-0931836.
PR 19-DEC-2001; 2001US-0028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-332040/31.
DR P-PSDB; ABU66822.
XX
PT New secreted and transmembrane PRO nucleic acids, useful for gene
PT therapy, in chromosome and gene mapping, as chromosome markers, in
PT tissue typing, and in chromosome identification -
XX
PS Claim 2; Fig 505; 660pp; English.
XX
CC The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The
CC PRO polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides are useful for detecting other PRO polypeptides, for
CC linking bioactive molecules to cells expressing PRO polypeptides,
CC for modulating biological activities of cells expressing PRO
CC polypeptides, and for for identifying agonists or antagonists.
CC The PRO polypeptides are useful for for stimulating the release of
CC tumour necrosis factor (TNF)-alpha from human blood, for stimulating
CC the proliferation or differentiation of chondrocytes, and detecting the
CC presence of tumours. The polynucleotide sequences encoding PRO
CC polypeptides are useful as hybridisation probes, in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptides, for generating transgenic animals or
CC knockout animals, for the genetic analysis of individuals with genetic
CC disorders, and in gene therapy. ACA03603-ACA03877 represent cDNAs
CC encoding the human PRO polypeptides of the invention.
CC Note: The sequence data for this patent was obtained in electronic
CC format directly from the USPTO web site at
CC seqdata.uspto.gov/psipsDIDEntry.html.
XX
SQ Sequence 1204 BP; 306 A; 364 C; 294 G; 240 T; 0 other;

Alignment Scores:

Pred. No.:	5.04e-105	Length:	1204
Score:	1258.00	Matches:	229
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	100.00%	Indels:	0
DB:	25	Gaps:	0

US-09-856-320A-2_COPY_54_282 (1-229) x ACA03855 (1-1204)

```
Qy          1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        169 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 228

Qy         21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        229 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 288

Qy         41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        289 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 348

Qy         61 GlyCysGluGlnThrArgThrAlaThrGluSerProHisProGlyPheAsnAsnSer 80
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        349 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 408

Qy         81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        409 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 468

Qy        101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        469 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 528

Qy        121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        529 TGCCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 588

Qy        141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        589 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 648

Qy        161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        649 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 708

Qy        181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        709 GACTCCGGGGGCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 768

Qy        201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        769 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 828

Qy        221 TrpIleGlnGluThrMetLysAsnAsn 229
              ||||||||||||||||||||||||||
Db        829 TGGATCCAGGAGACGATGAAGAACAAT 855
```

RESULT 13

```
ACA04276
ID   ACA04276 standard; cDNA; 1204 BP.
XX
AC   ACA04276;
XX
DT   27-MAY-2003  (first entry)
XX
DE   Human cDNA encoding a secreted/transmembrane protein, SEQ ID 505.
XX
KW   Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW   inflammatory disease; organ failure; atherosclerosis; cardiac injury;
KW   infertility; birth defects; premature aging; AIDS; biosensor;
KW   acquired immunodeficiency syndrome; cancer; diabetic complication;
KW   bioreactor; tumour.
XX
OS   Homo sapiens.
XX
PN   US2003032155-A1.
XX
PD   13-FEB-2003.
XX
PF   03-MAY-2002; 2002US-0137865.
XX
PR   31-MAR-1997;   97WO-US05230.
PR   12-JUN-1998;   98WO-US12456.
PR   14-JUL-1998;   98WO-US14552.
PR   28-AUG-1998;   98WO-US17888.
PR   10-SEP-1998;   98WO-US18824.
PR   14-SEP-1998;   98WO-US19093.
PR   14-SEP-1998;   98WO-US19094.
PR   14-SEP-1998;   98WO-US19177.
PR   16-SEP-1998;   98WO-US19330.
PR   17-SEP-1998;   98WO-US19437.
PR   07-OCT-1998;   98WO-US21141.
PR   29-OCT-1998;   98WO-US22991.
PR   29-OCT-1998;   98WO-US22992.
PR   20-NOV-1998;   98WO-US24855.
PR   01-DEC-1998;   98WO-US25108.
PR   05-JAN-1999;   99WO-US00106.
PR   08-MAR-1999;   99WO-US05028.
PR   10-MAR-1999;   99WO-US05190.
PR   20-APR-1999;   99WO-US08615.
PR   14-MAY-1999;   99WO-US10733.
PR   02-JUN-1999;   99WO-US12252.
PR   01-SEP-1999;   99WO-US20111.
PR   08-SEP-1999;   99WO-US20594.
PR   13-SEP-1999;   99WO-US20944.
PR   15-SEP-1999;   99WO-US21090.
PR   15-SEP-1999;   99WO-US21547.
PR   05-OCT-1999;   99WO-US23089.
PR   29-NOV-1999;   99WO-US28214.
PR   30-NOV-1999;   99WO-US28313.
PR   30-NOV-1999;   99WO-US28409.
PR   01-DEC-1999;   99WO-US28301.
PR   01-DEC-1999;   99WO-US28634.
PR   02-DEC-1999;   99WO-US28551.
PR   02-DEC-1999;   99WO-US28564.
PR   02-DEC-1999;   99WO-US28565.
PR   16-DEC-1999;   99WO-US30095.
PR   20-DEC-1999;   99WO-US30911.
PR   20-DEC-1999;   99WO-US30999.
PR   22-DEC-1999;   99WO-US30720.
PR   30-DEC-1999;   99WO-US31243.
PR   30-DEC-1999;   99WO-US31274.
PR   05-JAN-2000; 2000WO-US00219.
PR   06-JAN-2000; 2000WO-US00277.
PR   06-JAN-2000; 2000WO-US00376.
PR   11-FEB-2000; 2000WO-US03565.
PR   18-FEB-2000; 2000WO-US04341.
PR   18-FEB-2000; 2000WO-US04342.
PR   22-FEB-2000; 2000WO-US04414.
PR   24-FEB-2000; 2000WO-US04914.
PR   24-FEB-2000; 2000WO-US05004.
PR   01-MAR-2000; 2000WO-US05601.
PR   02-MAR-2000; 2000WO-US05746.
PR   02-MAR-2000; 2000WO-US05841.
PR   10-MAR-2000; 2000WO-US06319.
PR   15-MAR-2000; 2000WO-US06884.
PR   20-MAR-2000; 2000WO-US07377.
PR   21-MAR-2000; 2000WO-US07532.
PR   30-MAR-2000; 2000WO-US08439.
PR   17-MAY-2000; 2000WO-US13705.
PR   22-MAY-2000; 2000WO-US14042.
PR   30-MAY-2000; 2000WO-US14941.
PR   02-JUN-2000; 2000WO-US15264.
PR   28-JUL-2000; 2000WO-US20710.
PR   11-AUG-2000; 2000WO-US22031.
PR   23-AUG-2000; 2000WO-US23522.
PR   24-AUG-2000; 2000WO-US23328.
PR   08-NOV-2000; 2000WO-US30952.
PR   10-NOV-2000; 2000WO-US30873.
PR   01-DEC-2000; 2000WO-US32678.
PR   20-DEC-2000; 2000WO-US34956.
PR   28-FEB-2001; 2001WO-US06520.
PR   01-MAR-2001; 2001WO-US06666.
PR   25-MAY-2001; 2001WO-US17092.
PR   01-JUN-2001; 2001WO-US17800.
PR   20-JUN-2001; 2001WO-US19692.
PR   22-JUN-2001; 2001WO-US20116.
PR   29-JUN-2001; 2001WO-US21066.
PR   09-JUL-2001; 2001WO-US21735.
PR   20-DEC-2000; 2000US-0747259.
PR   28-FEB-2001; 2001US-0796498.
PR   09-MAR-2001; 2001US-0802706.
PR   14-MAR-2001; 2001US-0808689.
PR   22-MAR-2001; 2001US-0816744.
PR   05-APR-2001; 2001US-0828366.
PR   10-MAY-2001; 2001US-0854208.
PR   10-MAY-2001; 2001US-0854280.
PR   18-MAY-2001; 2001US-0860216.
PR   25-MAY-2001; 2001US-0866028.
PR   25-MAY-2001; 2001US-0866034.
PR   01-JUN-2001; 2001US-0872035.
PR   05-JUN-2001; 2001US-0874503.
PR   14-JUN-2001; 2001US-0882636.
PR   19-JUN-2001; 2001US-0886342.
PR   21-JUN-2001; 2001US-0887879.
PR   18-JUL-2001; 2001US-0908827.
PR   06-AUG-2001; 2001US-0924419.
PR   09-AUG-2001; 2001US-0927796.
PR   16-AUG-2001; 2001US-0931836.
PR   19-DEC-2001; 2001US-0028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR   WPI; 2003-331925/31.
DR   P-PSDB; ABU67098.
XX
PT   New secreted and transmembrane nucleic acids and polypeptides,
PT   designated as PRO, useful for treating inflammation, organ failure,
PT   atherosclerosis, cardiac injury, infertility, birth defects, premature
PT   aging, AIDS, or cancer -
XX
PS   Claim 2; Fig 505; 659pp; English.
XX
CC   The invention relates to an isolated nucleic acid comprising, or which is
CC   at least 80% identical to, or the full-length coding sequence of, any of
CC   the 275 nucleotide sequences, encoding the corresponding PRO polypeptide
CC   (one of 275 secreted or transmembrane proteins). The nucleic acid
CC   further comprises the full-length coding sequence of the DNA deposited
CC   under American Type Culture Collection (ATCC) accession number in a list
CC   given in the specification. Also included are vectors and host
```

```
CC   cells for producing PRO proteins, PRO fusion proteins, anti-PRO
CC   antibodies, PRO extracellular domains and mature sequences, methods
CC   of detecting PRO proteins, methods for stimulating the release of
CC   TNF-alpha (tumour necrosis factor alpha) from human blood,
CC   (and the proliferation of differentiation of chondrocyte cells, the
CC   proliferation of, or gene expression in pericyte cells, the release or
CC   proteoglycans from cartilage, proliferation of inner ear urticular
CC   supporting cells, the proliferation of T-lymphocyte cells, the release
CC   of a cytokine from peripheral blood mononuclear cells (PBMC), or the
CC   proliferation of endothelial cells), a method for modulating the uptake
CC   of glucose or free fatty acid (FFA) by skeletal muscle cells,
CC   a method for inhibiting the binding of A-peptide to factor VIIA,
CC   or the differentiation of adipocyte cells, a method for detecting the
CC   presence of a tumour in a mammal and an oligonucleotide probe derived
CC   from any of the nucleotide sequences cited above. The nucleic acids and
CC   polypeptides are useful for treating inflammatory diseases, organ
CC   failure, atherosclerosis, cardiac injury, infertility, birth defects,
CC   premature aging, AIDS (acquired immunodeficiency syndrome), cancer, or
CC   diabetic complications. The nucleic acids are useful as hybridisation
CC   probes, in chromosome and gene mapping, and in generating antisense RNA
CC   or DNA. The polypeptides are useful as pharmaceuticals, diagnostics,
CC   biosensors or bioreactors. Both are useful in tissue typing.
CC   The present sequence encodes a PRO protein of the invention.
XX
SQ   Sequence 1204 BP; 306 A; 364 C; 294 G; 240 T; 0 other;

Alignment Scores:
Pred. No.:                5.04e-105       Length:          1204
Score:                    1258.00         Matches:         229
Percent Similarity:       100.00%         Conservative:    0
Best Local Similarity:    100.00%         Mismatches:      0
Query Match:              100.00%         Indels:          0
DB:                       25              Gaps:            0

US-09-856-320A-2_COPY_54_282 (1-229) x ACA04276 (1-1204)

Qy          1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        169 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 228

Qy         21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        229 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 288

Qy         41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        289 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 348

Qy         61 GlyCysGluGlnThrArgThrAlaThrGluSerProHisProGlyPheAsnAsnSer 80
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        349 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 408

Qy         81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        409 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 468

Qy        101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        469 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 528

Qy        121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        529 TGCCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 588

Qy        141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        589 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 648

Qy        161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        649 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 708

Qy        181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        709 GACTCCGGGGGCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 768

Qy        201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        769 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 828

Qy        221 TrpIleGlnGluThrMetLysAsnAsn 229
              |||||||||||||||||||||||||||
Db        829 TGGATCCAGGAGACGATGAAGAACAAT 855

RESULT 14
ABX89393
ID   ABX89393 standard; cDNA; 1204 BP.
XX
AC   ABX89393;
XX
DT   13-MAY-2003  (first entry)
XX
DE   DNA encoding novel secreted and transmembrane protein PRO1279.
XX
KW   Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW   cardiac insufficiency disorder; cancer; tumour; immune response;
KW   adrenal cortical capillary endothelial growth; c-fos induction;
KW   vascular endothelial growth factor inhibition; VEGF inhibition;
KW   endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW   retinal neurons cell survival; rod photoreceptor cell survival;
KW   retinal disorder; retinitis pigmentosum; kidney disorder;
KW   mammalian kidney mesangial cell proliferation; Berger disease;
KW   dermatitis; herpetiformis; Crohn's disease; chondrocyte proliferation;
KW   chondrocyte redifferentiation; sports injury; arthritis; gene; ss.
XX
OS   Homo sapiens.
XX
PN   US2003017563-A1.
XX
PD   23-JAN-2003.
XX
PF   07-MAY-2002; 2002US-0140808.
XX
PR   31-MAR-1997;   97WO-US05230.
PR   12-JUN-1998;   98WO-US12456.
PR   14-JUL-1998;   98WO-US14552.
PR   28-AUG-1998;   98WO-US17888.
PR   10-SEP-1998;   98WO-US18824.
PR   14-SEP-1998;   98WO-US19093.
PR   14-SEP-1998;   98WO-US19094.
PR   14-SEP-1998;   98WO-US19177.
PR   16-SEP-1998;   98WO-US19330.
PR   17-SEP-1998;   98WO-US19437.
PR   07-OCT-1998;   98WO-US21141.
PR   29-OCT-1998;   98WO-US22991.
PR   29-OCT-1998;   98WO-US22992.
PR   20-NOV-1998;   98WO-US24855.
PR   01-DEC-1998;   98WO-US25108.
PR   05-JAN-1999;   99WO-US00106.
PR   08-MAR-1999;   99WO-US05028.
PR   10-MAR-1999;   99WO-US05190.
PR   20-APR-1999;   99WO-US08615.
PR   14-MAY-1999;   99WO-US10733.
PR   02-JUN-1999;   99WO-US12252.
PR   01-SEP-1999;   99WO-US20111.
PR   08-SEP-1999;   99WO-US20594.
PR   13-SEP-1999;   99WO-US20944.
PR   15-SEP-1999;   99WO-US21090.
PR   15-SEP-1999;   99WO-US21547.
PR   05-OCT-1999;   99WO-US23089.
PR   29-NOV-1999;   99WO-US28214.
PR   30-NOV-1999;   99WO-US28313.
PR   30-NOV-1999;   99WO-US28409.
PR   01-DEC-1999;   99WO-US28301.
PR   01-DEC-1999;   99WO-US28634.
PR   02-DEC-1999;   99WO-US28551.
```

```
PR   02-DEC-1999;   99WO-US28564.
PR   02-DEC-1999;   99WO-US28565.
PR   16-DEC-1999;   99WO-US30095.
PR   20-DEC-1999;   99WO-US30911.
PR   20-DEC-1999;   99WO-US30999.
PR   22-DEC-1999;   99WO-US30720.
PR   30-DEC-1999;   99WO-US31243.
PR   30-DEC-1999;   99WO-US31274.
PR   05-JAN-2000; 2000WO-US00219.
PR   06-JAN-2000; 2000WO-US00277.
PR   06-JAN-2000; 2000WO-US00376.
PR   11-FEB-2000; 2000WO-US03565.
PR   18-FEB-2000; 2000WO-US04341.
PR   18-FEB-2000; 2000WO-US04342.
PR   22-FEB-2000; 2000WO-US04414.
PR   24-FEB-2000; 2000WO-US04914.
PR   24-FEB-2000; 2000WO-US05004.
PR   01-MAR-2000; 2000WO-US05601.
PR   02-MAR-2000; 2000WO-US05746.
PR   02-MAR-2000; 2000WO-US05841.
PR   10-MAR-2000; 2000WO-US06319.
PR   15-MAR-2000; 2000WO-US06884.
PR   20-MAR-2000; 2000WO-US07377.
PR   21-MAR-2000; 2000WO-US07532.
PR   30-MAR-2000; 2000WO-US08439.
PR   17-MAY-2000; 2000WO-US13705.
PR   22-MAY-2000; 2000WO-US14042.
PR   30-MAY-2000; 2000WO-US14941.
PR   02-JUN-2000; 2000WO-US15264.
PR   28-JUL-2000; 2000WO-US20710.
PR   11-AUG-2000; 2000WO-US22031.
PR   23-AUG-2000; 2000WO-US23522.
PR   24-AUG-2000; 2000WO-US23328.
PR   08-NOV-2000; 2000WO-US30952.
PR   10-NOV-2000; 2000WO-US30873.
PR   01-DEC-2000; 2000WO-US32678.
PR   20-DEC-2000; 2000WO-US34956.
PR   28-FEB-2001; 2001WO-US06520.
PR   01-MAR-2001; 2001WO-US06666.
PR   25-MAY-2001; 2001WO-US17092.
PR   01-JUN-2001; 2001WO-US17800.
PR   20-JUN-2001; 2001WO-US19692.
PR   22-JUN-2001; 2001WO-US20116.
PR   29-JUN-2001; 2001WO-US21066.
PR   09-JUL-2001; 2001WO-US21735.
PR   20-DEC-2000; 2000US-0747259.
PR   28-FEB-2001; 2001US-0796498.
PR   09-MAR-2001; 2001US-0802706.
PR   14-MAR-2001; 2001US-0808689.
PR   22-MAR-2001; 2001US-0816744.
PR   05-APR-2001; 2001US-0828366.
PR   10-MAY-2001; 2001US-0854208.
PR   10-MAY-2001; 2001US-0854280.
PR   18-MAY-2001; 2001US-0860216.
PR   25-MAY-2001; 2001US-0866028.
PR   25-MAY-2001; 2001US-0866034.
PR   01-JUN-2001; 2001US-0872035.
PR   05-JUN-2001; 2001US-0874503.
PR   14-JUN-2001; 2001US-0882636.
PR   19-JUN-2001; 2001US-0886342.
PR   21-JUN-2001; 2001US-0887879.
PR   18-JUL-2001; 2001US-0908827.
PR   06-AUG-2001; 2001US-0924419.
PR   09-AUG-2001; 2001US-0927796.
PR   16-AUG-2001; 2001US-0931836.
PR   19-DEC-2001; 2001US-0028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR   WPI; 2003-148238/14.
DR   P-PSDB; ABU59903.
XX
PT   Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346
PT   and PRO1375, which stimulate proliferation of stimulated T-lymphocytes
PT   are therapeutically useful for enhancing immune response and in cancer
PT   treatments -
XX
PS   Claim 2; Fig 505; 659pp; English.
XX
CC   The invention describes an isolated human PRO polypeptide. The PRO
CC   polypeptides are useful in detecting PRO polypeptides in a sample, in
CC   linking a bioactive molecule to a cell expressing a PRO polypeptide, and
CC   in modulating at least one biological activity of a cell expressing a PRO
CC   polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus
CC   useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186
CC   stimulate adrenal cortical capillary endothelial growth, and PRO536,
CC   PRO943, PRO828, PRO826, PRO1068 or PRO535, PRO826, PRO819, PRO1126,
CC   PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus
CC   useful for treating conditions or disorders where angiogenesis would be
CC   beneficial, e.g. wound healing and antagonist of this polypeptide are
CC   useful for treating cancerous tumours. PRO812 inhibits vascular
CC   endothelial growth factor (VEGF) stimulated proliferation of endothelial
CC   cells and is thus useful for inhibiting endothelial cell growth in
CC   mammals which would be beneficial in inhibiting tumour growth. PRO826,
CC   PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of
CC   stimulated T-lymphocytes and are therapeutically useful for enhancing
CC   immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of
CC   retinal neurons cells (PRO1132 is also enhances survival/proliferation of
CC   rod photoreceptor cells) and therefore are useful for treating retinal
CC   disorders of injuries, e.g. retinitis pigmentosum, AMD. PRO819, PRO813
CC   and PRO11066 induce proliferation of mammalian kidney mesangial cells,
CC   and therefore are useful for treating kidney disorders associated with
CC   decreased mesangial cell function such as Berger disease or other
CC   nephropathies associated with dermatitis, herpetiformis or Crohn's
CC   disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the
CC   proliferation and/or redifferentiation of chondrocytes in culture and
CC   are thus useful for treating sports injuries, and arthritis. This
CC   sequence encodes a novel human PRO protein.
XX
SQ   Sequence 1204 BP; 306 A; 364 C; 294 G; 240 T; 0 other;

Alignment Scores:
Pred. No.:                  5.04e-105       Length:          1204
Score:                      1258.00         Matches:         229
Percent Similarity:         100.00%         Conservative:    0
Best Local Similarity:      100.00%         Mismatches:      0
Query Match:                100.00%         Indels:          0
DB:                         25              Gaps:            0

US-09-856-320A-2_COPY_54_282 (1-229) x ABX89393 (1-1204)

Qy          1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        169 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 228

Qy         21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        229 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 288

Qy         41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        289 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 348

Qy         61 GlyCysGluGlnThrArgThrAlaThrGluSerProHisProGlyPheAsnAsnSer 80
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        349 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 408

Qy         81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        409 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 468

Qy        101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
```

```
                    ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        469 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 528

Qy        121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
                    ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        529 TGCCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 588

Qy        141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
                    ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        589 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 648

Qy        161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
                    ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        649 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 708

Qy        181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
                    ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        709 GACTCCGGGGGCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 768

Qy        201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
                    ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        769 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 828

Qy        221 TrpIleGlnGluThrMetLysAsnAsn 229
                    ||||||||||||||||||||||||||||||
Db        829 TGGATCCAGGAGACGATGAAGAACAAT 855
```

RESULT 15
ABA83372
ID ABA83372 standard; cDNA; 1292 BP.
XX
AC ABA83372;
XX
DT 07-FEB-2002 (first entry)
XX
DE Human secreted protein gene 179 SEQ ID NO:189.
XX
KW Human; secreted protein; immunomodulatory; antisclerotic; anti-HIV;
KW dermatological; immunosuppressive; antiinflammatory; immunostimulant;
KW cytostatic; cardiant; vascular; anti-angiogenic; ophthalmological;
KW neuroprotective; nootropic; anticonvulsant; antialzheimers; vulnerary;
KW antiparkinsonian; antimicrobial; gene therapy; vaccine; immune disorder;
KW multiple sclerosis; systemic lupus erythematosus; HIV infection; cancer;
KW human immunodeficiency virus; hyperproliferative disorder; wound healing;
KW Gaucher's disease; cardiovascular disease; Scimitar syndrome; chemotaxis;
KW Chaga's cardiomyopathy; coronary arteriosclerosis; angiogenic disorder;
KW corneal graft neovascularisation; diabetic retinopathy; regeneration;
KW neurological disorder; Huntington's chorea; Alzheimer's disease;
KW Parkinson's disease; infectious disease; ss.
XX
OS Homo sapiens.
XX
PN WO200162891-A2.
XX
PD 30-AUG-2001.
XX
PF 21-FEB-2001; 2001WO-US05614.
XX
PR 24-FEB-2000; 2000US-184836P.
PR 29-MAR-2000; 2000US-193170P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ni J, Ebner R, Lafleur DW, Moore PA, Olsen HS, Rosen CA;
PI Ruben SM, Soppet DR, Young PE, Shi Y, Florence KA, Wei Y;
PI Florence C, Hu J, Li Y, Kyaw H, Fischer CL, Ferrie AM, Fan P;
PI Feng P, Endress GA, Dillon PJ, Carter KC, Brewer LA, Yu G;
PI Zeng Z, Greene JM;
XX
DR WPI; 2001-625724/72.
DR P-PSDB; ABB50479.
XX
PT Nucleic acids encoding 207 human secreted polypeptides, useful for
PT preventing, diagnosing and/or treating, e.g. cancers, Parkinson's
PT disease and diabetic retinopathy -
XX
PS Claim 1; Page 1032; 1533pp; English.
XX
CC ABB50301 to ABB51287 and ABA83194 to ABA83441 represent human secreted
CC proteins (I) and polynucleotide (II) sequences. (I) and (II) have various
CC activities based on the tissues and cells the genes are expressed in.
CC Example of these activities include: immunomodulatory; antisclerotic;
CC dermatological; immunosuppressive; antiinflammatory; immunostimulant;
CC anti-HIV; cytostatic; cardiant; anti-angiogenic; ophthalmological;
CC neuroprotective; nootropic; anticonvulsant; antialzheimers; vascular;
CC antiparkinsonian; antimicrobial; and vulnerary. (I) and (II) can be used
CC in gene therapy and vaccine production. (I) and (II) can be used in the
CC prevention, diagnosis and treatment of immune disorders (e.g. multiple
CC sclerosis, systemic lupus erythematosus and human immunodeficiency virus
CC (HIV) infections), hyperproliferative disorders (e.g. cancers and
CC Gaucher's disease), cardiovascular diseases (e.g. Scimitar syndrome,
CC Chaga's cardiomyopathy and coronary arteriosclerosis), angiogenic
CC disorders (e.g. corneal graft neovascularisation and diabetic
CC retinopathy), neurological disorders (e.g. Huntington's chorea,
CC Alzheimer's disease and Parkinson's disease), infectious diseases and/or
CC for promoting wound healing, regeneration and/or chemotaxis. ABA83185 to
CC ABA83193 and ABB50300 represent sequences used in the exemplification of
CC the present invention.
XX
SQ Sequence 1292 BP; 319 A; 387 C; 329 G; 253 T; 4 other;

Alignment Scores:

Pred. No.:	5.52e-105	Length:	1292
Score:	1258.00	Matches:	229
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	100.00%	Indels:	0
DB:	22	Gaps:	0

US-09-856-320A-2_COPY_54_282 (1-229) x ABA83372 (1-1292)

```
Qy          1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        270 ATCATCAAGGGGTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTCGAG 329

Qy         21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        330 AAGACGCGGCTACTCTGTGGGGCGACGCTCATCGCCCCCAGATGGCTCCTGACAGCAGCC 389

Qy         41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        390 CACTGCCTCAAGCCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAAGGAGGAG 449

Qy         61 GlyCysGluGlnThrArgThrAlaThrGluSerProProHisProGlyPheAsnAsnSer 80
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        450 GGCTGTGAGCAGACCCGGACAGCCACTGAGTCCTTCCCCCACCCCGGCTTCAACAACAGC 509

Qy         81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        510 CTCCCCAACAAAGACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCC 569

Qy        101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        570 ATCACCTGGGCTGTGCGACCCCTCACCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGC 629

Qy        121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        630 TGYCTCATTTCCGGCTGGGGCAGCACGTCCAGCCCCCAGTTACGCCTGCCTCACACCTTG 689

Qy        141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        690 CGATGCGCCAACATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAAC 749

Qy        161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        750 ATCACAGACACCATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGT 809
```

```
Qy        181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        810 GACTCCGGGGGCCCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAG 869

Qy        201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        870 GATCCGTGTGCGATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGAC 929

Qy        221 TrpIleGlnGluThrMetLysAsnAsn 229
              |||||||||||||||||||||||||||
Db        930 TGGATCCAGGAGACGATGAAGAACAAT 956
```

Search completed: October 23, 2003, 15:58:15
Job time : 260.855 secs

ScanProsite

Search a sequence against PROSITE

Nopepro-site Tang 6075 136 SID2

Sequence:

```
MQRLRWLRDW KSSGRGLTAA KEPGARSSPL QAMRILQLIL LALATGLVGG ETRIIKGFEC
KPHSQPWQAA LFEKTRLLCG ATLIAPRWLL TAAHCLKPRY IVHLGQHNLQ KEEGCEQTRT
ATESFPHPGF NNSLPNKDHR NDIMLVKMAS PVSITWAVRP LTLSSRCVTA GTSCLISGWG
STSSPQLRLP HTLRCANITI IEHQKCENAY PGNITDTMVC ASVQEGGKDS CQGDSGGPLV
CNQSLQGIIS WGQDPCAITR KPGVYTKVCK YVDWIQETMK NN
```

PROSITE Release 18.10, of 12-Oct-2003

>PDOC00001 PS00001 **ASN_GLYCOSYLATION** N-glycosylation site [pattern] [Warning: pattern with a high probability of occurrence].

```
131 - 134  NNSL
197 - 200  NITI
213 - 216  NITD
242 - 245  NQSL
```

>PDOC00005 PS00005 **PKC_PHOSPHO_SITE** Protein kinase C phosphorylation site [pattern] [Warning: pattern with a high probability of occurrence].

```
 13 - 15  SgR
164 - 166  SsR
192 - 194  TlR
259 - 261  TrK
278 - 280  TmK
```

>PDOC00006 PS00006 **CK2_PHOSPHO_SITE** Casein kinase II phosphorylation site [pattern] [Warning: pattern with a high probability of occurrence].

```
120 - 123  TatE
199 - 202  TiiE
222 - 225  SvqE
```

>PDOC00008 PS00008 **MYRISTYL** N-myristoylation site [pattern] [Warning: pattern with a high probability of occurrence].

```
 16 - 21  GLtaAK
 46 - 51  GLvgGE
114 - 119  GCeqTR
226 - 231  GGkdSC
252 - 257  GQdpCA
```

>PDOC00124 PS50240 **TRYPSIN_DOM** Serine proteases, trypsin domain [profile].

```
 47 - 280  LVGGEtriikgfECKPHSQPWQAALFEKT-RLLCGATLIAPRWLLTAAHCLKPR-----Y
           IVHLGQHNLQKEEGCEQTRTATESFPHPGFNnslpNKDHRNDIMLVKMASPVSITWAVRP
           LTL--SSRCVTAGTSCLISGWGSTSSPqLRLPHTLRCANITIIEHQKC-ENAYPGNITDT
           MVCASVQEGGKDSCQGDSGGPLVC----NQSLQGIISWGqDPCAITRKPGVYTKVCKYVD
           WIQETMK
```

>PDOC00124 PS00134 **TRYPSIN_HIS** Serine proteases, trypsin family, histidine active site [pattern].

```
 90 - 95  LTAAHC
```

>PDOC00124 PS00135 **TRYPSIN_SER** Serine proteases, trypsin family, serine active site [pattern].

```
229 - 240  DScqGDSGGPLV
```

Graphical summary of hits *(java applet)*

Click on items to see a description. Drag the two red cursors to select a zoom region.